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Abstract 
 
To date, no candidate markers of upper motor neuron (UMN) function have performed 
sufficiently well to enter widespread clinical use, and the lack of such markers impedes 
both the diagnostic process and clinical trials in motor neuron disease (MND). We 
studied 15-30Hz intermuscular coherence (IMC), a novel marker of UMN function, and 
central motor conduction time (CMCT), an established marker of UMN function based 
on transcranial magnetic stimulation (TMS), in healthy volunteers and patients newly 
diagnosed with MND. To clarify the relative contributions of different parts of the 
motor system to IMC generation, we examined IMC in patients with longstanding 
diagnoses of hereditary spastic paraparesis (HSP), multifocal motor neuropathy (MMN) 
and inclusion body myositis (IBM). 
 
Previous studies reported conflicting results for the relationship between CMCT and 
predictors such as age and height. We only found a significant correlation between 
lower limb CMCT and height. IMC did not vary significantly with age, allowing data 
from healthy subjects across all ages to be pooled into a single normative dataset. The 
variability of IMC between subjects was considerable, and within a given subject 
variability was greater between than within recording sessions; potential contributors 
are discussed. Anodal transcranial direct current stimulation (tDCS) caused a significant 
increase in IMC, but interindividual variability was substantial, which might hinder its 
future use as an adjunct to IMC. 
 
To compare individual disease groups to the normal cohort, we evaluated the area 
under the receiver-operating characteristic curve (AUC). IMC generally matched or 
exceeded the performance of CMCT in discriminating patients with MND from normal, 
achieving AUCs of 0.83 in the upper and 0.79 in the lower limb. Previous evidence 
suggests that IMC abnormalities are primarily attributable to corticospinal tract (CST) 
dysfunction. In line with this, most patients with HSP exhibited diminished IMC. 
However, patients with MMN also showed decreased IMC, suggesting either that 
subclinical CST involvement was present or that dysfunction of lower motor neurons 
(LMNs) may affect IMC; clarification through computational modelling is suggested. In 
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IBM, IMC was generally increased, which might reflect that the altered motor unit 
discharge pattern makes synchronisation more readily detectable. 
 
IMC appears to be a promising marker of CST function. It remains to be clarified how 
strongly it is influenced by LMN lesions, and optimisation of methods should help to 
minimise the variability of results. Since IMC is non-invasive and can be measured 
using commonly available EMG equipment, wider dissemination should prove 
straightforward.  
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1  Introduction and background 
   
  In this chapter, I present the motivation for and discuss the scientific background of 
the work presented in this thesis. I review the organisation of the primary motor 
system, the nature and management of motor neuron disease, as well as theoretical 
aspects of magnetic stimulation and coherence analysis. 
 
 
1.1 Introduction 
 
More than 1,700 people in the United Kingdom are newly diagnosed with motor 
neuron disease (MND) per year. MND is a fatal neurodegenerative disorder of 
unknown cause and typically follows a relentlessly progressive trajectory, with a 
median survival of 30 months from symptom onset (Chancellor et al., 1993). Early 
physical manifestations are protean, often leading to late presentation and delayed 
referral to a neurologist. Further delays arise through investigations and a possible 
need for serial follow-up. Intervals from symptom onset to diagnosis are often long, 
having a median of around one year (Househam & Swash, 2000; Mitchell et al., 2010). 
These diagnostic delays are a burden for patients, their families and the health service; 
they are also likely to limit the survival benefits offered by neuroprotective treatment. 
 
Common forms of MND involve the simultaneous degeneration of upper and lower 
motor neurons (UMNs, LMNs). UMNs project from the primary motor cortex to the 
brainstem and spinal cord, where they connect to LMNs which supply the peripheral 
musculature. The diagnosis of MND requires evidence of damage to both UMNs and 
LMNs in the absence of alternative causes. Initially relying on clinical examination 
findings alone (Brooks, 1994), the diagnostic process has been modified to incorporate 
electromyographic (EMG) features of LMN damage (Brooks et al., 2000; De Carvalho et 
al., 2008), thus increasing sensitivity (De Carvalho & Swash, 2009). By contrast, 
assessment of UMN function remains entirely clinical. If a reliable test of UMN 
integrity were available, it might help to decrease diagnostic delays and may also 
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prove useful in the longitudinal follow-up of patients, both for individual prognosis and 
as a surrogate marker in clinical trials. 
 
For over two decades, the development of tests for UMN function has focussed on 
transcranial magnetic stimulation (TMS). TMS-based measures, such as central motor 
conduction time (CMCT), have shown only moderate performance (Mills, 2003) and 
require expensive specialist equipment. In consequence, they have not entered 
widespread clinical use. Our group has recently described intermuscular coherence 
(IMC) as a novel test for UMN function (Fisher et al., 2012). IMC is non-invasive and 
can be performed using widely available EMG equipment. Previous work focussed on 
an animal model of UMN damage and rare subtypes of MND in humans, but paid little 
attention to commoner forms of MND (Fisher et al., 2012). 
 
In this thesis, I aim to advance the field by studying IMC and CMCT in large cohorts of 
healthy human volunteers and patients with suspected MND of any type, as well as in 
smaller groups of patients with established diagnoses of other motor conditions. My 
results show that IMC is a promising marker of UMN function which meets or exceeds 
the performance of CMCT. 
 
Individual chapters in this thesis are self-contained but do not provide detailed 
background regarding descending motor pathways, MND, TMS and coherence analysis. 
These areas are introduced below, followed by an overview of all chapters. 
 
 
1.2 Descending motor pathways 
 
Mammals possess several descending motor pathways which vary in relative size and 
importance between species but retain the same overall functions (Figure 1.1; for an 
extensive review of descending pathways, see Porter & Lemon, 1993). The dorsolateral 
pathways of the corticospinal and rubrospinal tracts provide fine control of distal 
muscles, particularly in the hand. The ventromedial pathways, which include the 
reticulospinal, vestibulospinal and tectospinal tracts, are traditionally viewed as 
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controlling proximal limb and truncal muscles for posture and balance, although small 
projections to hand motor neurons also exist (Riddle & Baker, 2010; Riddle et al., 2009). 
 
 
 
Figure 1.1: Descending motor pathways. The lateral corticospinal tract (CST) 
decussates at the level of the medulla and projects to the spinal motor neurons (blue 
area) both directly and indirectly via the dorsolateral (red area) and ventromedial  
interneurons (green area, A). The anterior CST partly crosses at the spinal level and 
projects to ventromedial interneurons only. The remaining descending tracts are either 
crossed or uncrossed and mostly project to spinal interneurons (B). Spinal motor 
neurons exit through the ventral horn and run in the peripheral nerves to supply 
multiple fibres in a given muscle, thus forming a motor unit (adapted from Lemon, 
2008). 
 
1.2.1 The corticospinal tract 
Primates have a unique ability to perform fine, skilled movements of distal muscles. 
This ability has evolved in parallel with the CST, which is most prominent in the higher 
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apes, particularly humans. The size of the CST and the proportion of direct 
corticomotorneuronal (CM) connections are related to manual dexterity (Heffner & 
Masterton, 1983). 
 
1.2.2 Anatomical organisation of the corticospinal tract 
CST fibres arise from pyramidal cells in layer V of the cerebral cortex (Ramón y Cajal, 
1893). These cells are named according to the shape of their soma; those giving rise to 
large axons are sometimes referred to as Betz cells. The CST originates primarily in the 
primary motor cortex (M1), with further contributions from the supplementary motor 
area, premotor cortex, somatosensory cortex and parietal lobe (Dum & Strick, 1991; 
Jane et al., 1967; Murray & Coulter, 1981; Russell & DeMyer, 1961). M1 is arranged in 
a broadly somatotopic manner, epitomised by the classical homunculus in 
humans (Penfield & Rasmussen, 1950) and the simiusculus in monkeys (Woolsey et al., 
1952). Cortical representations of the lower limbs, upper limbs and the face are 
arranged mediolaterally, with proximal and distal muscles represented along a 
rostrocaudal gradient. The size of the cortical representation is related to the 
complexity of movements of the relevant body part; the hand, for example, has a 
disproportionately large representation. However, this somatotopy only involves gross 
representations of body parts. Representations of smaller body regions or individual 
muscles are more widely distributed and overlap considerably. Furthermore, there is 
substantial convergence and divergence within the motor system, as well as plasticity 
throughout life (Schieber, 2001). Hence, the homunculus and simiusculus represent 
useful but invariably oversimplified concepts. 
 
In humans, the CST contains approximately one million fibres which have mostly small 
diameters and slow conduction velocities, with a smaller proportion being large, 
myelinated and fast conducting (Humphrey & Corrie, 1978). It descends through the 
cerebral peduncles and the brainstem to the level of the medullary pyramids, which 
give the tract its alternative name (pyramidal tract; its origin from pyramidal cells 
being coincidental). Approximately 85% of fibres decussate and descend in the lateral 
CST (Figure 1.1 A; Rosenzweig et al., 2009). They project directly onto spinal motor 
neurons to form monosynaptic CM connections (Palmer & Ashby, 1992), as well as 
having additional indirect projections through interneurons. Uncrossed CST fibres 
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enter the anterior CST but only have very weak effects on ipsilateral muscles 
(Soteropoulos et al., 2011). Recently, it has been reported that corticospinal fibres may 
also decussate and/or branch at a spinal level, pointing to an even greater complexity 
of corticospinal projections (Rosenzweig et al., 2009). 
 
1.2.3 Corticospinal tract lesions 
In humans, naturally occurring lesions rarely affect the CST in isolation. Lacunar 
infarcts may appear to cause pure motor deficits on clinical assessment, but the infarct 
zone often extends beyond the CST to involve neighbouring descending outputs to the 
brainstem nuclei as well as ascending sensory inputs. Nonetheless, truly isolated 
involvement of the pyramids can occur with medial medullary infarcts (Bassetti et al., 
1997), and such cases help to delineate the role of the CST. Pyramidal strokes cause a 
unilateral motor deficit which is most pronounced for fine, distal voluntary movements. 
Similar to more extensive infarcts, recovery tends to be weighted towards synergistic, 
proximal movements, and thus appears to be driven by brainstem motor pathways 
(Lang et al., 2006). 
 
In monkeys, selective CST lesions result in little gross deficit post recovery, with 
animals being able to stand, run and climb in an apparently normal manner. However, 
there are substantial, persistent deficits in independent finger movements, 
exemplified by difficulties in grooming (Schwartzman, 1978) or retrieving food from 
small wells (Lawrence & Kuypers, 1968). In addition, reaction speeds are slower due to 
delayed EMG onset times (Hepp-Reymond et al., 1974). Hence, the CST appears to 
superimpose speed and fractionation on movements produced by other descending 
motor pathways (Lawrence & Kuypers, 1968). This hypothesis is backed by more 
recent studies where the GABAA agonist muscimol was used to effect reversible 
inactivation of small areas of M1, causing transient impairment of fractionated finger 
movements (Brochier et al., 1999; Schieber & Poliakov, 1998).  
 
1.2.4 Nomenclature 
The terms ‘CST’ and ‘spinal motor neurons’ are used mostly in the scientific community, 
whereas the corresponding terms ‘UMNs’ and ‘LMNs’ are preferred in a clinical setting. 
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Strictly speaking, UMNs include not only the CST but also brainstem motor pathways, 
but this distinction is rarely made in practice. 
 
 
1.3 Motor neuron disease 
 
MND is characterised by degeneration and loss of motor neurons, involving variable 
proportions of UMNs and LMNs. The classical form of MND, first described by Charcot 
in the late 19th century (Charcot, 1874), has a phenotype called amyotrophic lateral 
sclerosis (ALS) with signs of both UMN and LMN dysfunction. Although the term ALS is 
sometimes used synonymously with MND, this is misleading as MND also encompasses 
three related syndromes: progressive bulbar palsy (PBP), primary lateral sclerosis (PLS) 
and progressive muscular atrophy (PMA), respectively presenting with bulbar 
dysfunction, pure UMN signs and pure LMN signs. Nonetheless, ALS is the commonest 
subtype and accounts for more than 85% of MND. 
 
1.3.1 Aetiology 
Approximately 90% of cases are considered to be sporadic. In around 10%, there is a 
family history of MND, and an increasing number of pathogenic mutations have been 
identified across multiple genes (Al-Chalabi et al., 2012; Turner et al., 2013). 
 
1.3.2 Epidemiology 
MND is a rare condition occurring worldwide with an incidence of approximately 2 per 
100,000 per year (McGuire & Nelson, 2006). The incidence is 20-60% higher in men 
than women, and peaks between 65 and 75 years of age (Figure 1.2 A). The prevalence 
is estimated at 6 per 100,000. 
  
1.3.3 Pathology 
Macroscopically, there are few if any abnormalities. In advanced cases, atrophy of the 
precentral gyrus and atrophy and discolouration of the anterior spinal nerve roots may 
be apparent (Figure 1.2 B, C). Microscopically, there is loss of motor neurons with 
secondary loss of myelin from M1, the CST, hypoglossal nucleus and ventral horn of 
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the spinal cord; cortical interneurons in M1 are also lost (Nihei et al., 1993). Cell loss is 
accompanied by gliosis, and surviving motor neurons typically contain cytoplasmic 
inclusions of TDP-43 (transactive response DNA binding protein 43kDa; Arai et al., 
2006). There is mounting evidence of extra-motor pathology, highlighting that MND is 
only relatively selective for the motor system (Wharton & Ince, 2003), and this is 
exemplified by the clinical and molecular association of MND with fronto-temporal 
dementia (Arai et al., 2006; Lomen-Hoerth & Strong, 2006). 
 
 
 
Figure 1.2: Age-specific incidence (A) and macroscopic pathology (B, C) for MND. MND 
presents across a wide age-range but shows a clear peak in the seventh decade (A; 
adapted from McGuire and Nelson, 2006). At post mortem, clear macroscopic 
abnormalities are infrequent but may include atrophy of the precentral gyrus (B, 
arrows), and atrophy and discolouration of the anterior spinal nerve roots (C, arrows; 
adapted from Jeans and Ansorge, 2009).  
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1.3.4 Diagnosis 
Typically, MND is focal in onset. Initial features occur more commonly in the limbs than 
in the bulbar territory. The diagnosis is clinical and depends on detection of an 
appropriate phenotype paired with exclusion of other potential causes (Table 1.1 A). 
 
Table 1.1: Diagnostic criteria for ALS. ‘Regions’ refer to the bulbar, cervical, thoracic 
and lumbosacral territories (adapted from Turner et al., 2013). 
 
A. The diagnosis of ALS requires: 
• The presence of 
o Evidence of LMN degeneration by clinical, electrophysiological or 
neuropathological examination; 
o Evidence of UMN degeneration by clinical examination; and 
o Progression of motor syndrome within a region or to other regions, as 
determined by history or examination 
• The absence of 
o Electrophysiological and pathological evidence of other disease 
processes that might explain the signs of LMN and UMN degeneration; 
and 
o Neuroimaging evidence of other disease processes that might explain 
the observed clinical and electrophysiological signs 
 
B. El Escorial criteria 
• Definite ALS: UMN and LMN signs in three regions 
• Probable ALS: UMN and LMN signs in at least two regions with UMN signs 
rostral to the LMN signs 
• Possible ALS: UMN and LMN signs in one region, UMN signs in two or more 
regions, or LMN signs above UMN signs 
• Suspected ALS: LMN signs only in two or more regions 
 
C. Revised El Escorial (Airlie House) criteria 
• Clinically definite ALS: clinical evidence alone of UMN and LMN signs in three 
regions 
• Clinically probable ALS: clinical evidence alone of UMN and LMN signs in at 
least two regions with some UMN signs rostral to the LMN signs 
• Clinically probable/laboratory-supported ALS: clinical signs of UMN and LMN 
dysfunction in only one region, or UMN signs alone in one region, together with 
LMN signs defined by EMG criteria in at least two regions, together with proper 
application of neuroimaging and clinical laboratory protocols to exclude other 
causes 
• Possible ALS: clinical signs of UMN and LMN dysfunction in only one region, or 
UMN signs alone in two or more regions, or LMN signs rostral to UMN signs and 
the diagnosis of clinically probable/laboratory-supported ALS cannot be proven 
• Suspected ALS: category deleted 
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Diagnostic criteria have been formulated to aid research by standardising patient 
groups (Belsh, 2000). The first widely used criteria were defined in El Escorial, and 
classify cases as definite, probable, possible or suspected ALS depending on the nature 
and extent of clinical and electrophysiological findings (Table 1.1 B; Brooks, 1994). For 
the assessment of LMN function, EMG is regarded as an extension of the clinical 
examination and serves to confirm clinical signs, to detect clinically occult 
abnormalities and to exclude other pathological processes. By contrast, UMN integrity 
is assessed by clinical means only. 
 
The revised El Escorial criteria abolished the category of suspected ALS and introduced 
a new category of clinically probable/laboratory-supported ALS, thus giving more 
weight to EMG findings in certain scenarios (Table 1.1 C; Brooks et al., 2000). In 
addition, the list of relevant EMG features was streamlined to make them more user-
friendly. The Awaji-Shima criteria marked a further strengthening of the role of EMG 
(De Carvalho et al., 2008). By allowing clinical and EMG findings to be used additively 
when grading a limb, the category of clinically probable/laboratory-supported ALS was 
rendered obsolete. Moreover, additional EMG features of LMN dysfunction were 
introduced. 
 
These changes have boosted sensitivity, with one report describing an increase from 
53% for the revised El Escorial criteria to 95% for the Awaji criteria (De Carvalho & 
Swash, 2009). However, the study employed a cohort with an established clinical 
diagnosis of MND; sensitivity is likely to be lower when the disease is at an earlier 
stage, a clinical diagnosis has not been made yet, and greater diagnostic uncertainties 
remain. Advances have been limited to improved detection of LMN dysfunction, with 
assessment of UMN integrity remaining entirely clinical. In a study applying the revised 
El Escorial criteria to almost 400 patients, 41% were classified as possible ALS at the 
point of clinical diagnosis, with 10% remaining in this category at their death (Traynor 
et al., 2000b). Patients with possible ALS show the same clinical progression as those 
with definite ALS, but have too few demonstrable UMN signs to attain a higher 
diagnostic category. This has caused frustration with the current diagnostic framework 
(Turner et al., 2013) and highlights the need for biomarkers of UMN function (Turner 
et al., 2009).  
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1.3.5 Management 
Management is principally supportive and focuses on regular, individualised, 
multidisciplinary follow-up to assess the rate of progression and maintain well-being 
where possible (Miller et al., 2009b). In selected patients, non-invasive ventilation and 
percutaneous endoscopic gastrostomy (PEG) can prolong survival (Miller et al., 2009a). 
 
The only disease-modifying drug licensed for the treatment of MND is riluzole, an 
agent thought to ameliorate glutamatergic excitotoxicity. Treatment with 100mg of 
riluzole per day is reasonably safe and prolongs survival by approximately two to three 
months (Miller et al., 2012), though the evidence base only pertains to patients with 
an ALS phenotype (Talbot, 2009). It is plausible that earlier introduction of riluzole 
could delay the onset of disability and extend survival further (Swash, 1998). Any 
future neuroprotective agents should also be administered as early as possible to 
maximise impact. 
 
1.3.6 Prognosis 
Although the median survival is 30 months from symptom onset (Chancellor et al., 
1993) the survival curve tapers out to 20 years or more. Death usually results from 
respiratory failure. Older age at onset, bulbar onset and early respiratory involvement 
are predictors of reduced survival (Talbot, 2009). 
 
 
1.4 Transcranial magnetic stimulation 
 
1.4.1 Basic principles 
Unlike an electric current, a time-varying magnetic field traverses bone with little 
attenuation. Such a field induces a current in conductive tissue in accordance with 
Faraday’s Law (Barker, 2002), and can therefore be used to deliver stimulating currents 
to many areas of the nervous system where bony structures make direct electrical 
stimulation difficult, including the brain and the spinal nerve roots (Lemon, 2002; 
Maccabee, 2002). Magnetic stimulation of the spinal cord (Tomberg, 1995) or the 
cauda equina within the spinal canal (Maccabee et al., 1996) has been achieved only 
rarely unless special stimulation coils are used (Matsumoto et al., 2009b), and this may 
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be attributable to the depth of stimulation required, focussing of the induced current 
by bony structures, and shielding of the current by cerebrospinal fluid (Efthimiadis et 
al., 2010; Maccabee et al., 1991; Ugawa et al., 1989). When applied to M1 or the 
peripheral motor pathways, suprathreshold magnetic stimulation leads to motor 
evoked potentials (MEPs) recordable from the surface of the corresponding muscles 
(Figure 1.3 A; Barker et al., 1985). 
 
 
 
Figure 1.3: Magnetic stimulation. MEPs recorded from abductor digiti minimi (ADM) 
after magnetic stimulation to the contralateral M1 (A, top) and to the ulnar nerve at 
the elbow (A, bottom; adapted from Barker et al., 1985). Variability of MEPs recorded 
from first dorsal interosseous (FDI) after magnetic stimulation to the contralateral M1 
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under constant experimental conditions (B). Generation of M-wave and F-wave after 
electrical stimulation of a peripheral motor nerve (C). Consecutive recordings from the 
thenar muscles showing M-waves and F-waves after ulnar nerve stimulation at the 
elbow (D; adapted from Kimura, 2001). MEPs evoked by magnetic stimulation over the 
cervical spine and over the contralateral M1, during voluntary contraction and at rest. 
Voluntary contraction decreases the latency of cortical but not spinal MEPs (E, F; 
adapted from Kimura, 2001). 
 
1.4.2 Measures of MEP size 
MEPs resulting from TMS to M1 reflect sequential activity of UMNs, LMNs and muscle 
fibres. They show considerable intertrial variability (Figure 1.3 B; Ellaway et al., 1998; 
Kiers et al., 1993) which appears to be attributable to multiple factors. Firstly, the 
descending volley in the CST varies between trials (Burke et al., 1995), potentially due 
to background oscillatory activity in the motor system (Mitchell et al., 2007). Errors in 
coil positioning do not appear to contribute (Gugino et al., 2001). Secondly, LMNs may 
fire repetitively (Day et al., 1987; Hess et al., 1987). Thirdly, surface EMG reflects the 
summed activity of many muscle fibres, with low-pass filtering by conduction through 
soft tissue (Merletti & Parker, 2004). Since the descending volley is desynchronised 
(Magistris et al., 1998), the surface EMG response involves a variable amount of phase 
cancellation. 
 
Although widely used, averages of multiple MEPs do not truly address the issues 
underlying MEP variability, and measures of average MEP size such as amplitude, 
duration and area must be interpreted with caution. At sufficiently high stimulation 
intensities, MEPs can be detected in the distal muscles of virtually all normal subjects, 
and consistent absence of a response is likely to be abnormal. 
 
The triple and quadruple stimulation techniques (TST, QuadS) use collision of action 
potentials to circumvent the issues of desynchronisation and repetitive discharges 
(Magistris et al., 1998; Z'Graggen et al., 2005) but have several drawbacks. Firstly, they 
are time-consuming. Secondly, protocols exist only for three muscles in the upper limb 
(Humm et al., 2004; Magistris et al., 1998) and one muscle in the lower limb (Bühler et 
al., 2001). Thirdly, they require supramaximal electrical stimulation of proximal 
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peripheral nerves, which is uncomfortable and, in the lower limb, involves use of a 
needle electrode. These downsides have prevented widespread adoption. 
 
1.4.3 Central motor conduction time 
Central motor conduction time (CMCT) estimates the conduction delay from M1 to 
LMNs. Magnetic stimulation is performed over M1 to measure cortical latency to the 
target muscle; CMCT is then calculated by subtracting an estimate of peripheral motor 
conduction time (PMCT). 
 
PMCT may be estimated by two main methods. In the first method, magnetic 
stimulation over the spinal column activates LMNs at the level of the exit foramina 
(Chokroverty et al., 1993; Chokroverty et al., 1991; Maccabee et al., 1991; Ugawa et al., 
1989), and the corresponding MEP latency provides an estimate of PMCT. Conduction 
delays along proximal nerve roots are not included in such PMCTs and remain part of 
CMCT. 
 
The second method involves electrical stimulation of a distal motor nerve. The 
orthodromic volley travels to the muscles to elicit an M-wave (Figure 1.3 C, D). The 
antidromic volley runs to the LMN cell bodies; a fraction of the LMNs fire 
regeneratively and an orthodromic volley travels back to the muscles, giving rise to a 
second, smaller wave of activity called an F-wave (Kimura, 2001). If the point of 
stimulation is moved along the length of the nerve, there are equal but opposite 
changes in the latencies of M-waves and F-waves; the sum of their latencies remains 
constant. Assuming a turnaround time of 1ms at the cell body (Kimura, 2001), the 
PMCT may be calculated as 
 
𝑃𝑀𝐶𝑇 =  (𝐹 𝑙𝑎𝑡𝑒𝑛𝑐𝑦) + (𝑀 𝑙𝑎𝑡𝑒𝑛𝑐𝑦) − 1𝑚𝑠2  (1.1)  
 
Although the F-wave method results in PMCT estimates which include the proximal 
root segment (Cros et al., 1990; Mills & Murray, 1986), it has other weaknesses which 
are discussed in Chapter 2. 
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Cortical MEPs for CMCT estimation are routinely recorded during a weak background 
contraction, which shortens MEP latency by approximately 2-3ms and facilitates the 
MEP response (Figure 1.3 E; Hess et al., 1986), allowing lower stimulus intensities to be 
used. Although spinal MEPs are also facilitated by voluntary activity (Shafiq & 
Macdonell, 1994), their latency does not appear to be affected (Figure 1.3 F) and they 
are usually recorded at rest. 
 
1.4.4 Threshold 
MEP threshold is defined as the stimulus intensity at which the response probability is 
50%, and is usually measured at rest (resting motor threshold, RMT). RMT is thought to 
reflect neuronal membrane excitability (Chen et al., 2008), and is also inversely related 
to the strength of the corticospinal projection, being lower in intrinsic hand muscles 
than in the proximal upper limb, lower limb or trunk. A range of methods for threshold 
estimation have been described (Awiszus, 2003; Mills & Nithi, 1997b; Rossini et al., 
1994; Rothwell et al., 1999; Tranulis et al., 2006), and there is no universal agreement 
how threshold should be determined. Considerable variability within subjects has been 
reported (Tranulis et al., 2006), and owing to the extent of intrasubject and 
intersubject variability the clinical utility of RMT has been called into 
question (Wassermann, 2002). 
 
1.4.5 Recruitment curves 
Recruitment curves, also known as input-output or stimulus-response curves, plot MEP 
amplitude against stimulus intensity. The slope of such curves is thought to provide a 
further measure of cortical excitability (Currà et al., 2002), and tends to be greater in 
muscles with low RMT (Chen et al., 2008). 
 
1.4.6 Cortical silent period 
The cortical silent period (CSP) refers to a period of post-stimulus EMG silence 
occurring when TMS is applied during sustained contraction. CSP is deemed to have 
intracortical and intrinsic spinal components (Chen et al., 2008). As a marker of disease, 
CSP has several weaknesses. Interindividual variability of CSP is high (Orth & Rothwell, 
2004), measurements of CSP are only comparable between subjects if acquired at a 
stimulus intensity defined relative to threshold, and CSP might no longer be reliable 
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once threshold is affected by a disease process (Attarian et al., 2005). In addition, CSP 
has been shown to be abnormal in a wide range of neurological conditions including 
non-motor conditions (Chen et al., 2008), implying poor specificity for individual 
conditions and for involvement of the motor system. 
 
1.4.7 Paired-pulse measures 
Corticospinal output results from the interplay of multiple excitatory and inhibitory 
systems in the motor cortex, and these can be investigated using paired-pulse TMS to 
M1 (Chen et al., 2008). Paradigms involve a conditioning stimulus and a test stimulus 
separated by a specified interstimulus interval (ISI). Depending on the stimulation 
intensities and the ISI, several phenomena including short-interval intracortical 
inhibition (SICI), long-interval intracortical inhibition (LICI) and intracortical facilitation 
(ICF) can be observed via the resultant MEPs. SICI, LICI and ICF are thought to be 
intracortical rather than corticospinal effects, but the neural substrates probed by 
these techniques are less well defined than those involved in single-pulse MEPs. 
Similar to the situation for CSP, anomalies of intracortical inhibition and facilitation 
have been described in a wide range of neurological disorders (Berardelli et al., 2008; 
Chen et al., 2008). 
 
1.4.8 TMS-based measures in MND 
TMS-based measures may capture two pathophysiological changes occurring in MND: 
loss of UMNs and cortical hyperexcitability (Gooch et al., 2006). 
 
MEP amplitude In cross-sectional studies, MEPs were often absent (Berardelli et al., 
1991; Caramia et al., 1988; De Carvalho et al., 2003; Eisen & Shtybel, 1990; Eisen et al., 
1990; Miscio et al., 1999; Osei-Lah & Mills, 2004; Pohl et al., 2001; Schriefer et al., 
1989; Uozumi et al., 1991; Urban et al., 2001) or diminished in size, either in absolute 
terms (Eisen & Shtybel, 1990; Eisen et al., 1990) or relative to a response evoked by 
supramaximal peripheral nerve stimulation (Attarian et al., 2005; De Carvalho et al., 
1999; De Carvalho et al., 2003; Schriefer et al., 1989; Uozumi et al., 1991; Urban et al., 
2001). They were also frequently dispersed (Eisen & Shtybel, 1990). Longitudinal 
studies report MEP amplitude to decrease gradually (Floyd et al., 2009) or to remain 
unchanged (De Carvalho et al., 1999).  
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CMCT Although CST damage in MND is axonal rather than demyelinating, CMCT 
prolongation is sometimes seen. Several potential mechanisms have been 
invoked (Sandbrink, 2009): preferential loss of fast-conducting fibres in the CST early 
on in the disease (Kohara et al., 1999; Sobue et al., 1987), transmission through 
brainstem motor pathways (Weber et al., 2000), and reduced size and synchrony of 
the descending volley increasing the time required for temporal summation at the 
LMN. CMCT in MND was variably reported to be either normal or prolonged (Attarian 
et al., 2005; Barker et al., 1986, 1987; Berardelli et al., 1991; Caramia et al., 1991; Claus 
et al., 1995; Cruz Martínez & Trejo, 1999; De Carvalho et al., 1999; De Carvalho et al., 
2003; Desiato & Caramia, 1997; Eisen & Shtybel, 1990; Floyd et al., 2009; Mills & Nithi, 
1998; Miscio et al., 1999; Osei-Lah & Mills, 2004; Pohl et al., 2001; Schriefer et al., 
1989; Schulte-Mattler et al., 1999; Triggs et al., 1999; Truffert et al., 2000; Urban et al., 
2001). Four of these studies were longitudinal and found that CMCT remained 
unchanged or increased only slightly over time (Claus et al., 1995; De Carvalho et al., 
1999; Floyd et al., 2009; Triggs et al., 1999). 
 
Threshold RMT varies considerably in MND (De Carvalho et al., 2002; Eisen et al., 
1993). Several cross-sectional studies reported that thresholds are reduced early on in 
the disease before gradually rising (Desiato & Caramia, 1997; Eisen et al., 1993; Mills & 
Nithi, 1997a; Vucic & Kiernan, 2006; Zanette et al., 2002). However, other reports 
disagree. Two cross-sectional (Attarian et al., 2005; De Carvalho et al., 2002) and one 
longitudinal study (De Carvalho et al., 1999) described no change in threshold, whilst 
other longitudinal studies reported a monotonic increase in threshold with disease 
progression (Floyd et al., 2009; Triggs et al., 1999), limited in one study to a subgroup 
of patients with mixed UMN and LMN signs (Mills, 2003). 
 
Recruitment curves One cross-sectional study found that recruitment curves become 
steeper in early MND before flattening off again later in the course of the 
disease (Zanette et al., 2002). Two other cross-sectional reports describe that 
recruitment curves in MND were steeper than normal but did not perform an analysis 
by disease duration (Vucic & Kiernan, 2006; Vucic et al., 2008). 
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Cortical silent period CSP was variably reported as being decreased (Attarian et al., 
2006; Schelhaas et al., 2007; Vucic et al., 2011; Vucic & Kiernan, 2006; Zanette et al., 
2002) or unchanged in MND (Karandreas et al., 2007; Prout & Eisen, 1994; Ziemann et 
al., 1997). 
 
Paired-pulse measures SICI, whilst being described as normal in one report (Hanajima 
et al., 1996), was found to be reduced in most studies (Salerno & Georgesco, 1998; 
Sommer et al., 1999; Stefan et al., 2001; Vucic et al., 2011; Vucic & Kiernan, 2006; 
Vucic et al., 2008; Yokota et al., 1996; Zanette et al., 2002; Ziemann et al., 1997). 
Threshold tracking TMS (TTTMS) constitutes a recent refinement of SICI, and has been 
reported to discriminate between groups of normal subjects, patients with MND and 
patients with MND mimic disorders (Vucic et al., 2011; Vucic & Kiernan, 2006). ICF was 
variably reported as being reduced (Hanajima et al., 1996; Salerno & Georgesco, 1998; 
Stefan et al., 2001), unchanged (Ziemann et al., 1997) or increased (Vucic et al., 2011; 
Vucic & Kiernan, 2006; Vucic et al., 2008). 
 
In summary, the literature yields mixed information and interpretation regarding the 
presence and evolution of abnormalities in TMS-based measures in MND. The variable 
nature of study results is probably partly attributable to differences in study 
populations, methods and gold standards for determining normal ranges and 
diagnostic success. Despite TMS-based measures being explored in MND as early as 
1986 (Barker et al., 1986), they have not entered routine clinical use, and their future 
diagnostic utility remains questionable. Nonetheless, they remain the best available 
electrophysiological biomarker of CST function. In our study, we decided to measure 
CMCT as it is the only TMS-based marker which aims to assess UMN function in 
isolation, and its neural substrates are relatively well defined. 
 
 
1.5 Coherence analysis 
 
1.5.1 Motor system oscillations 
In the motor system, oscillations are widespread and occur across a broad range of 
frequencies (Table 1.2). Beta-band oscillations have been observed in M1 local field 
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potentials (LFPs) in monkeys (Figure 1.4 A; Baker et al., 1997; Murthy & Fetz, 1992; 
Sanes & Donoghue, 1993), and on electrocorticogram (ECoG; Ohara et al., 2000), 
electroencephalogram (EEG) (Halliday et al., 1998; Pfurtscheller, 1981; Pfurtscheller et 
al., 1996) and magnetoencephalogram (MEG; Conway et al., 1995; Salenius et al., 1997; 
Salmelin & Hari, 1994) in humans. They are also detectable on EMG in distal limb 
muscles (Figure 1.4 B). In all instances, they are task-dependent, being prominent 
during delay or hold phases and diminished during movement (Baker et al., 1997; 
Kilner et al., 1999; Sanes & Donoghue, 1993). 
 
Table 1.2: Oscillations in the motor system (adapted from Grosse et al., 2002, with 
additional input from Williams et al., 2010). 
 
Frequency Name(s) Origin Seen in 
2Hz Common drive Unknown Isometric contractions, slow 
movements 
5-12Hz Alpha Probably reticular formation, 
cerebellum and spinal cord 
Isometric contractions, slow 
movements, physiological 
tremor 
15-30Hz Beta Probably M1 Submaximal voluntary 
contractions 
30-60Hz Low gamma, 
Piper rhythm 
Probably M1 Strong voluntary 
contractions, slow 
movements 
60-100Hz High gamma Probably brainstem Eye movements, respiration 
 
1.5.2 Coherence 
Coupling of oscillations between the motor cortex and contralateral muscles can be 
quantified by coherence analysis. Coherence is a measure of linear correlation 
between two signals at a given frequency. It ranges from 0 to 1, indicating absolute 
linear independence and a perfect linear relationship respectively. As such, coherence 
is analogous to the correlation coefficient r2, except that it is interpreted as a function 
of frequency. 
 
Beta-band coherence between M1 and contralateral limb muscles (corticomuscular 
coherence, CMC) has been demonstrated in monkeys using LFPs (Figure 1.4 C; Baker et 
al., 1997) and in humans using ECoG (Ohara et al., 2000), EEG (Halliday et al., 1998; 
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Mima & Hallett, 1999) and MEG (Conway et al., 1995; Salenius et al., 1997). ECoG is 
invasive, MEG is only available in selected centres and EEG is suboptimal due to its low 
focality, modest signal-to-noise ratio and the low-pass characteristics of the skull and 
scalp, which might explain why beta-band coherence between EEG and EMG is not 
universally detectable in humans (Fisher et al., 2012; Ushiyama et al., 2011b). By 
contrast, beta-band coherence can be reliably found between pairs of muscles co-
activated in a task (Figure 1.4 D) or even between pairs of motor units in the same 
muscle (Farmer et al., 1993; Kilner et al., 1999), and such intermuscular or 
intramuscular coherence (IMC, IntraMC) is thought to reflect the same drive as CMC. 
 
 
 
Figure 1.4: Oscillations and coherence. LFP recorded from M1 of a monkey carrying 
out a precision grip task, along with position of the thumb and finger levers (A). 
Oscillations appear during the hold phase. LFP and rectified EMG from contralateral 
adductor pollicis on an expanded timebase (B). Bursts of EMG activity appear to be in 
phase with the cortical oscillations. Coherence between cortical LFP and EMG (C). A 
single peak is present at ca. 20Hz. The 15-30Hz beta-band is demarcated by the vertical 
green lines, and the dotted horizontal line indicates the significance level for 
coherence. Coherence between EMGs from adductor pollicis and FDI (D). A peak is 
visible at ca. 20Hz, although coherence lies above the significance level at all 
20 
 
frequencies shown, presumably due to electrical cross-talk between the muscles 
(adapted from Baker et al., 1997). Coherence between two motor units in FDI of a 
normal subject and a patient who suffered a contralateral capsular stroke four months 
before the recording (E; adapted from Farmer et al., 1993). Average coherence 
between EMGs from FDS and FDI in 16 normal control subjects and eight patients with 
PLS (F). Coherence between EMGs from biceps and FDI in a monkey three months after 
unilateral pyramidotomy above the medullary decussation, ipsilateral and 
contralateral to the lesion (G; adapted from Fisher et al., 2012). 
 
1.5.3 Origin of beta-band oscillations and coherence 
Primary motor cortex Beta-band oscillations reverse in phase as the cortex is 
traversed (Murthy & Fetz, 1992, 1996) and diminish once the white matter is 
entered (Steriade et al., 1996). In brain slices, similar oscillations are observed in layer 
V pyramidal cells, and are unaffected by a cut through layer IV, thus demonstrating 
their independence from apical dendritic electrogenesis (Roopun et al., 2006). These 
results suggest that beta-band oscillations are generated by neuronal networks in layer 
V which involve pyramidal cells. 
 
Corticospinal tract A variety of evidence suggests that beta-band oscillations are 
transmitted to the peripheries via the CST. Firstly, beta-band oscillations have been 
shown to be present in M1 pyramidal tract neurons (Baker et al., 2003). Secondly, 
beta-band coherence is abolished after damage to the descending motor tracts 
through capsular strokes (Figure 1.4 E; Farmer et al., 1993) and spinal cord lesions 
(Hansen et al., 2005; Norton et al., 2003). More selective damage to the CST, for 
example through primary lateral sclerosis in humans (Figure 1.4 F; Fisher et al., 2012) 
or experimental lesioning in monkeys (Figure 1.4 F; Fisher et al., 2012; Nishimura et al., 
2009), is similarly associated with absence of beta-band coherence. Thirdly, pyramidal 
tract stimulation resets the phase of cortical beta-band oscillations in monkeys 
(Jackson et al., 2002), implying that the CST is involved not only in the transmission but 
also in the generation of the beta rhythm. 
 
Afferent pathways If a cortical generator drives peripheral oscillations with a fixed 
conduction delay, the phase difference between oscillations in cortex and muscle 
should vary linearly with frequency, with a slope related to the delay (Rosenberg et al., 
1989). However, in some reports the phase difference was constant across a range of 
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frequencies (Halliday et al., 1998; Riddle & Baker, 2005; Witham et al., 2011) or the 
phase changed in a way which implied that oscillations in muscle lead those in the 
cortex (Grosse et al., 2003; Witham et al., 2011). These results are explicable in terms 
of bidirectional coupling between cortex and muscle. 
 
Three lines of evidence suggest that coherence is mediated by an efferent-afferent 
feedback loop. Firstly, beta-band coherence is markedly reduced by deafferentation, 
whether permanently through severe sensory neuropathy (Kilner et al., 2004), or 
reversibly through ischaemia of the forearm (Pohja & Salenius, 2003) or anaesthesia of 
the digital nerves, which are purely afferent (Fisher et al., 2002). Cooling of the upper 
limb slows conduction in both motor and sensory pathways, and the increase in 
conduction delay estimated from the phase-frequency slope is around twice the 
increase in motor conduction time, thus pointing towards the existence of a 
sensorimotor loop (Riddle & Baker, 2005). Secondly, beta-band oscillations can be 
observed in muscle spindle afferents (Baker et al., 2006) as well as in somatosensory 
and posterior parietal cortex (Graziadio et al., 2010; Murthy & Fetz, 1992, 1996; 
Witham et al., 2011; Witham et al., 2010; Witham et al., 2007), and these are coherent 
with similar oscillations in EMG and/or M1. Finally, coherence as a correlational 
measure does not allow determination of the direction of the interaction between two 
signals. By contrast, directed coherence (Granger causality) can do so, and suggests 
bidirectional corticomuscular coupling in monkeys (Witham et al., 2010) and humans 
(Witham et al., 2011). 
 
1.5.4 Function of coherence 
The function of beta-band oscillations and coherence has been controversial. 
 
A role analogous to sensory binding has been proposed. Oscillations might bind 
together either neuronal ensembles in the motor cortex that are involved in the same 
task (Conway et al., 1995), or areas of motor and somatosensory cortex to enable 
sensorimotor integration (Murthy & Fetz, 1992), but there is little evidence to support 
these hypotheses. Oscillations are abolished during movement, when binding would 
be expected to be most critical, but are prominent before and after. 
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In light of this, it has been suggested that oscillations could represent an ‘idling’ 
rhythm that occurs when the motor cortex is ‘resting’ before and after the demands of 
task execution. However, cortical oscillations depend on neuronal activity, which is 
metabolically demanding and would be a surprising feature of a resting state. The 
activity of pyramidal tract neurons remains elevated above baseline during the hold 
phase (Lemon et al., 1986), militating against a decrease in cortical activity. Finally, this 
theory would imply that oscillations in the somatosensory system are merely an 
epiphenomenon. 
 
A further hypothesis states that oscillations are an efficient mechanism for recruiting 
motor neurons with minimal corticospinal activity during sustained contractions (Baker 
et al., 1997). Again, this explanation does not encompass oscillations in the sensory 
pathways. 
 
Most recently, it has been suggested that oscillations might act as a ‘test pulse’ which 
drives peripheral feedback to allow recalibration of the sensorimotor system (Witham 
et al., 2011). This would plausibly explain the involvement of both motor and sensory 
pathways. In keeping with this hypothesis, coherence during a steady contraction 
increases with the degree of recalibration required after a preceding task. For example, 
larger displacements during the ramp phase of a precision grip task are associated with 
larger potential errors and greater coherence in a subsequent hold phase (Riddle & 
Baker, 2006). Similarly, a period of dynamic rather than static force matching is 
associated with increased coherence during a subsequent steady contraction, 
particularly if the pattern of the dynamic force is unpredictable (Omlor et al., 2011). 
Beta-band oscillations and coherence fluctuate during a prolonged steady contraction, 
and epochs of elevated coherence are associated with increases in beta-band tremor 
and reaction times (Gilbertson et al., 2005; Matsuya et al., 2013). Hence, brief bursts 
of beta-band oscillations would help to maintain sensorimotor precision whilst 
minimising the transient deterioration in motor performance that accompanies the 
calibration process. 
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1.6 Overview of this thesis 
 
MND presents across a broad age range. Potential markers of disease might be subject 
to age-related changes, and to investigate this possibility I recruited a large, age-
stratified cohort of healthy volunteers, which formed the basis for the experiments 
described in Chapters 2, 3 and 4. 
 
Many previous reports have considered how CMCT and PMCT vary with age, height or 
sex using single-variable regression models. In Chapter 2, I re-investigate these 
relationships using multiple regression modelling, and reconcile some past 
discrepancies. The resulting model allows a degree of individualisation of normal 
ranges. 
 
In Chapter 3, I demonstrate that the amplitude of beta-band IMC does not vary with 
age. However, IMC varies substantially between individuals; within a given individual, 
variability is greater in the long than in the short term. Possible strategies for 
dissecting the causes of variability are considered. 
 
It has been suggested that transcranial direct current stimulation (tDCS) might help to 
make IMC a more sensitive marker of CST dysfunction. In Chapter 4, I reproduce 
previously described effects of tDCS on IMC. Noting marked variability between 
subjects, I discuss how the size of the effect could be increased. The classically 
described effects of tDCS on MEPs remain elusive, and potential reasons are discussed. 
 
In Chapters 5 and 6, IMC and/or CMCT are measured in patients with neurological 
conditions and compared to the normal data gathered in Chapters 2 and 3. 
 
Chapter 5 describes that, in MND, IMC matches or exceeds the performance of CMCT 
as a potential marker of CST dysfunction. I consider further steps required to translate 
IMC into a clinical test. 
 
In Chapter 6, IMC is measured in other neurological conditions affecting different parts 
of the motor system in order to illuminate the relative contribution of these parts to 
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IMC generation. One issue is that individual conditions may have affected more than 
one part of the motor system, and computational modelling of coherence is suggested 
as a complementary approach. 
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2  Central and peripheral motor conduction times in normal adults 
   
  For almost three decades, magnetic stimulation has been used to examine 
central and peripheral motor conduction times. Many studies have reported 
simple regression models involving predictors such as age, height and sex, 
often arriving at conflicting results. Here, I formulate a multiple regression 
model based on data from a large normal cohort, and attempt to reconcile 
previous contradictions. 
 
 
2.1 Abstract 
 
Objective: To analyse the effects of age, height and sex on central and peripheral 
motor conduction times (CMCT, PMCT) by means of a multiple regression model. 
 
Methods: Motor evoked potentials were recorded from upper and lower limb muscles 
in 91 healthy volunteers stratified by age. Magnetic stimulation was performed over 
the primary motor cortex (cortical latency) and over the cervical and lumbar spine 
(spinal latency). The spinal latency was taken as an estimate of PMCT, and was 
subtracted from cortical latency to yield CMCT. 
 
Results: Lower limb CMCT significantly correlated with height only; there were no 
significant predictors for upper limb CMCT. Upper and lower limb PMCT correlated 
with both age and height. 
 
Conclusions: To our knowledge, this is the first study applying a multiple regression 
model to CMCT data. Our results are in keeping with reported simple regression 
models, and condense their hitherto separate findings into a unified model. The model 
presented allows normal ranges to be individualised, thereby potentially improving the 
diagnostic performance of clinical central motor conduction studies. 
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2.2 Introduction 
 
The function of the corticospinal tract (CST) can be assessed non-invasively using 
magnetic stimulation. Central motor conduction time (CMCT) has emerged as the most 
reliable parameter (Chen et al., 2008; Claus, 1990; Di Lazzaro et al., 1999), and 
estimates the conduction time from the primary motor cortex (M1) to spinal motor 
neurons. Magnetic stimulation is performed over M1 to measure the cortical latency 
for the target muscle; CMCT is then calculated by subtracting an estimate of the 
peripheral motor conduction time (PMCT). Clinical CMCT studies commonly estimate 
PMCT using magnetic stimulation of the spinal roots as this is well tolerated and avoids 
the use of a further stimulation modality. We therefore adopted this method for the 
present study. 
 
Normal ranges of CMCT have been described in several past reports (Table 2.1). The 
set of muscles examined was usually small and varied between studies, and results are 
only in partial agreement where comparisons are possible. Contributing factors may 
include small study populations and methodological discrepancies, particularly 
regarding the type of stimulator and coil used. Additionally, the lower limb 
representation of M1 was stimulated with a circular coil, whereas a double cone coil is 
probably better suited to this task, especially for distal muscles (Groppa et al., 2012; 
Terao et al., 1994). 
 
Previous studies have also considered the effect of age, height and sex on CMCT. 
Statistical methods ranged from comparisons between discrete groups (Dvorak et al., 
1991; Eisen & Shtybel, 1990; Kloten et al., 1992; Mano et al., 1992; Mills & Nithi, 1997b; 
Rossini et al., 1992) to correlation and regression analysis with individual predictors 
(Chu, 1989; Claus, 1990; Dvorak et al., 1990; Furby et al., 1992; Garassus et al., 1993). 
Multiple regression modelling is required to take into account any cross-correlations 
between the predictors age, height and sex (e.g. young male subjects being taller on 
average than older female ones). This approach has been applied to somatosensory 
evoked potentials (SEP; Allison et al., 1983; Chu, 1986; Dorfman & Bosley, 1979) but 
not, to our knowledge, to CMCT. 
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Table 2.1: Previously reported normal CMCT and PMCT data (mean±SD). Studies have only been included if a facilitatory background contraction was 
maintained during cortical stimulation and if PMCT was estimated using magnetic root stimulation. All used circular coils in conjunction with the 
stimulators listed, but other methods – including coil size – were described in variable detail and cannot be compared easily. Results are limited to 
the set of muscles considered in the present study; we did not find any reported data for FDS. Where comparisons are possible, results often agree 
only partially; potential causes include small study populations and methodological differences. Two studies categorised some results by age or 
height without giving pooled data so results are listed separately for each group (Dvorak et al., 1991; Kloten et al., 1992). One report provided an 
upper limit of normal as mean+3SD without individually stating the mean or SD (Di Lazzaro et al., 1999), and another one specified only CMCT but 
not PMCT (Eisen & Shtybel, 1990). (NS=not specified) 
 
 Muscle CMCT (ms) PMCT (ms) Stimulator n Reference 
Upper limb APB 6.88±0.56 13.12±1.35 Magstim 200 30 Abbruzzese et al. (1993) 
  8.0±1.2 13.1±1.0 Own design 27 Barker et al. (1987) 
  5.2±0.6 15.6±1.2 Dantec or Magstim 200 53 Dvorak et al. (1990) 
  6.7±1.2 NS Dantec 95 Eisen and Shtybel (1990) 
  6.73±1.01 13.58±0.98 Magstim 200 30 Garassus et al. (1993) 
  6.7±1.7 (age 31.2±16.8) 
6.3±1.0 (age 78.7±4.8) 
11.1±0.7 (age 31.2±16.8) 
11.7±0.9 (age 78.7±4.8) 
Own design 14 
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Mano et al. (1992) 
  8.0±1.2 11.8±1.0 Own design 30 Ugawa et al. (1990) 
 FDI 6.0±1.0 14.6±1.3 Magstim 200 57 Bischoff et al. (1993) 
  5.8±1.0 (age ≤29) 
6.0±0.9 (age 30-59) 
6.5±1.1 (age ≥60) 
14.0±1.3 
14.6±1.3 
14.9±1.4 
Magstim 200 57 Kloten et al. (1992) 
 EDC 5.6±0.9 9.1±0.8 Magstim 200 57 Bischoff et al. (1993) 
  6.4±1.2 NS Dantec 42 Eisen and Shtybel (1990) 
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 Muscle CMCT (ms) PMCT (ms) Stimulator n Reference 
Lower limb EDB 13.4±1.7 (pooled) 23.9±2.0 (height 150-174cm) 
25.4±1.9 (height 175-191cm) 
Dantec or Magstim 200 46 Dvorak et al. (1991) 
  14.53±1.50 21.71±1.92 Magstim 200 30 Garassus et al. (1993) 
  15.7±2.4 (age ≤29) 
15.9±2.0 (age 30-59) 
18.2±3.9 (age ≥60) 
24.8±1.8 
23.3±2.6 
23.9±2.8 
Magstim 200 57 Kloten et al. (1992) 
 AH 16.7±2.4 24.5±2.1 Own design 27 Barker et al. (1987) 
  15.9±2.0 24.3±2.6 Magstim 200 57 Bischoff et al. (1993) 
  18.2 (mean+3SD) 30.1 (mean+3SD) Magstim 200 30 Di Lazzaro et al. (1999) 
  16.9±0.9 23.3±2.5 Magstim 200 15 Di Lazzaro et al. (2004) 
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 Muscle CMCT (ms) PMCT (ms) Stimulator n Reference 
 TA 14.35±0.85 11.73±1.37 Magstim 200 30 Abbruzzese et al. (1993) 
  14.3±1.7 14.7±1.8 Magstim 200 57 Bischoff et al. (1993) 
  14.8±1.1 11.7±1.1 Magstim 200 52 Chu (1989) 
  17.1 (mean+3SD) 16.1 (mean+3SD) Magstim 200 30 Di Lazzaro et al. (1999) 
  12.8±1.4 (height 150-174cm) 
14.0±1.3 (height 175-191cm) 
16.1±2.3 (pooled) Dantec or Magstim 200 46 Dvorak et al. (1991) 
  13.8±1.5 12.3±1.2 Magstim 200 50 Furby et al. (1992) 
  14.23±1.71 13.22±1.19 Magstim 200 30 Garassus et al. (1993) 
  13.4±1.9 (age ≤29) 
14.3±1.7 (age 30-59) 
16.1±1.9 (age ≥60) 
14.7±1.3 
14.7±2.1 
15.5±2.0 
Magstim 200 57 Kloten et al. (1992) 
  14.6±1.2 11.5±0.9 Magstim 200 51 Matsumoto et al. (2010) 
  14.7±1.3 11.5±1.1 Magstim 200 100 Matsumoto et al. (2012) 
  15.3±1.0 12.7±1.6 Own design 30 Ugawa et al. (1990) 
 MG 14.2±1.5 13.4±1.0 Magstim 200 57 Bischoff et al. (1993) 
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Here, we sought to clarify the effects of age, height and sex on CMCT using a stepwise 
multiple regression model in a large study population stratified by age. PMCT data 
were modelled likewise. We employed modern equipment and routine clinical 
methods, including the use of standard circular and double cone coils to stimulate the 
upper and lower limb representations of M1 respectively. Lower limb CMCT was 
correlated significantly with height, whereas there were no significant predictors for 
upper limb CMCT. Upper and lower limb PMCT correlated significantly with age and 
height but not sex. Regression models and normal ranges are described. 
 
 
2.3 Methods 
 
2.3.1 Subjects 
At least 15 volunteers were recruited for each decade of age between 20 and 80 (50 
men and 41 women). Age and height averaged 48.9±17.3 years (SD; range 22-77) and 
171.0±9.6cm (range 155.0-188.0) respectively. Eighty-two subjects were right-handed 
and 9 left-handed as assessed by self-reporting. None had any history of neurological 
disorders or diabetes mellitus, or any contraindications to magnetic stimulation, and 
none took any neurotropic medication. All subjects provided written informed consent. 
The study was approved by the research ethics committee of Newcastle University’s 
Medical Faculty, and conformed to the Declaration of Helsinki. 
 
2.3.2 Recording 
Every effort was made to maintain subjects at a constant level of alertness, and all 
assessments were carried out on the dominant side. Subjects were seated in a 
comfortable chair with their arm resting on a cushion. Surface EMG was recorded from 
abductor pollicis brevis (APB), first dorsal interosseous (FDI), flexor digitorum 
superficialis (FDS) and extensor digitorum communis (EDC) in the upper limb, and 
extensor digitorum brevis (EDB), abductor hallucis (AH), tibialis anterior (TA) and 
medial gastrocnemius (MG) in the lower limb. Adhesive electrodes (Bio-Logic M0476; 
Natus Medical, Mundelein, IL) were placed in a belly-tendon montage over the intrinsic 
muscles of the hand or foot; for the long muscles of the forearm or calf, the electrodes 
were placed 4cm apart, one third along the muscle from its proximal origin. Signals 
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were amplified, band-pass filtered (30Hz-2kHz; Digitimer D360, Digitimer, Welwyn 
Garden City, UK) and digitised at 5kHz (Micro1401, Cambridge Electronic Devices, 
Cambridge, UK). 
 
2.3.3 Stimulation 
Magnetic stimulation was delivered using a Magstim 200 stimulator (Magstim 
Company, Whitland, UK) at a frequency of 0.2Hz. For upper limb cortical motor evoked 
potentials (MEPs), a circular coil (13cm outer diameter) was held over the vertex, with 
its orientation optimised for stimulation of the dominant hemisphere (A side up: left 
hemisphere, B side up: right hemisphere). For lower limb cortical MEPs, a double cone 
coil was used in an analogous manner (posterior coil current: left hemisphere, anterior 
coil current: right hemisphere). Stimulation intensity was set at 10% of maximum 
stimulator output above the resting motor threshold as defined by the Rossini-
Rothwell method (Rossini et al., 1994). Cortical MEPs are facilitated and their onset 
latencies minimised by a weak background contraction of the target muscle, with no 
requirement for strictly controlling the force of the contraction (Chen et al., 2008; 
Kimura, 2001). Ten MEPs were recorded in the upper limb during opposition of index 
finger and thumb, and in the lower limb during either dorsiflexion (EDB, TA) or 
plantarflexion (AH, MG) of ankle and toes. Upper and lower limb root MEPs were 
recorded at rest with the circular coil centred over the spinous processes of C7 and L1. 
The range of stimulation intensities used was 35-80% and 40-100% for cortical MEPs of 
the upper and lower limbs respectively, and 40-90% and 40-100% for corresponding 
root MEPs. 
 
2.3.4 Data analysis 
Analysis was performed in Matlab (Mathworks, Natick, MA) using custom scripts. The 
shortest onset latency for each set of ten MEPs was assigned interactively. In the 
presence of a background contraction, the earliest deflection of the MEP with the 
shortest latency was often ambiguous on superimposed raw traces because of 
background EMG activity, but could be easily identified on averages of rectified MEPs 
(Figure 2.1). Hence, such averages were used for assigning latencies throughout. 
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Figure 2.1: Single-subject cortical (A) and root MEPs (B) in APB. For each site of 
stimulation, two types of trace are shown: ten superimposed raw sweeps (top) and an 
average of rectified sweeps (bottom). For cortical MEPs, which were recorded in the 
presence of a background contraction, the earliest deflection of the MEP with the 
shortest latency was frequently ambiguous on superimposed raw traces, but could be 
easily identified on the average of rectified MEPs. All latencies (dashed lines) were 
assigned using such averages. 
 
Stepwise multiple regression models were constructed for all CMCT and PMCT using 
age, height and sex as potential predictors (‘stepwise’ command in Matlab). Each step 
involved evaluating the residuals of the model and the associated probability for each 
predictor, and moving a single predictor into or out of the model as recommended by 
the interactive tool. Significance thresholds were set at ≤0.05 for a predictor to enter 
the model and at ≥0.10 for it to be removed. The model was deemed complete when 
no further movement of predictors was recommended. 
 
 
2.4 Results 
 
One subject did not tolerate lower limb cortical MEPs, but all remaining subjects 
completed all parts of the protocol. 
 
Means, standard deviations and regression models are presented numerically in Table 
2.2. For a given latency measurement (CMCT or PMCT) and within a given limb, the 
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same predictors were found to be significant across all muscles. Figures 2.2 and 2.3 
display results for APB and EDB as examples of upper and lower limb muscles. 
 
2.4.1 CMCT 
Upper limb CMCT was not significantly related to any of the potential predictors (Table 
2.2, Figure 2.2 A-C). 
 
Lower limb CMCT showed a significant positive relationship with height; there was no 
significant relationship with age or sex. The regression models accounted for 
approximately 5-12% of the variance observed (r2, Table 2.2). The model for EDB is 
shown in Figure 2.2 E along with 95% confidence and prediction intervals. 
 
2.4.2 PMCT 
Upper and lower limb PMCT was significantly and positively related to age and height. 
There was no significant relationship with sex. The regression models explained 
approximately 19-53% of the variance observed (Table 2.2). Figures 2.3 A and 2.3 C 
illustrate the regression model on a plot of PMCT against age and height. The shaded 
plane represents the model prediction, with the vertical lines showing the residuals of 
individual data points above (black) and below the plane (red). In order to keep the 
plot easily interpretable, 95% confidence and prediction intervals are only shown for 
the upper extremes of age and height. 
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Figure 2.2: Scatterplots of CMCT to APB (A-C) and EDB (D-F) against age (A, D) and 
height (B, E), and dot plots of CMCT against sex (C, F). CMCT to APB was not 
significantly related to any of the predictors. CMCT to EDB was significantly related to 
height but not age or sex; the corresponding regression model is shown (CMCT to 
EDB=0.1055*height - 3.40, r2=0.1225, p<0.001) together with 95% confidence (dotted 
lines) and prediction intervals (dashed lines). 
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Figure 2.3: 3D scatterplots of PMCT to APB and EDB against age and height (A, C), and 
dot plots of PMCT against sex (B, D). PMCT in both muscles was significantly related to 
age and height but not sex. The shaded plane shows the regression model (PMCT to 
APB=0.0560*age + 0.0881*height - 3.28, r2=0.4318, p<0.001; PMCT to EDB= 
0.1214*age + 0.2106*height - 17.97, r2=0.4819, p<0.001). Vertical lines indicate the 
residuals of individual data points above (black) and below the plane (red). Examples 
of 95% confidence (dotted lines) and prediction intervals (dashed lines) are shown for 
the upper extremes of age and height. 
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Table 2.2: Means, standard deviations (SD) and regression models for CMCT and PMCT in muscles of upper and lower limbs in this study (A=age, 
H=height). For upper limb CMCT, no significant regression model could be formulated (NA=not applicable). The proportion of variance explained by 
the model (r2) was 5-12% for lower limb CMCT, 19-48% for lower limb PMCT, and 25-53% for upper limb PMCT. 
 
 Muscle  CMCT      PMCT     
   Mean±SD (ms) Regression model SD of residuals (ms) r2 p  Mean±SD (ms) Regression model SD of residuals (ms) r2 p 
Upper limb APB  7.2±1.6 NA NA NA NA  14.5±1.6 0.0560*A + 0.0881*H - 3.28 1.10 0.432 <0.001 
 FDI  7.2±1.4 NA NA NA NA  15.2±1.6 0.0549*A + 0.1082*H - 6.03 1.21 0.526 <0.001 
 FDS  7.7±2.0 NA NA NA NA  8.7±1.2 0.0373*A + 0.0412*H - 0.18 1.00 0.291 <0.001 
 EDC  6.7±1.7 NA NA NA NA  9.3±1.2 0.0340*A + 0.0483*H - 0.62 1.08 0.250 <0.001 
Lower limb EDB  14.6±2.9 0.1055*H - 3.40 2.74 0.123 <0.001  23.9±3.5 0.1214*A + 0.2106*H - 17.97 2.49 0.482 <0.001 
 AH  16.0±3.3 0.0801*H + 2.29 3.16 0.057 0.024  25.8±4.0 0.0938*A + 0.2133*H - 15.22 3.37 0.293 <0.001 
 TA  14.5±2.7 0.0919*H - 1.23 2.57 0.107 0.002  13.7±2.4 0.0648*A + 0.0769*H - 2.63 2.07 0.227 <0.001 
 MG  15.3±3.7 0.0813*H + 1.43 3.62 0.045 0.044  15.1±3.3 0.0856*A + 0.0964*H - 5.56 2.99 0.194 <0.001 
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2.5 Discussion 
 
In this study, we investigated the relationship of CMCT and PMCT with three potential 
predictors chosen for their ready availability. We found that lower limb CMCT 
depended on height only and that upper limb CMCT was not significantly related to 
any of the predictors. By contrast, upper and lower limb PMCT both depended on age 
and height. For each type of latency, the same predictors were consistently significant 
across all muscles of a given limb, which increases confidence in the individual findings. 
 
2.5.1 Methods for PMCT estimation 
Several methods are available for estimating PMCT, and the approach used must be 
borne in mind when comparing the corresponding CMCT readings between studies. 
Magnetic (Maccabee et al., 1991; Ugawa et al., 1989) or electrical stimulation (Mills & 
Murray, 1986) over the vertebral column excites spinal roots near the exit foramina 
and the MEP latency provides an estimate of PMCT. The conduction time along the 
proximal root segments is not included in PMCT and remains part of CMCT (often 
called CMCT-M). This peripheral component of CMCT is particularly pronounced in the 
lower limbs where a greater length of the roots is located within the spinal canal. 
 
Alternatively, PMCT can be estimated using F-wave latencies from electrical 
stimulation of peripheral nerves (Kimura, 2001). Such PMCT values include the 
conduction time along the proximal root segments; corresponding CMCT readings 
(often called CMCT-F) are shorter and reflect a purer measure of CST conduction than 
those obtained using root stimulation. Drawbacks of F-wave latencies include a high 
intertrial variability and the assumption of a fixed turnaround time of 1ms, which does 
not take into account that the regenerative volley might be slowed by travelling along 
a partially refractory axon (Rossini & Pauri, 2002). In addition, a different population of 
motor neurons, at different ends of the conduction velocity spectrum, may be 
recruited by the F-wave and cortical MEPs (Olivier et al., 2002). 
 
Using a special (magnetic augmented translumbosacral stimulation, MATS) coil, one 
group has selectively stimulated either the lumbosacral nerve roots near the exit 
foramina – akin to conventional magnetic root stimulation – or the conus medullaris 
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within the spinal canal (Matsumoto et al., 2009a; Matsumoto et al., 2009b). This 
makes it possible to estimate the latency from cortex to conus (cortico-conus 
conduction time) and the peripheral component of CMCT-M (cauda equina conduction 
time). However, two lines of evidence suggest that the MATS coil excites spinal roots 
at a more distal point than standard coils, thus increasing the peripheral component of 
CMCT-M. Firstly, MATS-based root latencies are relatively low and corresponding 
CMCT-M readings relatively high compared to results obtained with conventional coils 
(Table 2.1; Matsumoto et al., 2010; Matsumoto et al., 2012). Secondly, root latencies 
are 0.9ms shorter than for electrical root stimulation, equivalent to a distance of about 
4.5cm if a nerve conduction velocity of 50m/s is assumed (Matsumoto et al., 2009a). In 
the same study, root stimulation was also performed with standard coils but latencies 
were unfortunately not compared between different coil types. Hence, CMCT-M 
determined using MATS-based root latencies cannot easily be compared to data 
obtained using conventional coils.  
 
2.5.2 CMCT and height 
Our finding of a significant relationship between lower limb CMCT-M and height is in 
agreement with several previous studies which described similar results in some 
(Dvorak et al., 1991) or all muscles under investigation (Chu, 1989; Claus, 1990; Furby 
et al., 1992); one study reported a trend which did not reach significance (Garassus et 
al., 1993). Furthermore, our regression model for TA (CMCT=0.0919*height - 1.23) 
concurs with those previously published, particularly regarding the coefficient for 
height (CMCT=0.08*height - 0.73, p<0.001, Claus et al., 1990; CMCT=0.083*height - 
0.47, p<0.0001, Furby et al., 1992). 
 
It has been suggested that this relationship might be attributable to the peripheral 
component of CMCT-M. If this were the case, no such relationship should exist for 
CMCT-F. Whilst several studies have reported both CMCT-M and CMCT-F, few have 
considered how both types of CMCT might differ in their relationship with height. In 
one report, CMCT-M was related to height in one of three muscles whereas CMCT-F 
was not (Dvorak et al., 1991); another study described a significant correlation of 
CMCT-M with height without commenting on CMCT-F data (Furby et al., 1992); and a 
further one did not make it clear whether both types of CMCT were analysed in a 
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separate or pooled fashion (Garassus et al., 1993). Recently, a study described height 
to be uncorrelated to lower limb cortico-conus conduction time whilst being 
significantly correlated to CMCT-M and cauda equina conduction time (Matsumoto et 
al., 2010). However, the use of a MATS coil for root stimulation would have 
exaggerated the peripheral component of CMCT-M. It therefore remains unclear to 
what extent the peripheral component underlies the correlation of height and 
conventional lower limb CMCT-M. This could be addressed with a study in which the 
conus is stimulated with a MATS coil and the roots with a standard coil, thus allowing 
measurement of cortico-conus conduction time as well as true conventional CMCT-M 
and its peripheral component. 
 
There is consensus that upper limb CMCT does not correlate with height (Chu, 1989; 
Claus, 1990; Dvorak et al., 1990; Furby et al., 1992; Garassus et al., 1993). This may be 
because of the shorter proximal root segments in the cervical spine, because height 
relates less strongly to the length of the CST to the upper limb (Chu, 1989; Claus, 1990), 
or both. 
 
2.5.3 CMCT and age 
The effect of age on CMCT is controversial. We observed no correlation between age 
and CMCT-M, and this concurs with six past reports which each measured both 
CMCT-M and CMCT-F and found neither of them to be significantly related to age 
(Claus, 1990; Dvorak et al., 1990; Dvorak et al., 1991; Garassus et al., 1993; Mano et al., 
1992; Rossini et al., 1992). However, three other studies reported a significant positive 
relationship. The first employed a MATS coil, and whilst cortico-conus conduction time 
did not correlate with age, CMCT-M and cauda equina conduction time did. The 
reported correlation of CMCT-M with age is explicable in terms of an exaggerated 
peripheral component (Matsumoto et al., 2012). A second investigation calculated 
PMCT from F-wave latencies in such a way that a peripheral component of unclear 
magnitude remained part of the CMCT-F (Eisen & Shtybel, 1990; Matsumoto et al., 
2012). The final study compared CMCT-M in two muscles between three groups of 
different ages which had been matched for height, but did not make any adjustment 
for multiple comparisons (Kloten et al., 1992). Thus, where a significant relationship 
between CMCT and age was reported, this could usually be attributed to an increased 
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peripheral component. By contrast, the peripheral component of conventional 
CMCT-M appears to be sufficiently small to avoid giving rise to a significant 
relationship. 
 
2.5.4 CMCT and sex 
Similar to our findings, previous investigations found CMCT to be unaffected by sex 
(Dvorak et al., 1990; Kloten et al., 1992), or any differences between males and 
females were attributed to height differences between the sexes (Chu, 1989; Dvorak et 
al., 1991; Furby et al., 1992; Mills & Nithi, 1997b). 
 
2.5.5 PMCT 
It is well known that age and height are negatively correlated with peripheral nerve 
conduction velocities and positively correlated with distal motor and F-wave latencies, 
whereas sex is generally not thought to be a significant predictor (Kong et al., 2010; 
Rivner et al., 2001). Similarly, PMCT is related to age (Dvorak et al., 1991; Kloten et al., 
1992; Mano et al., 1992; Matsumoto et al., 2012) and height (Chu, 1989; Dvorak et al., 
1991; Furby et al., 1992). The proportion of variance explained by our model (r2) was 
greater for PMCT than for CMCT. We are not aware of any previous multiple regression 
models for PMCT, but the proportion of variance explained by our model for PMCT is 
in broad agreement with values reported for multiple regression models of related 
peripheral conduction parameters (Kong et al., 2010; Rivner et al., 2001). 
 
The relationship between PMCT and height is readily explained by the strong 
correlation between height and limb length and thus length of the peripheral nerves 
(Chu & Hong, 1985). The observation that PMCT but not CMCT correlates with age 
might be attributable to the greater exposure of peripheral nerves to minor trauma 
and injuries (Matsumoto et al., 2012). Indeed, ageing is not only known to cause 
subclinical peripheral nerve lesions at common entrapment sites (Cruz Martinez et al., 
1978), but also leads to progressive loss of motor units, particularly affecting the 
largest and fastest units (Wang et al., 1999). 
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2.5.6 Clinical application 
In clinical practice, numerical results are typically compared to normal ranges or cut-
off values, which constitutes fixed-level testing at a pre-determined significance level. 
Here, an appropriate cut-off would be the upper bound of a chosen prediction interval. 
The bound can be approximated by evaluating the regression model with the 
parameters of the patient and adding q1-α/2 standard deviations, where α is the desired 
significance level and q is the inverse of the normal cumulative distribution function. 
For example, a 95% prediction interval has α=0.05 and q1-α/2=q0.975=1.960; this upper 
bound would be exceeded by α/2=0.025=2.5% of normal readings. 
 
Alternatively, we can evaluate the probability of observing a latency at least as high as 
that of the patient, under the null hypothesis that the latency of the patient is normal. 
The regression model is evaluated with the parameters of the patient, and a Z-score 
calculated as Z=(actual result - regression result)/(standard deviation of residuals). The 
corresponding probability is then computed as ϕ(-|Z|), where ϕ is the cumulative 
normal distribution. 
 
The data provided allow either approach to be implemented easily; we have 
deliberately not provided prescribed cut-off values as they would force the reader into 
fixed-level testing with a chosen significance level. 
 
 
2.6 Conclusion 
 
This is one of the largest studies of CMCT-M in normals and, to our knowledge, the 
only one to employ multiple regression modelling. Such an approach was applied to 
somatosensory evoked potentials more than three decades ago. Its application to MEP 
data was long overdue and has shed some light on longstanding controversies 
surrounding the effects of age and height on CMCT. In addition, the model is able to 
account for 5-12% (CMCT) or 19-53% (PMCT) of variance. Paired with side-to-side 
comparisons within a given subject, this should boost the diagnostic accuracy and 
precision of CMCT-M. MATS coils constitute a promising development in CST 
assessment, and cortico-conus conduction time might ultimately replace CMCT-M in 
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CST assessment. However, when using a MATS coil for root stimulation, the resultant 
CMCT-M are not wholly comparable to results obtained using conventional coils. 
Previously reported inferences about conventional CMCT-M must therefore be viewed 
with caution.  
  
 43 
 
3  Intermuscular coherence in normal adults: variability and changes with age 
   
  The effect of aging on coherence is controversial, and previous studies suggest 
that coherence can vary considerably between and within subjects. In this 
chapter, I seek to clarify whether intermuscular coherence changes across 
adulthood, and consider its short- and long-term variability. 
 
 
3.1 Abstract 
 
Objective: To examine changes in beta-band intermuscular coherence (IMC) across 
adulthood, and to analyse variability between and within subjects. 
 
Methods: 92 healthy volunteers were recruited, stratified by decade of age. In the 
dominant upper limb, IMC was estimated between extensor digitorum communis (EDC) 
and first dorsal interosseous (FDI) as well as between flexor digitorum superficialis 
(FDS) and FDI. In the ipsilateral lower limb, IMC was measured between medial 
gastrocnemius (MG) and extensor digitorum brevis (EDB) as well as between tibialis 
anterior (TA) and EDB. Age-related changes in IMC were analysed with age as a 
continuous variable or binned by decade. We analysed intrasession variance of IMC by 
dividing sessions into pairs of epochs and comparing coherence estimates between 
these pairs. Eight volunteers returned for a further session after one year, allowing us 
to compare intrasession and intersession variance. 
 
Results: We found no age-related changes in IMC amplitude across almost six decades 
of age. Interindividual variability ranged over two orders of magnitude. Intrasession 
variance was significantly greater than expected from statistical variability alone, and 
intersession variance was even larger. 
 
Conclusion: The lack of age-related variability allowed us to pool results across all ages 
into an aggregate normative dataset. Variability between and within individuals was 
considerable, and we propose potential causes. With variability being critical to future 
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applications of IMC as a biomarker, we propose several experiments that should help 
to define the causes of variability so that it potentially can be minimised. 
 
 
3.2 Introduction 
 
Oscillations in the beta-band (15-30Hz) have been demonstrated in the motor systems 
of monkeys (Murthy & Fetz, 1992) and humans (Ohara et al., 2000; Pfurtscheller, 1981; 
Salmelin & Hari, 1994). During sustained contractions, these oscillations are coherent 
between sensorimotor cortex and contralateral muscles (corticomuscular coherence, 
CMC; Baker et al., 1997; Conway et al., 1995; Halliday et al., 1998; Ohara et al., 2000). 
Coherence is also demonstrable between different co-contracting muscles within the 
same limb (intermuscular coherence, IMC; Baker et al., 1997) and between different 
single motor units in a given muscle (intramuscular coherence, IntraMC; Farmer et al., 
1993). Whilst measured between different pairs of signals, CMC, IMC and IntraMC are 
thought to reflect the same central coupling mechanism. Initially hypothesised to be a 
purely efferent, corticofugal phenomenon mediated by the corticospinal tract (CST; 
Baker et al., 2003), beta-band coherence has been increasingly documented to depend 
on afferent pathways, leading to the current concept of an underlying efferent-
afferent feedback loop (Witham et al., 2011; Witham et al., 2010). 
 
Several recent studies have investigated the development of coherence during 
childhood and its potential alteration in old age. There is agreement that beta-band 
CMC (Graziadio et al., 2010; James et al., 2008) and IMC (Farmer et al., 2007) are 
absent in infancy and develop during the early teenage years, probably in parallel to 
the rising capacity for fractionated movement (Gibbs et al., 1997). Although the CST 
establishes functional monosynaptic projections onto spinal motor neurons before 
birth (Eyre et al., 2000) and becomes fully myelinated by two years of age (Eyre et al., 
1991), the patterning of the corticospinal drive only completes during adolescence 
(Farmer et al., 2007) when maturation of GABAergic systems leads to increased 
intracortical inhibition (Mall et al., 2004). Computational models suggest that 
inhibitory mechanisms are critical to oscillatory activity (Pauluis et al., 1999) and thus 
to the emergence of coherence.  
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The extent and nature of senescent changes in coherence are controversial. One study 
reported that beta-band CMC shows a single peak at 23Hz in young adults which is 
replaced by multiple peaks at lower or higher frequencies in the elderly (Graziadio et 
al., 2010). Other reports described age-related decreases but not increases in the peak 
frequency of CMC (Kamp et al., 2013) or IntraMC (Semmler et al., 2003). A similar lack 
of agreement applies to peak coherence amplitude, which was reported either to 
remain unchanged (Graziadio et al., 2010; Semmler et al., 2003) or to increase with 
age (Kamp et al., 2013). These divergent results are not easily reconciled. Motor 
function is known to deteriorate in old age (Incel et al., 2009; Krampe, 2002; Seidler et 
al., 2010). Several potential substrates have been proposed, including decreases in 
neuronal size (Haug & Eggers, 1991), dendritic arborisation (Anderson & Rutledge, 
1996) and synaptic density (Huttenlocher, 1979) in the cortical grey matter, reduced 
intracortical inhibition (Peinemann et al., 2001), diminished white matter volume (Raz 
& Rodrigue, 2006) with accumulation of leukoaraiosis on MRI (Moscufo et al., 2011), a 
decline in peripheral motor and sensory conduction velocities (Kong et al., 2010; 
Rivner et al., 2001) and remodelling of motor units (Rods et al., 1997). It is unclear 
whether coherence is sensitive to these morphological and functional changes; indeed, 
CMCT proved surprisingly robust to them (Chapter 2). However, two factors which 
might plausibly affect coherence in old age are decreased intracortical inhibition and 
prolonged conduction delays in the efferent-afferent loop. 
 
We are aware of only two studies which have investigated the variability of coherence 
within subjects. One study compared pairs of CMC measurements from either the 
same session (‘intrasession’) or two sessions separated by one year (‘intersession’) in 
ten subjects (Pohja et al., 2005). In the intrasession comparison, frequency and 
amplitude of the 15-30Hz CMC peak were each strongly correlated between both 
measurements. Equivalent correlations were weaker for the intersession condition, 
with the amplitude of coherence varying by 17-220% in individual subjects. In one 
subject, CMC was estimated eight times over a 20 month interval, demonstrating 
relative constancy of the frequency of the CMC peak but marked variation in its 
amplitude. Unfortunately, correlation analysis constitutes a suboptimal approach as it 
fails to exploit known distributional properties of intraindividual differences in 
coherence. The second study assessed CMC three times in a single subject over the 
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course of two years (Witham et al., 2011). Peak amplitude of CMC showed substantial 
variability, accompanied by changes in the directionality of CMC within the efferent-
afferent loop. 
 
Here, we aimed to define age-related changes in beta-band IMC in a large, age-
stratified sample of adults. In a subset, we analysed the variability of IMC within and 
between sessions using dedicated statistical methods. IMC requires only a single 
recording modality and is present more consistently than CMC in healthy subjects 
(Ushiyama et al., 2011b). Our task involved minimal instrumentation and weak, phasic 
contractions, optimising applicability of IMC as a biomarker of CST function in patients 
with neurological deficits (Fisher et al., 2012). We found that IMC did not change 
significantly over almost six decades of adulthood. There was considerable between-
subject variability; within a given subject and session, variability was larger than 
statistically expected, and between sessions variability was even greater. We propose 
experimental approaches for dissecting the causes of variability. 
 
 
3.3 Methods 
 
3.3.1 Subjects 
At least 15 volunteers were recruited for each decade of age between 20 and 80 (51 
men and 41 women); age averaged 48.6±17.2 years (SD; range 22-77). Eighty-three 
subjects were right-handed and nine left-handed as assessed by self-reporting. None 
had any history of neurological disorders or diabetes mellitus, and none took any 
neurotropic medication. All subjects provided written informed consent. The study 
was approved by the research ethics committee of Newcastle University’s Medical 
Faculty, and conformed to the Declaration of Helsinki. 
 
3.3.2 Recording 
Every effort was made to maintain subjects at a constant level of alertness, and all 
assessments were carried out on the dominant side. Subjects were seated in a 
comfortable chair with their arm resting semi-pronated on a cushion. Surface EMG was 
recorded from first dorsal interosseous (FDI), flexor digitorum superficialis (FDS) and 
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extensor digitorum communis (EDC) in the upper limb, and extensor digitorum brevis 
(EDB), tibialis anterior (TA) and medial gastrocnemius (MG) in the lower limb. Adhesive 
electrodes (Bio-Logic M0476; Natus Medical, Mundelein, IL) were placed in a belly-
tendon montage over the intrinsic muscles of the hand or foot; for the long muscles of 
the forearm or calf, the electrodes were placed 4cm apart, one third along the muscle 
from its proximal origin. Signals were amplified, band-pass filtered (30Hz-2kHz; 
Digitimer D360, Digitimer, Welwyn Garden City, UK) and digitised at 5kHz (Micro1401, 
Cambridge Electronic Devices, Cambridge, UK). 
 
3.3.3 Experiment 1: IMC 
In the upper limb, subjects were asked to perform a repetitive precision grip task. A 
length of compliant plastic tubing (length 19cm, Portex translucent PVC tubing 
800/010/455/800; Smith Medical, Ashford, UK) was attached to the index finger and 
thumb with Micropore tape (3M Health Care, Neuss, Germany), and subjects were 
asked to oppose both ends of the tubing when prompted by visual and auditory cues. 
This auxotonic task – so-called because force increases with displacement in a spring-
like fashion – required a minimum force of 1N (Fisher et al., 2012) and was similar to a 
precision grip task used in our previous studies, albeit without measuring digit 
displacement (Kilner et al., 2000; Riddle & Baker, 2006). In the lower limb, subjects 
were asked to dorsiflex ankle and toes in the air while resting the heel on the ground. 
Subjects produced 4s of contraction alternating with 2s of relaxation, and at least 100 
repetitions. Visual feedback of raw EMG traces was provided to facilitate consistent 
task performance. 
 
3.3.4 Experiment 2: IMC repeated after one year 
After a period of at least one year, eight subjects were asked to repeat the above 
experiment (six men and two women). The average age was 33.5±8.9 years (range 24-
52). All subjects were right-handed. 
 
3.3.5 Data analysis 
Analysis was performed in Matlab (Mathworks, Natick, MA) using custom scripts. 
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Raw data were visually inspected and the first 100 adequately performed trials 
examined further. Analysis focussed on the early hold phase of the contraction where 
beta-band oscillations are known to be maximal (Baker et al., 1997; Sanes & Donoghue, 
1993). EMG signals were full-wave rectified. Starting 0.8s after the cue prompting 
contraction, two contiguous 0.82s-long sections of data from each trial were subjected 
to a 4096-point fast Fourier transform (FFT), giving a frequency resolution of 1.22Hz. 
Many subjects showed a drop-off in EMG activity so the last 1.56s of the 4s active 
phase did not enter the analysis. Denoting the Fourier transform of the 𝑙th section of 
the first EMG signal as 𝐹1,𝑙(𝜆), the auto-spectrum is given by 
 
𝑓11(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹1,𝑙(𝜆)�������� (3.1)  
 
where 𝜆 is the frequency (Hz), 𝐿 is the total number of sections and where the overbar 
denotes the complex conjugate. The cross-spectrum for two EMG signals with Fourier 
transforms 𝐹1,𝑙(𝜆) and 𝐹2 ,𝑙(𝜆) was calculated as 
 
𝑓12(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹2,𝑙(𝜆)�������� (3.2)  
 
Coherence was computed as the cross-spectrum normalised by the auto-spectra 
 
𝐶(𝜆) = |𝑓12(𝜆)|2
𝑓11(𝜆)𝑓22(𝜆) (3.3) 
 
Coherence was calculated for the muscle pairs EDC-FDI, FDS-FDI, MG-EDB and TA-EDB. 
The wide anatomical spacing between the paired muscles minimised the risk of volume 
conduction causing inflated coherence values (Grosse et al., 2002). 
 
Under the null hypothesis of linear independence between the signals, a level of 
significant coherence was determined as (Rosenberg et al., 1989) 
 
 49 
 
𝑍 = 1− 𝛼1/(𝐿−1) (3.4)  
 
where the significance level 𝛼 was set at 0.05. 
 
Analyses of coherence described below were conducted separately for each muscle 
pair. 
 
To provide a group summary, coherence spectra were averaged across all subjects. The 
significance level for averaged coherence was determined using the method described 
by Evans and Baker (2003). 
 
In each subject, coherence was averaged across the 15-30Hz window. Log-transformed 
15-30Hz coherence was plausibly normally distributed within each decade of age 
(Shapiro-Wilk test, p≥0.013 for all groups, Bonferroni-corrected significance level 
α/n=0.05/(4*6)=0.002). However, for the lower limb there was an indication that a 
normal distribution was not an ideal fit since 8 out of 12 groups had an uncorrected 
significance level of <0.1, a result which itself has a probability of <0.001 as calculated 
using the binomial distribution (p=1-F(7), where F is the cumulative distribution 
function of B(12,0.1)). In addition, larger samples derived by pooling coherence across 
all ages (see below) or obtained from cohorts with neurological conditions (Chapters 5 
and 6) could not be modelled adequately with a normal distribution (Shapiro-Wilk test, 
p<0.001 in at least one muscle pair for pooled normal data, Bonferroni-corrected 
significance level α/n=0.05/4=0.0125). Therefore, we chose to model coherence 
distributions non-parametrically. The variable kernel method adapts the amount of 
smoothing to the local density of the data (Silverman, 1986) and estimates the 
probability density function (PDF) as 
 
?̂?(𝑥) = 1
𝑁
� �
1
ℎ𝑑𝑛,𝑘 ∙ 𝜙 �𝑥 − 𝑋𝑛ℎ𝑑𝑛,𝑘 ��
𝑁
𝑛=1
 (3.5)  
 
where 𝑥  denotes the log-transformed independent variable, 𝑋𝑛  the 𝑛
th log-
transformed observation out of a total 𝑁 observations, 𝑑𝑛,𝑘  the distance from 𝑋𝑛 to its 
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𝑘th nearest neighbour, ℎ the global smoothing parameter and 𝜙 the standard normal 
PDF. To understand this intuitively: each observation 𝑋𝑛  was convolved with a 
Gaussian kernel with unit AUC as specified inside the square brackets, and the sum of 
these kernels was normalised by 𝑁 to yield ?̂?(𝑥). The window width of the kernel 
centred on a given observation 𝑋𝑛 was proportional to 𝑑𝑛,𝑘  so that broader kernels 
were associated with observations in regions with sparse data; for any fixed 𝑘, the 
amount of smoothing depended on the global smoothing parameter ℎ. 𝑘 was set as 
√𝑛 rounded to the nearest integer as suggested by Silverman (1986). Theoretically 
optimal methods for calculating ℎ have been described but, for our data, resulted in 
overfitting. Therefore, ℎ was optimised by eye for several datasets; the resulting values 
of ℎ were empirically fitted with simple algebraic expressions and the approximation 
√𝑛 − 512  was chosen to determine ℎ subsequently. It should be emphasised that this 
expression has no theoretical value, but merely provided a convenient shorthand way 
of determining ℎ objectively for each dataset. 
 
Log-transformed coherence has a bounded domain of (−∞,0]. To ensure that the PDF 
was zero for 𝑥>0, ?̂?(𝑥) was modified by reflection in the boundary (Silverman, 1986): 
 
𝑔�(𝑥) = �?̂?(𝑥) + ?̂?(−𝑥), 𝑥 ≤ 00, 𝑥 > 0 (3.6)  
 
The resulting PDF still integrated to unity and observations near the boundary retained 
the same magnitude of contribution to the PDF. The estimated cumulative distribution 
function (CDF) was calculated as 
 
𝐺�(𝑦) = � 𝑔�(𝑥)𝑑𝑥𝑦
−∞
 (3.7)  
 
where 𝑦 is the log-transformed independent variable. 
 
Log-transformed coherence was compared between all decades of age using a Kruskal-
Wallis test, and between individual muscle pairs or limbs using a paired t-test. 
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To measure changes in coherence occurring during experiment 1 (‘intrasession’), the 
recording session from each subject was split into two epochs of 50 trials. Coherence 
spectra were estimated separately for each epoch, and the significance of changes 
between both epochs was determined by calculating single-subject Z-scores as 
 
𝑍𝑛𝑠 = � 𝐿𝑁𝜆 � �atanh��𝐶𝑛𝑠𝑠𝑒𝑐𝑜𝑛𝑑 (𝜆)� − atanh��𝐶𝑛𝑠𝑓𝑖𝑟𝑠𝑡(𝜆)��𝜆2
𝜆=𝜆1
 (3.8)  
 
where 𝐶𝑛𝑠
𝑓𝑖𝑟𝑠𝑡(𝜆) and 𝐶𝑛𝑠𝑠𝑒𝑐𝑜𝑛𝑑(𝜆) denote the coherence at frequency 𝜆 for subject 𝑛𝑠 
during the first and second epoch. 𝑍𝑛𝑠 was summed over all 𝑁𝜆 frequency bins in the 
15-30Hz window (𝑁𝜆=bin number(𝜆2)-bin number(𝜆1)+1=12), and normalised so that it 
should be normally distributed with zero mean and unit variance under the null 
hypothesis of no change in coherence between epochs (Baker & Baker, 2003; 
Rosenberg et al., 1989). 
 
The mean compound Z-score across all 𝑁𝑆 subjects was calculated as 
 
𝑍̅ = � 1
𝑁𝑠
� 𝑍𝑛𝑠
𝑁𝑠
𝑛𝑠=1
 (3.9)  
 
The associated two-tailed probability (pZ) was computed with reference to the 
standard normal distribution. 
 
The significance of the variance of single-subject Z-scores was estimated using Monte-
Carlo simulations. Each simulation involved drawing 𝑁𝑆  random samples from a 
standard normal distribution and calculating their variance. This procedure was 
repeated 106 times, allowing the distribution of the variance to be estimated under the 
null hypothesis that coherence did not change between epochs. The two-tailed 
probability for the observed variance (pMC) was calculated from this estimated null 
distribution. 
 
 52 
 
For experiment 2, we calculated both intersession and intrasession variances. 
Coherence spectra were estimated separately for two epochs per session as described 
above. Intrasession changes were quantified in each subject by calculating one Z-score, 
comparing both epochs of session 1, and a second Z-score, comparing both epochs of 
session 2. The intrasession variance was computed as the variance of all resulting 
Z-scores, i.e. two Z-scores from each subject. Similarly, intersession changes were 
measured in each subject by calculating one Z-score, comparing the first epochs of 
both sessions, and a second Z-score, comparing the second epochs; intersession 
variance was calculated from all resultant Z-scores. 
 
The significance of the difference between intersession and intrasession variance was 
estimated by means of Monte-Carlo simulations. For each subject, coherence spectra 
were shuffled across epochs and sessions, and the difference between intersession 
and intrasession variance was recalculated. This process was repeated 106 times, 
allowing the null distribution of the difference in variances to be estimated. The two-
tailed probability for the observed difference was computed with reference to the 
estimated null distribution. 
 
 
3.4 Results 
 
Single-subject data are shown in Figure 3.1 for the lower limb and in Figure 4.2 for the 
upper limb. In most subjects, power and coherence peaked in the 15-30Hz band. On 
group averages, coherence in all muscle pairs was significant across the 15-30Hz 
window and showed either a peak or an inflexion inside this frequency band (Figure 
3.2). 
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Figure 3.1: Single-subject power and coherence in the lower limb. Raw EMG is shown 
for three sample trials (A, D, G). The grey boxes indicate the cued contraction phase of 
the task, and the vertical blue lines represent the two FFT windows during the hold 
phase. The spectral plots show relative power (B, E, H) and coherence with EDB (C, F). 
The 15-30Hz beta-band is designated by the vertical green lines, and the dotted 
horizontal lines indicate the significance level for coherence. In most subjects, power 
and coherence spectra peaked in the 15-30Hz band. 
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Figure 3.2: Group data for coherence. Average coherence spectra are shown for MG-
EDB and TA-EDB in the lower limb (A, C) and for EDC-FDI and FDS-FDI in the upper limb 
(B, D). The dotted horizontal lines represent the significance level for average 
coherence, and the vertical green lines indicate the 15-30Hz beta-band. Significant 
average coherence was present in the 15-30Hz band for each muscle pair. Typically, 
coherence demonstrated a peak or an inflexion within this window and a further one 
around 9-12Hz whilst dropping off at higher frequencies. 
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Coherence was averaged across the 15-30Hz window in each subject; individual 
averages are listed in Appendix A. There was no significant correlation between 
coherence and age in any muscle pair (Spearman’s 𝜚≤0.104, p≥0.325; Figure 3.3), with 
interindividual variability spanning up to two orders of magnitude. The distribution of 
coherence was similar for all decades of age as illustrated by the stairstep curves in 
Figure 3.4 A, B, E, F. The smooth curves show the corresponding variable kernel density 
models. Summary statistics derived from these models are illustrated by the boxplots 
in Figure 3.4 C, D, G, H, superimposed on dot plots of individual coherence values. 
Coherence did not vary significantly between decades (Kruskal-Wallis p≥0.531). 
 
 
Figure 3.3: Correlation between coherence and age. For each muscle pair, average 
15-30Hz coherence is plotted against age. There was no significant correlation 
between coherence and age in any muscle pair (Spearman’s 𝜚). 
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Figure 3.4: Coherence by decade of age with corresponding variable kernel density 
estimates and summary statistics. Each decade is illustrated in a different colour. The 
stairstep curves show the distribution of average 15-30Hz coherence for subjects 
within a given decade, with the smooth curves showing corresponding density 
estimates (A, B, E, F). Quartiles derived from density estimates are shown by the box 
plots with additional horizontal lines indicating 5th and 95th centiles, overlain on a dot 
plot of individual coherence values (C, D, G, H). Coherence did not vary significantly 
with age (Kruskal-Wallis test). 
 
Because there was no dependence on age, we pooled coherence values across all ages 
into a single dataset (Figure 3.5). The combined dataset was modelled empirically with 
a normal distribution (blue) and a variable kernel density estimate (red). The latter 
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achieved a closer fit throughout whilst still smoothing out much of the small-scale 
variability of the data. We propose this cumulative distribution as a normative dataset 
for healthy subjects, against which future experimental findings can be compared. 
 
 
Figure 3.5: Coherence across all ages with normal and variable kernel density models. 
Since coherence did not vary with age, we pooled coherence readings across all ages 
into a single dataset. The stairstep curves illustrate the distribution of average 15-30Hz 
coherence for subjects of all ages. The data were modelled with a normal distribution 
(blue) and variable kernel density estimation (red). The density estimation model 
achieved a closer fit throughout, whilst still smoothing out some of the variability of 
the data. 
 
Log-transformed coherence was significantly greater in FDS-FDI than in EDC-FDI 
(paired t-test, p<0.001) and in MG-EDB than in TA-EDB (p<0.001). By contrast, there 
was no significant difference in log-transformed coherence between upper and lower 
limbs (p=0.596). 
 
In order to assess the stability of coherence within a recording session (‘intrasession’), 
we determined single-subject Z-scores for differences in coherence between two 
halves of the same session (Figure 3.6). For all muscle pairs, the mean compound 
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Z-scores were not significantly different from zero (pZ≥0.274) but the variances of 
single-subject Z-scores were significantly greater than unity (pMC<0.001). Thus, 
coherence showed greater variability within a recording session than would be 
statistically expected. 
 
  
Figure 3.6: Z-scores for intrasession differences in coherence. In each subject, the 
recording session was divided into two epochs for which separate 15-30Hz coherence 
values were calculated. Single-subject Z-scores quantify the difference between both 
coherence values in each individual and their distribution is shown by the stairstep 
curves; under the null hypothesis, they should follow a standard normal distribution 
(blue curve). The mean compound Z-score for all subjects (𝑍̅; vertical dotted lines) was 
not significant in any muscle pair (pZ; blue box showing range of ±1.96). However, in all 
muscle pairs the variance of individual Z-scores (Var) was significantly greater than 
unity as estimated by Monte-Carlo simulations (pMC). 
 
A subset of the cohort returned after one year for a second recording session, allowing 
us to investigate whether coherence exhibited greater variability between than within 
sessions. We calculated single-subject Z-scores for differences in coherence between 
both halves of the same session (‘intrasession’) and for differences in coherence 
between corresponding halves of both sessions (‘intersession’). In all muscle pairs, the 
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intersession variance of single-subject Z-scores was greater than the intrasession 
variance (Figure 3.7), with the differences reaching significance in TA-EDB (pMC=0.009) 
and EDC-FDI (pMC=0.029). 
 
 
Figure 3.7: Difference between variances of intersession and intrasession Z-scores. 
Each recording session from experiment 2 was split into two epochs for which separate 
15-30Hz coherence values were computed. Single-subject Z-scores were calculated for 
differences in coherence between both halves of the same session (‘intrasession’) and 
for differences in coherence between corresponding halves of both sessions 
(‘intersession’). The difference of the variances of intersession and intrasession 
Z-scores was then computed (ΔVar; vertical dotted lines). For each muscle pair, the 
null distribution was estimated using Monte-Carlo simulations (green histograms). The 
probability of the observed value occurring under the null hypothesis was calculated 
with reference to the estimated null distribution (pMC). Intersession variance exceeded 
intrasession variance in all muscle pairs, with the differences reaching significance in 
TA-EDB and EDC-FDI. 
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3.5 Discussion 
 
3.5.1 IMC in adulthood 
We found no significant age-related changes in beta-band IMC amplitude across 
almost six decades of adulthood. This agrees with two previous studies describing no 
significant differences in CMC (Graziadio et al., 2010) or IntraMC amplitude (Semmler 
et al., 2003) between young and old adults. Whilst another study reported an increase 
in CMC with age, significance levels were borderline (p=0.04; Kamp et al., 2013). The 
weight of the evidence therefore suggests that coherence amplitude remains 
unchanged throughout adult age. 
 
Senescent alterations in the efferent-afferent feedback loop might be expected to 
disrupt beta-band coherence. There is strong evidence that peripheral nerve 
conduction velocities decline with age (Kong et al., 2010; Rivner et al., 2001). Whilst 
central conduction velocities appear to remain constant (Chapter 2), ageing is 
associated with morphological changes in the central sensorimotor pathways (Moscufo 
et al., 2011; Raz & Rodrigue, 2006) and may alter transmission in a manner which is 
not detectable on motor or sensory evoked potentials. Beta-band coherence is thus 
surprisingly robust to alterations in conduction pathways, and this is supported by two 
observations unrelated to old age: IMC reaches adult values in early teenage although 
peripheral conduction times continue to increase with limb length for several years 
(Farmer et al., 2007); and beta-band coherence is present in primates of different sizes 
despite marked size-related differences in conduction delays (Baker et al., 1997).  
 
Reduced intracortical inhibition in old age (Peinemann et al., 2001) might be expected 
to lead to diminished coherence, but no such change was observed. It is possible that 
intracortical inhibition is critical to the initial patterning of the corticospinal drive but 
has a less prominent role in maintaining oscillatory activity in the efferent-afferent 
feedback loop. One study boosted intracortical inhibition in adults using diazepam, a 
GABAergic agent. The power of 15-30Hz oscillations on EEG increased yet CMC 
amplitude decreased (Baker & Baker, 2003). These results highlight that coherence can 
be dissociated from alterations in cortical oscillatory activity, suggesting that that the 
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relationship between intracortical inhibition and coherence might not be 
straightforward. 
 
One aim of this study was to gather a normative dataset for use of IMC as a biomarker 
of CST function. Since IMC across the 15-30Hz band appears to be related to the 
integrity of the CST, we focussed on average 15-30Hz IMC as our summary measure, 
thus also ensuring comparability with our previous study (Fisher et al., 2012). By 
contrast, most past reports analysed the amplitude and frequency of peak coherence 
in the 15-30Hz window (Graziadio et al., 2010; James et al., 2008; Kamp et al., 2013; 
Pohja et al., 2005). Coherence estimates include a noise component and do not always 
show a clear single peak. Our approach of averaging across 𝑁𝜆=12 frequency bins 
sidestepped any difficulties in quantifying single or multiple peaks and boosted signal-
to-noise ratio by √12≈3.5. We did not analyse coherence outside the 15-30Hz window 
as it is less clearly associated with the CST. At lower frequencies, potential generators 
of coherence include the reticular formation, cerebellum and local spinal circuits 
(Williams et al., 2010). At higher frequencies, coherence may involve neural substrates 
other than the CST and only becomes prominent during tasks involving strong (Mima 
et al., 1999) or dynamically modulated contractions (Omlor et al., 2007). 
 
The lack of age-related changes allowed us to pool results, thus maximising the 
effective size of the control group for studies of IMC in neurological conditions 
(Chapters 5 and 6). The aggregate dataset could not be fitted adequately by a normal 
distribution or simple empirical formulae. Whilst variable kernel density estimation 
provided a good fit, it did not allow the data to be summarised using a small number of 
numerical parameters. 
 
3.5.2 Variability of IMC 
Interindividual variability of IMC ranged over two orders of magnitude. The degree of 
variability did not appear to change with age, militating against the possibility that 
undiagnosed neurological issues in older subjects could have caused a greater spread 
of coherence readings. Other than genuine differences between subjects, sources of 
variability within individuals may also have played a role. 
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Intrasession variance of IMC was significantly greater than predicted by statistical 
variation alone. Two potential causes are fluctuations in task performance and random 
moment-to-moment variation of coherence. Previous studies employed tasks which 
can be readily standardised but require prolonged activity or a high level of dexterity 
and thus are not suitable for use in patients with neurological deficits (Chapters 5 and 
6). Our task involved weak, phasic contractions and a minimum of instrumentation. 
Inherent disadvantages were a greater freedom of movement and less precisely 
defined targets, making it more difficult to ensure consistent performance. It would be 
helpful to carry out an experiment where normal subjects perform different tasks in 
the same session so that resulting coherence estimates can be compared. Random 
moment-to-moment variation of coherence is seen during sustained contractions in 
normal subjects. Periods of increased coherence are thought to promote sensorimotor 
recalibration at the expense of increased 15-30Hz tremor and delayed reaction times 
(Gilbertson et al., 2005; Matsuya et al., 2013). Such variation contributes to the overall 
variability of coherence and appears to be neither consciously controlled nor related to 
specific features of the task. 
 
Intersession variance was greater than intrasession variance, reaching significance in 
two muscle pairs. Two aspects may have contributed in addition to the above factors. 
Firstly, it is not possible to achieve an identical electrode montage after one year. In a 
previous study, electrode position significantly influenced coherence between two 
intrinsic hand muscles (Keenan et al., 2011), but the proximity of the two muscles 
means that electrical cross-talk may have confounded the results. It would be useful to 
study this issue in a more widely spaced muscle pair. Secondly, coherence amplitude 
and directionality can change substantially within an individual over a timeframe of 
one or two years, even with a highly instrumented task (Witham et al., 2011). The 
timeframe of these changes should be clarified by obtaining multiple coherence 
estimates at shorter intervals. 
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3.6 Conclusion 
 
This is one of the largest studies of beta-band coherence in healthy adults to date. IMC 
showed no significant age-related changes across almost six decades of age; therefore 
results were pooled across all ages into a combined normative dataset. 
 
Interindividual variability of IMC spanned two orders of magnitude. Intrasession 
variance was significantly greater than statistically expected; potential reasons include 
moment-to-moment variability of coherence and changes in task performance. In a 
smaller cohort, we examined intersession variance for two sessions separated by one 
year and found even greater variability. Additional causes include longer-term changes 
in coherence within individuals and differences in electrode montage. Variability of 
IMC in normal subjects is critical to future applications as a biomarker, and we 
proposed a number of control experiments to delineate the origins of variability so 
that it potentially can be minimised. 
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4  Effect of transcranial direct current stimulation on intermuscular coherence 
   
  A small study reported that transcranial direct current stimulation (tDCS) modulates 
coherence in healthy subjects. Here, I re-examine this effect in a larger cohort. 
 
 
4.1 Abstract 
 
Objective: To measure the effect of anodal transcranial direct current stimulation 
(tDCS) on beta-band intermuscular coherence (IMC). 
 
Methods: 91 healthy volunteers were recruited. IMC was estimated between extensor 
digitorum communis (EDC) and first dorsal interosseous (FDI) as well as between flexor 
digitorum superficialis (FDS) and FDI in the dominant upper limb, both before and after 
10min of 1mA anodal tDCS to the contralateral M1. tDCS electrode positions were 
determined by surface measurements relative to bony landmarks. Six volunteers also 
participated in a second experiment where we sought to reproduce the classical 
effects of anodal tDCS on motor evoked potentials (MEPs). Here, we determined tDCS 
electrode positions using TMS hotspot mapping, and compared them to those 
resulting from surface measurements. 
 
Results: IMC increased very significantly in both muscle pairs (EDC-FDI: 12.9±12.1% 
(change in geometric mean of post/pre-tDCS ratios±1.96*SE), p<0.001; FDS-FDI: 
11.3±11.5%, p<0.001). In the second experiment, only one subject showed the classical 
rise of MEP amplitude, and group effects were not significant. The discrepancy in 
electrode position resulting from the two positioning methods was small and probably 
insignificant. 
 
Conclusion: The magnitude of the observed effects on beta-band IMC was similar to 
previously reported results. The duration of the effects was in keeping with classical 
MEP results but exceeded that previously reported for IMC. Notably, we did not 
observe the classical effects on MEPs in most subjects. Our study highlights that tDCS-
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associated effects are subject to a substantial degree of interindividual variability. 
Future work should assess IMC at multiple time points after tDCS until all results have 
returned to baseline, and include a control condition with sham tDCS. 
 
 
4.2 Introduction 
 
Transcranial direct current stimulation (tDCS) is a subthreshold neuromodulatory 
technique which alters cortical excitability in a non-invasive, focal and reversible 
manner. A weak direct current (0.5-2mA) is applied to the scalp through two plate 
electrodes (3.5-35cm2), both of which are usually placed on the head (bicephalic 
montage). Excitability is typically enhanced under the anode and diminished under the 
cathode (Figure 4.1 A; Nitsche & Paulus, 2000). Such excitability changes occur during 
ongoing stimulation (‘acute effects’) and, if stimulation is applied for a sufficiently long 
period and with a sufficiently strong current, they can outlast the period of stimulation 
by one hour or more (‘after-effects’, Figure 4.1 B; Nitsche & Paulus, 2001). Acute 
effects are thought to arise through subthreshold, tonic membrane polarisation of 
cortical neurons. Blockade of voltage-gated sodium or calcium channels abolishes 
anodal but not cathodal acute effects (Liebetanz et al., 2002; Nitsche et al., 2003), 
suggesting that anodal acute effects are mediated by inward sodium and calcium 
currents, whilst cathodal ones might be attributable to outward flow of potassium. 
After-effects of both polarities are contingent on preceding acute effects and are 
abolished by NMDA receptor antagonists (Liebetanz et al., 2002; Nitsche et al., 2003), 
indicating mechanisms akin to long-term potentiation and depression. 
 
The excitability of the primary motor cortex is usually probed through TMS-evoked 
motor responses (Figure 4.1 A, B). However, tDCS affects not only evoked activity but 
also spontaneous oscillations of cortical neurons, as shown by extracellular recordings 
and EEG in animals (Creutzfeldt et al., 1962) as well as EEG in humans (Ardolino et al., 
2005). Beta-band (15-30Hz) oscillations propagate from the motor cortex through the 
corticospinal tract (CST) to the muscles (Baker et al., 1997; Baker et al., 2003; Fisher et 
al., 2012). Synchronisation of beta-band oscillations between muscles in the same limb 
is demonstrable as intermuscular coherence (IMC) and indicates a shared cortical drive.  
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A small previous study showed that anodal or cathodal tDCS to M1 respectively 
increases or decreases beta-band IMC in the contralateral upper limb with a time 
course paralleling the changes in motor evoked potential (MEP) amplitude (Figure 4.1 
D, E; Power et al., 2006). This finding is of potential relevance to the use of beta-band 
IMC as a biomarker of CST dysfunction. In some subjects with known CST damage from 
motor neuron disease (MND), beta-band IMC remains significant at baseline but fails 
to increase after anodal tDCS (J. A. Norton, personal communication, 16 November 
2010). Similarly, TMS-evoked motor responses fail to be modulated by tDCS in patients 
with MND (Munneke et al., 2011; Quartarone et al., 2007). The sensitivity of beta-band 
IMC to detect subclinical CST dysfunction might therefore be boosted by measuring 
IMC before and after adjunctive anodal tDCS, and analysing both the baseline value 
and any change after tDCS. In a broader context, this might help to extend the remit of 
tDCS from basic neuroscience and exploratory therapeutic studies (Nitsche et al., 2008; 
Nitsche & Paulus, 2011) into novel diagnostic approaches.  
 
The previous study of tDCS and IMC was based on ten subjects (Power et al., 2006). 
We set out to corroborate the reported effect of anodal tDCS on beta-band IMC in a 
larger cohort, allowing more precise quantification. A limiting factor of the present 
study was that most subjects were only able to attend once. In order to maximise the 
amount of data gathered for anodal tDCS, we performed a study without a control 
(sham stimulus) group. The position of the electrode over the motor cortex was 
determined by surface measurements relative to bony landmarks (Ardolino et al., 2005) 
rather than TMS hotspot mapping (Nitsche & Paulus, 2000; Power et al., 2006) to 
ensure applicability in the absence of TMS facilities. Beta-band IMC increased very 
significantly after tDCS; the changes were similar in amplitude but longer in duration 
compared to those reported by Power et al. (2006). To exclude the possibility that this 
discrepancy was due to differences in electrode positioning, we carried out a second, 
smaller study comparing both positioning methods and aiming to reproduce the 
classical effect of anodal tDCS on MEP amplitude. 
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Figure 4.1: Previously reported after-effects of 1mA tDCS to M1. 5min of anodal or 
cathodal stimulation cause MEP amplitude to increase (red) or decrease (blue), 
respectively, for several minutes after the end of stimulation before returning to 
baseline (A; n=19; adapted from Nitsche & Paulus, 2000). Filled symbols indicate a 
statistically significant difference from baseline (p<0.05, paired t-test). If the duration 
of anodal stimulation is increased, MEP amplitudes remain raised for longer intervals 
(B; circles=5min, diamonds=7min, upward-pointing triangles=9min, downward-
pointing triangles=11min, squares=13min; n=12; adapted from Nitsche & Paulus, 2001). 
Filled symbols designate a statistically significant difference from baseline (p<0.05, 
Fisher’s protected least significant difference post hoc test). Single-subject data show 
considerable inter- and intra-subject variability (C; 9min); each point is an average of 
the amplitudes of 15 MEPs. Outline and filled symbols are used to differentiate 
subjects only and do not imply statistical significance. 10min of anodal or cathodal 
stimulation leads to an increase (red) or decrease (blue) in 15-35Hz intermuscular 
coherence respectively, with sham stimulation (black) having no significant effect (D; 
n=10; adapted from Power et al., 2006). Filled symbols denote a statistically significant 
difference from baseline (p<0.05, paired t-test). This is also evident when plotting the 
difference in coherence before and after tDCS, averaged across all subjects (E).  
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4.3 Methods 
 
4.3.1 Subjects 
At least 15 volunteers were recruited for each decade of age between 20 and 80 (50 
men and 41 women); age averaged 48.9±17.3 years (SD; range 22-77). Eighty-two 
subjects were right-handed and nine left-handed as assessed by self-reporting. None 
had any history of neurological disorders or diabetes mellitus, or any contraindications 
to magnetic stimulation, and none took any neurotropic medication. All subjects 
provided written informed consent. The study was approved by the research ethics 
committee of Newcastle University’s Medical Faculty, and conformed to the 
Declaration of Helsinki. 
 
4.3.2 Recording 
Every effort was made to maintain subjects at a constant level of alertness. All 
assessments were carried out on the dominant arm, with tDCS and TMS targeting the 
contralateral M1. Subjects were seated in a comfortable chair with their arm resting 
semi-pronated on a cushion. Surface EMG was recorded from first dorsal interosseous 
(FDI), flexor digitorum superficialis (FDS) and extensor digitorum communis (EDC) in 
experiment 1, and from abductor digiti minimi (ADM) in experiment 2. Adhesive 
electrodes (Bio-Logic M0476; Natus Medical, Mundelein, IL) were placed in a belly-
tendon montage over FDI and ADM; for FDS and EDC, the electrodes were placed 4cm 
apart, one third along the muscle from its proximal origin. Signals were amplified, 
band-pass filtered (30Hz-2kHz; Digitimer D360, Digitimer, Welwyn Garden City, UK) 
and digitised at 5kHz (Micro1401, Cambridge Electronic Devices, Cambridge, UK). 
 
4.3.3 tDCS 
tDCS was delivered by a battery-powered constant current stimulator (custom-built by 
the Medical Physics Department, Newcastle upon Tyne Hospitals) through a pair of 
5x7cm conductive rubber electrodes covered in saline-soaked sponges (neuroConn, 
Ilmenau, Germany). The anode was centred on a point 7cm lateral to the vertex in 
experiment 1, and on the TMS hotspot for ADM in experiment 2; the cathode was 
placed over the contralateral forehead. The long axis of both electrodes was 
orientated in a coronal plane. Direct current stimulation at 1mA was administered for 
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10min; similar paradigms have been shown to increase MEP amplitude for at least 
40min after the end of stimulation (Nitsche & Paulus, 2001). The current was ramped 
up or down over 5s at the start and end of stimulation respectively. Subjects reported 
no side-effects other than a mild tingling or burning sensation under the electrodes 
during stimulation. 
 
4.3.4 Experiment 1: IMC 
Subjects were asked to perform a repetitive precision grip task, both before and 
immediately after tDCS. A length of compliant plastic tubing (length 19cm, Portex 
translucent PVC tubing 800/010/455/800; Smith Medical, Ashford, UK) was attached to 
the index finger and thumb with Micropore tape (3M Health Care, Neuss, Germany), 
and subjects were asked to oppose both ends of the tubing when prompted by visual 
and auditory cues. This auxotonic task – so-called because force increases with 
displacement in a spring-like fashion – required a minimum force of 1N (Fisher et al., 
2012) and was similar to a precision grip task used in our previous studies, albeit 
without measuring digit displacement (Kilner et al., 2000; Riddle & Baker, 2006). 
Subjects produced 4s of contraction alternating with 2s of relaxation, and at least 100 
repetitions. Visual feedback of raw EMG traces was provided to facilitate consistent 
task performance. 
 
4.3.5 Experiment 2: MEP amplitude 
Six subjects were asked to return for experiment 2; at least one week had elapsed 
since the previous experiment to prevent carry-over effects. Subjects maintained a 
constant head position in a HeadSpot frame (UHCOtech, Houston, TX), placing their 
chin in a cup and their forehead against a bar. Auditory feedback of surface EMG was 
provided to aid the subject in maintaining complete relaxation of ADM. 
 
Magnetic stimulation was then delivered at a frequency of 0.2Hz using a Magstim 200 
stimulator (Magstim Company, Whitland, UK) and a figure-of-eight coil (70mm outer 
diameter). The coil was placed tangentially to the scalp with the handle pointing 
posterolaterally at 45 degrees from the sagittal plane. The TMS hotspot was 
determined as the position that evoked the largest MEP in ADM and stimulation 
intensity adjusted to yield a MEP amplitude of approximately 1mV. The range of final 
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stimulation intensities was 42-68%. The hotspot was marked on the scalp and 
registered relative to the head frame using a Liberty motion tracking system with six 
degrees of freedom (Polhemus, Colchester, VT). Positional data were sampled at 
240Hz and deviations from the hotspot were displayed using a custom interface 
written in Delphi (Borland, Austin, TX). Typically, this allowed the experimenter to 
maintain coil position within ±1mm (x/y/z) and ±1 degree (roll/bank/yaw) of the 
registered position. 
 
20 baseline MEPs were recorded. The subject then sat back from the frame to receive 
tDCS. Immediately after tDCS, the subject resumed their position in the frame. The 
TMS coil was repositioned over the hotspot and a further 20 MEPs were recorded. This 
was repeated 5, 10, 15, 25, 35 and 45min after tDCS.  
 
4.3.6 Data analysis 
Analysis was performed in Matlab (Mathworks, Natick, MA) using custom scripts. 
 
For experiment 1, raw data were visually inspected and the first 100 adequately 
performed trials examined further. Analysis focussed on the early hold phase of the 
contraction where beta-band oscillations are known to be maximal (Baker et al., 1997; 
Sanes & Donoghue, 1993). EMG signals were full-wave rectified. Starting 0.8s after the 
cue prompting contraction, two contiguous 0.82s-long sections of data from each trial 
were subjected to a 4096-point fast Fourier transform (FFT), giving a frequency 
resolution of 1.22Hz. Many subjects showed a drop-off in EMG activity so the last 1.56s 
of the 4s active phase did not enter the analysis. Denoting the Fourier transform of the 
𝑙th section of the first EMG signal as 𝐹1,𝑙(𝜆), the auto-spectrum is given by 
 
𝑓11(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹1,𝑙(𝜆)�������� (4.1)  
 
where 𝜆 is the frequency (Hz), 𝐿 is the total number of sections and where the overbar 
denotes the complex conjugate. The cross-spectrum for two EMG signals with Fourier 
transforms 𝐹1,𝑙(𝜆) and 𝐹2 ,𝑙(𝜆) was calculated as  
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𝑓12(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹2,𝑙(𝜆)�������� (4.2)  
 
Coherence was computed as the cross-spectrum normalised by the auto-spectra 
 
𝐶(𝜆) = |𝑓12(𝜆)|2
𝑓11(𝜆)𝑓22(𝜆) (4.3) 
 
Coherence was calculated for the muscle pairs EDC-FDI and FDS-FDI. The wide 
anatomical spacing between the paired muscles minimised the risk of volume 
conduction causing inflated coherence values (Grosse et al., 2002). 
 
Under the null hypothesis of linear independence between the signals, a level of 
significant coherence was determined as (Rosenberg et al., 1989) 
 
𝑍 = 1− 𝛼1/(𝐿−1) (4.4)  
 
where the significance level 𝛼 was set at 0.05. 
 
Analyses of power and coherence described below were conducted separately for 
each muscle or muscle pair respectively. 
 
The significance of changes in coherence after tDCS was determined by calculating 
single-subject Z-scores as 
 
𝑍𝑛𝑠 = � 𝐿𝑁𝜆 � �atanh��𝐶𝑛𝑠𝑎𝑓𝑡𝑒𝑟(𝜆)� − atanh��𝐶𝑛𝑠𝑏𝑒𝑓𝑜𝑟𝑒(𝜆)��𝜆2
𝜆=𝜆1
 (4.5)  
 
where 𝐶𝑛𝑠
𝑏𝑒𝑓𝑜𝑟𝑒(𝜆) and 𝐶𝑛𝑠𝑎𝑓𝑡𝑒𝑟(𝜆) denote the coherence at frequency 𝜆 for subject 𝑛𝑠 
before and after tDCS. 𝑍𝑛𝑠  was summed over all 𝑁𝜆 frequency bins in the 15-30Hz 
window (𝑁𝜆=bin number(𝜆2)-bin number(𝜆1)+1=12), and normalised so that it should 
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be normally distributed with zero mean and unit variance under the null hypothesis of 
no change in coherence after tDCS (Baker & Baker, 2003; Rosenberg et al., 1989).  
 
The mean compound Z-score across all 𝑁𝑆 subjects was calculated as 
 
𝑍̅ = � 1
𝑁𝑠
� 𝑍𝑛𝑠
𝑁𝑠
𝑛𝑠=1
 (4.6)  
 
The associated two-tailed probability (pZ) was computed with reference to the 
standard normal distribution. 
 
The assumption that single-subject Z-scores should be normally distributed under the 
null hypothesis could not be tested, and to allay potential concerns about its validity 
we also performed distribution-free testing using Monte-Carlo simulations. Arithmetic 
means of coherence in the 15-30Hz window were calculated before and after tDCS 
(‘paired means’) for each subject. The ratio of paired means summarised any change 
on a single-subject level, and the geometric mean of the ratios for all subjects 
encapsulated any change on a group level. For each subject, paired means were 
shuffled, randomly reassigning each member of the pair to the ‘before’ or ‘after’ 
condition, before recalculating the geometric mean. The shuffling procedure was 
repeated 106 times, allowing the distribution of the geometric mean to be estimated 
under the null hypothesis that tDCS did not alter mean 15-30Hz coherence. The two-
tailed probability for the observed geometric mean (pMC) was calculated with 
reference to the estimated null distribution. 
 
Raw auto-spectra represent absolute power, which has little meaning as it is 
influenced by uncontrolled factors such as electrode position relative to the muscle 
generators. They were therefore normalised to the average total power in the 0-48Hz 
band before tDCS to yield relative power spectra. For each subject, arithmetic means 
of relative power in the 15-30Hz band were calculated before and after tDCS (‘paired 
means’). The sample distributions of these means were right-skewed and could not be 
modelled adequately by a normal distribution even after applying logarithmic or 
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inverse transforms (Shapiro-Wilk test, p<0.001 in at least one muscle, Bonferroni-
corrected significance level α/n=0.05/3=0.017). Therefore, paired means were 
compared using a two-sided Wilcoxon signed rank test (pW). In addition, we performed 
Monte-Carlo simulations similar to those outlined above. 
 
To test for changes in power and coherence during task performance, each session 
before or after tDCS was divided into two epochs. Power and coherence were analysed 
separately for each epoch, and results compared between both epochs of a given 
session using the above statistical procedures. 
 
For experiment 2, MEPs from each time point were averaged. The peak-to-peak 
amplitude of each average was normalised to the baseline (pre-tDCS) value, and 
normalised amplitudes were analysed using one-way analysis of variance (ANOVA) 
(Nitsche & Paulus, 2000). 
 
 
4.4 Results 
 
4.4.1 Experiment 1: IMC 
Single-subject data are illustrated in Figure 4.2. Raw EMG recordings were very similar 
before and after tDCS. In most subjects, power and coherence spectra showed a peak 
in the 15-30Hz band, which often appeared to increase in amplitude after tDCS. 
 
Relative power and coherence were averaged across the 15-30Hz band. Figure 4.3 
plots the ratio of post-tDCS to pre-tDCS values for each subject (grey histograms; 
Figure 4.3 A, B, E, F, I) and their geometric mean across all subjects as a group 
summary (dotted red lines). The distribution of geometric means under the null 
hypothesis of no change after tDCS was estimated using Monte-Carlo simulations 
(green histograms, with dotted red lines indicating the observed value; Figure 4.3 C, D, 
G, H, J). Power increased in all muscles after tDCS but these changes did not reach 
significance on the primary test (EDC: 14.5±27.7% (change in geometric 
mean±1.96*SE), pW=0.106; FDS: 17.7±39.2%, pW=0.148; FDI: 2.5±25.8%, pW=0.558). 
Monte-Carlo analysis showed borderline significance for changes in EDC and 
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significance for changes in FDS (EDC: pMC=0.052; FDS: pMC=0.022; FDI: pMC=0.729). 
Coherence increased very significantly in both muscle pairs (EDC-FDI: 12.9±12.1%, 
pZ<0.001; FDS-FDI: 11.3±11.5%, pZ<0.001; also see Figure 4.4 A, C), with Monte-Carlo 
analysis also demonstrating significance (EDC-FDI: pMC=0.011; FDS-FDI: pMC=0.027). The 
coefficients of variation for within-subject increases in coherence were 52.3% (EDC-FDI) 
and 50.1% (FDS-FDI). 
 
 
Figure 4.2: Single-subject power and coherence in the upper limb. Raw EMG is shown 
for three sample trials before and after tDCS (A, D, G). The cued contraction phase of 
the task is designated by the grey boxes, and the two FFT windows during the hold 
phase of the contraction are shown by the vertical blue lines. Spectra of relative power 
(B, E, H) and coherence with FDI (C, F) are plotted for data recorded before (black) and 
after tDCS (red). The 15-30Hz beta-band is flanked by the green lines, and the dotted 
horizontal lines indicate the significance level for coherence. In most subjects, power 
and coherence spectra demonstrated a peak in the 15-30Hz band, which often 
appeared to increase in amplitude after tDCS. 
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Figure 4.3: Group data for power and coherence. Relative power (left; A, C, E, G, I, J) 
and coherence with FDI (right; B, D, F, H) were averaged across the 15-30Hz band, and 
the ratio of post-tDCS and pre-tDCS averages was calculated for each subject (grey 
histograms; A, B, E, F, I). The geometric mean of these ratios summarised the data on a 
group level (vertical dotted red lines; Δ denotes change from unity±1.96SE). For each 
geometric mean, the null distribution was estimated using Monte-Carlo simulations 
(green histograms; C, D, G, H, J). The probability of the observed value occurring under 
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the null hypothesis was calculated with reference to the estimated null distribution. 
Power increased slightly in all muscles after tDCS without these changes reaching 
significance on the primary test (pW). On Monte-Carlo analysis (pMC), the changes were 
significant in FDS and borderline in EDC. Coherence increased in both muscle pairs, 
with both the primary test (pZ; also see Figure 4.4) and Monte-Carlo analysis (pMC) 
demonstrating significance in each case. 
 
Power increased in 52.8% (EDC), 61.5% (FDS) and 51.7% (FDI) of all subjects. A rise in 
coherence was seen in 62.6% (EDC-FDI) and 63.7% (FDS-FDI) of subjects, with 80.2% 
showing an increase in at least one muscle pair. 
 
Figure 4.4 shows Z-scores for differences in coherence. In the intersession comparison 
between pre-tDCS and post-tDCS sessions (Figure 4.4 A, C), the compound mean Z-
scores (dotted red lines) indicated a significant increase in coherence for each muscle 
pair as mentioned above (EDC-FDI: 𝑍̅=5.86, pZ<0.001; FDS-FDI: 𝑍̅=6.67, pZ<0.001). In 
the intrasession analysis (Figure 4.4 B, D), data from the pre-tDCS and post-tDCS 
sessions were each split into two epochs; both epochs of a given session were then 
compared to each other. The pre-tDCS comparison yielded compound mean Z-scores 
(dotted black lines) which were not significantly different from zero (EDC-FDI: 𝑍̅=-0.594, 
pZ=0.553; FDS-FDI: 𝑍̅=0.313, pZ=0.754); Monte-Carlo analysis likewise showed no 
significant difference between epochs (EDC-FDI: -1.0±13.9%, pZ=0.538; FDS-FDI: 
2.1±13.1%, pMC=0.663; see also Chapter 3 and Figure 3.6 B, D). In the post-tDCS 
comparison, the compound mean Z-score from FDS-FDI but not EDC-FDI (dotted red 
lines) was significantly increased (EDC-FDI: 𝑍̅=0.911, pZ=0.362; FDS-FDI: 𝑍̅=3.113, 
pZ=0.002). This suggested a further increase in coherence in FDS-FDI during the post-
tDCS session, though Monte-Carlo analysis did not reach significance (EDC-FDI: 
5.1±14.4%, pMC=0.298; FDS-FDI: 6.3±10.6%, pMC=0.157). 
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Figure 4.4: Z-scores for differences in coherence. In the intersession analysis (A, C), 
single-subject Z-scores quantified the difference between post-tDCS and pre-tDCS 
coherence. Their distribution is plotted by the stairstep curves (red); under the null 
hypothesis, they should follow a standard normal distribution (blue curve). The mean 
compound Z-score for all subjects (𝑍̅; vertical dotted lines) was significantly increased 
in both muscle pairs (pZ; blue box indicating range of ±1.96), demonstrating a group 
increase in coherence after tDCS. In the intrasession analysis (B, D), data from the pre-
tDCS and the post-tDCS sessions were each divided into two epochs. Both epochs from 
the same session were compared to each other as outlined above. In the pre-tDCS 
comparison (black), the mean compound Z-score for all subjects was not significantly 
different from zero for either muscle pair; in the post-tDCS comparison (red), it was 
significantly increased in FDS-FDI (pZ), indicating a further increase in coherence during 
the post-tDCS session. Note that the intrasession pre-tDCS data are identical to those 
presented in Figure 3.6. 
 
Intrasession analysis of power for pre-tDCS data showed no significant changes on the 
primary test (EDC: -1.8±14.8%, pW=0.689; FDS: -2.2±18.4%, pW=0.698; FDI: -18.5±13.7%, 
pW=0.207) although Monte-Carlo analysis suggested that power in FDI had declined 
significantly (EDC: pMC=0.807; FDS: pMC=0.755; FDI: pMC=0.007). In the post-tDCS 
session, power decreased between both epochs, reaching significance in EDC and FDS 
on both the primary test (EDC: -18.0±18.0%, pW=0.020; FDS: -18.9±11.3%, pW=0.001; 
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FDI: -10.8±17.8%, pW=0.256) and Monte-Carlo analysis (EDC: pMC=0.006; FDS: 
pMC<0.001; FDI: pMC=0.063). 
 
4.4.2 Experiment 2: MEP amplitude 
Figure 4.5 A displays averages of 20 MEPs at baseline and at several time points after 
tDCS for one subject. Peak-to-peak amplitudes were measured for each average, 
normalised to the baseline value and plotted against time for each subject (Figure 
4.5 B). In one subject, MEP amplitude increased immediately after tDCS, reaching a 
broad peak between 5 and 15min with amplitudes of up to 4.2x baseline before 
gradually decreasing towards baseline from 25min onwards. In all other subjects, MEP 
amplitudes after tDCS mostly remained below or around baseline. 
 
The average of all subjects (Figure 4.5 C) showed an initial decrease in MEP amplitude 
followed by a sustained increase between 5 and 35min, with a return to baseline at 
45min after tDCS. However, changes of MEP amplitude over time were not statistically 
significant (p=0.995). 
 
Figure 4.6 compares the tDCS montages used in experiments 1 and 2. In experiment 1, 
the anode was centred on a point 7cm lateral to the vertex (‘measured position’, 
Figure 4.6 A). In experiment 2, the anode was centred on the TMS hotspot of ADM 
(Figure 4.6 B; striped yellow box). In four subjects participating in experiment 2, the 
measured position was also determined at the end of the session (Figure 4.6 B; solid 
coloured boxes). In each case, the measured position was no further than 30mm from 
the hotspot, and an electrode centred on the measured position would still have 
overlapped the hotspot. 
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Figure 4.5: Single-subject and group data for MEPs. Averages of 20 MEPs are shown 
before tDCS and at multiple time points after tDCS for a single subject (A). The blue 
arrowheads indicate the time of the TMS pulse. Peak-to-peak amplitudes were 
measured between the blue bars, normalised to the pre-tDCS value and plotted 
against time after tDCS for all subjects (B). Error bars were omitted for clarity; the 
dotted horizontal line indicates no change. Normalised MEP amplitudes were averaged 
across all subjects (C). Error bars indicate 1.96*SE; no significant change was seen post-
tDCS (p=0.995). 
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Figure 4.6: Comparison of surface measurements and TMS hotspot mapping. In the 
coherence experiment, the tDCS electrode over M1 was centred on a point 7cm lateral 
to the vertex (‘measured position’), determined as the intersection of the nasion-inion 
and interaural lines. The reference electrode was placed over the contralateral 
forehead (A). In the TMS experiment, the electrode over M1 was centred on the TMS 
hotspot of ADM (B; different scale; striped yellow box). In four subjects, the measured 
position was also determined, and was found to be located no further than 30mm 
from the TMS hotspot. If the tDCS electrode had been centred on the measured 
position it would still have overlapped the TMS hotspot in each case. 
 
4.5 Discussion 
 
4.5.1 Changes in IMC and power 
The observed elevation in beta-band IMC after anodal tDCS (EDC-FDI: 12.9%; FDS-FDI: 
11.3%) was comparable in magnitude to that reported in the previous study (EDC-FDI: 
18%; Power et al., 2006). Notably the value of 18%, stated on p. 797 of Power et al. 
(2006), disagrees with their diagram which is reproduced in Figure 4.1 D. It also 
appears to be an arithmetic mean, which tends to overestimate the magnitude of any 
change compared to the geometric means reported in the present study. 
 
In addition to the increases in IMC being highly significant on a group level, around 80% 
of individuals showed an increase in at least one muscle pair, suggesting that anodal 
tDCS is a potentially useful adjunct to beta-band IMC for individual diagnostics. 
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However, the coefficients of variation were over 50%, highlighting that within-subject 
increases in coherence were small relative to between-subject variability. 
 
Use of tDCS for individual diagnostics will require increases in coherence which are 
sufficiently large to be reliably distinguished from random variability. Increases in 
current density (current per unit area of electrode) and/or duration of stimulation 
enhance the effects of tDCS on MEPs (Nitsche et al., 2007; Nitsche & Paulus, 2000, 
2001), and similar augmentation of the effects on IMC ought to be pursued. The most 
intense tDCS protocol to date delivered a current of 2mA through 5x5cm electrodes for 
20min without adverse effects (Iyer et al., 2005). This is equivalent to a current density 
of 0.8A/m2 and a charge density (total charge delivered per unit area of electrode) of 
960C/m2, respectively around three and five times greater than those used in the 
present study (0.286A/m2, 171C/m2). A histological study of rat brains exposed to 
epicranial DC stimulation reported that no damage was evident unless current density 
exceeded 28.6A/m2 and charge density exceeded 52400C/m2 (Liebetanz et al., 2009). It 
is therefore likely that even more powerful tDCS protocols than that applied by Iyer et 
al. (2005) will prove safe in humans (Bikson et al., 2009). 
 
Besides the rise in IMC, there was a trend to increases in beta-band power after tDCS. 
Although Power et al. (2006) reported no change in beta-band power as assessed by 
ANOVA, the underlying assumption of normality may have been invalid. There are 
several potential explanations for the increase in beta-band power we observed. Firstly, 
a pure learning effect is unlikely as there was no significant increase during task 
performance before tDCS. Secondly, power may have increased due to a subtle change 
in task performance, such as using greater force on average after tDCS. Such a change 
was not evident during the experiment but cannot be excluded as force and 
displacement were not measured. Finally, power may have increased as a 
consequence of anodal tDCS, and it would be helpful to perform a control experiment 
with sham tDCS to investigate this possibility. 
 
The primary statistical test indicated that power and coherence were stable between 
the two epochs before tDCS, though Monte-Carlo analysis suggested that the decline 
in beta-band power in FDI was significant. One possible explanation is that subjects 
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might have altered their performance of the task to minimise use of FDI, which might 
be more readily fatigable than the long forearm muscles. Nonetheless, coherence 
remained almost constant. As a correlational measure normalised to power (Equation 
4.3), one might expect that coherence should be relatively insensitive to changes in 
power. However, it must be kept in mind that the nervous system often shows non-
linear response characteristics and therefore concomitant changes in coherence and 
power may not be related to each other in a straightforward manner (Baker & Baker, 
2003). 
 
Between the two epochs after tDCS, power decreased in all muscles, reaching 
significance in EDC and FDS on the primary test and Monte-Carlo analysis. Again, this 
could be attributable to subtle alterations in task performance. However, coherence 
continued to increase, reaching significance in one of the muscle pairs on the primary 
test only. This might reflect ongoing consolidation of tDCS-induced plasticity. A similar, 
ongoing increase in tDCS-induced effects has not been described for MEP amplitudes 
in humans (Figure 4.1 A, B; Nitsche & Paulus, 2000, 2001). However, a study in mouse 
slices designed to mimic human tDCS reported that excitatory post-synaptic potentials 
continued to increase in amplitude for over an hour after 15min of DC stimulation 
(Fritsch et al., 2010). Although species and methodological differences must be taken 
into account, this might suggest that changes in MEPs capture only part of the plastic 
changes, with ongoing further changes beyond the period of stimulation which can be 
detected on invasive recordings and potentially through IMC analysis. 
 
Monte-Carlo analyses were principally employed to back up the results of testing for 
changes in coherence using Z-transformed data (Equation 4.5), as the latter involved 
an assumption of normality under the null hypothesis which could not be tested. The 
freedom from distributional assumptions offered by Monte-Carlo approaches comes at 
the price of lower statistical power, and this is reflected in pMC values usually being 
higher than corresponding pZ values. The reverse situation applies when comparing 
results from Monte-Carlo analysis with those of the Wilcoxon signed-rank test (pW). 
The latter is not only distribution-free but also discards much information by 
comparing ranks rather than numerical values, and would therefore be expected to be 
less powerful than Monte-Carlo analysis. 
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4.5.2 Methodological differences from previous study 
We used a topographical method for determining the location of the motor cortical 
tDCS electrode. This location differed slightly from the TMS hotspot for ADM, which 
was the target in most classical tDCS studies and is located adjacent to the hotspot for 
FDI (Wilson et al., 1993) over which Power et al. (2006) centred the electrode. 
Nonetheless, the tDCS montage proved effective at modulating IMC, probably because 
the electrode area still overlapped the M1 representation of the relevant muscles 
(Nitsche et al., 2007) or the stimulation current was sufficiently dispersed by the 
extracerebral structures (Datta et al., 2009; Miranda et al., 2006). Combined with the 
results of the previous study, this makes it unlikely that a montage based on TMS or 
neuronavigation would substantially increase the effect of anodal tDCS on IMC. Such 
measures would also markedly increase cost and restrict availability. 
 
There were several other methodological differences between the present study and  
Power et al. (2006). Firstly, our task involved phasic rather than sustained contraction 
as coherence is known to be maximal during the early hold phase (Baker et al., 1997; 
Sanes & Donoghue, 1993). Absolute results before tDCS were not reported by Power 
et al. (2006) so no direct comparison can be made. Secondly, we used a slightly 
narrower beta-band (15-30Hz cf. 15-35Hz). This is unlikely to have had a significant 
effect as coherence tended to peak within our 15-30Hz window and was low or absent 
above the upper 30Hz boundary (also see Figure 3.2 B, D). Thirdly, we summed total 
coherence within the beta-band window, whereas Power et al. (2006) only included 
coherence above the significance level. As our significance level was markedly lower 
than in Power et al. (2006; 0.015 cf. 0.04), a substantial effect is improbable. Finally, 
our study did not include a control group. Subjects were blind to the intended effects 
of tDCS, there is no evidence that IMC can be consciously manipulated, and no practice 
effects were evident when IMC data were compared between two epochs before tDCS. 
Nonetheless, a sham condition would help to rule out any spurious effects. 
 
Muscle activity in the target limb is a prerequisite for IMC analysis yet might interfere 
with tDCS-induced modifications of cortical plasticity. Similar to de-potentiation and 
de-depression observed in animal experiments, the effects of tDCS on MEPs and 
measures of intracortical excitability can be attenuated or abolished if the period of DC 
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stimulation is succeeded by voluntary muscle contraction (Thirugnanasambandam et 
al., 2011). The effect was demonstrated using a sustained contraction of FDI at 20% 
maximum voluntary contraction (MVC) for two minutes, a task not unlike that used by 
Power et al. (2006) for coherence estimation. Whilst Power et al. (2006) described 
significant alterations of IMC and MEPs after tDCS, the time course of the MEP changes 
was much more short-lived than expected from previous work in which the subject 
was at rest throughout (0-5min vs. 40min; Nitsche & Paulus, 2001). This difference 
could be explained in terms of modification of plasticity by voluntary activity. The 
coherence alterations described by Power et al. (2006) were also brief (5-10min), 
contrasting with our study where changes in coherence prevailed for at least 10min 
and appeared to increase rather than decrease during this period. It has been 
suggested that activity influences the effects of neuromodulation in a task-specific 
manner (Thirugnanasambandam et al., 2011) and our phasic task might have 
interfered less with tDCS-induced plasticity than a sustained contraction. The task-
dependence of these effects has not been systematically characterised, and needs to 
be regarded as a caveat when studying the effect of tDCS on coherence. 
 
4.5.3 Changes in MEP amplitude 
We failed to reproduce clearly the classical effects of tDCS on TMS-evoked motor 
responses. The trend in the group data principally resulted from one subject showing 
an unusually large increase in MEP amplitude after tDCS, whereas MEP amplitude in 
the remaining subjects remained largely unchanged or even decreased. Previous 
studies reported a high degree of interindividual and intraindividual variability, but 
even in individual subjects most MEP amplitudes at relevant time points after anodal 
tDCS exceeded baseline (Figure 4.1 B; Nitsche & Paulus, 2001). 
 
The reasons for not observing the classical effects on MEPs in this investigation are 
obscure. Our protocol closely paralleled previously reported methods (Nitsche et al., 
2008; Nitsche & Paulus, 2000, 2001). With few exceptions (Ardolino et al., 2005), past 
studies used a figure-of-eight coil for evoking motor responses. The focality of this coil 
ensures that the cortical area effectively stimulated by TMS is no larger than that 
affected by tDCS (M. A. Nitsche, personal communication, 16 October 2012), but also 
makes TMS exquisitely sensitive to positional changes. All classical studies used hand-
 85 
 
held coils without positioning aids. The risk of positioning errors is high, particularly 
when replacing the coil after tDCS, and we attempted to mitigate this problem by use 
of a motion tracking system and all TMS being performed by the same experienced 
operator. However, the head was not fully immobilised by the frame so small 
positioning errors might still have occurred. This could be addressed by use of a bite-
bar or automated robotic head tracking. Our previous approach of using a modified 
motorcycle helmet to keep the coil in a constant position relative to the head (Mitchell 
et al., 2007) would not have been workable as the application of the tDCS electrode 
over the motor cortex required the coil to be removed. 
 
 
4.6 Conclusion 
 
In summary, the magnitude of the observed effects of anodal tDCS on beta-band IMC 
is in keeping with previously reported results. The duration of the increase in beta-
band IMC agrees with the timecourse of classical MEP data but not the previous report 
of tDCS-associated changes in IMC. It would be useful to measure power and 
coherence at multiple time points after tDCS until all results have returned to baseline, 
and to perform a control experiment with sham tDCS. Additionally, the effects of more 
powerful tDCS protocols on IMC ought to be studied. 
 
Thus far, most investigations of tDCS have targeted the M1 representation of the hand. 
Only a small number of studies have considered the effects of tDCS on the 
representation of the lower limb (Jeffery et al., 2007; Madhavan & Stinear, 2010; 
Roche et al., 2011; Tanaka et al., 2009). It would be of interest to explore any impact of 
tDCS on lower limb IMC, but the scope of our study should only be extended in this 
manner once the aforementioned issues have been addressed. 
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5  Intermuscular coherence and central motor conduction times in patients with motor neuron disease 
   
  Having investigated central motor conduction times (CMCT) and intermuscular 
coherence (IMC) in normal individuals, we now turn our attention to CMCT and IMC 
in motor neuron disease. 
 
 
5.1 Abstract 
 
Objective: To investigate beta-band intermuscular coherence (IMC) and central motor 
conduction times (CMCT) as biomarkers of corticospinal tract (CST) integrity in patients 
with motor neuron disease (MND). 
 
Methods: 61 patients with MND, recruited at first presentation to a tertiary MND 
service, and 92 healthy control subjects were included. In the upper limb, IMC was 
estimated between extensor digitorum communis (EDC) and first dorsal interosseous 
(FDI) as well as between flexor digitorum superficialis (FDS) and FDI. In the lower limb, 
IMC was measured between medial gastrocnemius (MG) and extensor digitorum 
brevis (EDB) as well as between tibialis anterior (TA) and EDB. Magnetic stimulation 
was performed over the primary motor cortex (cortical latency) and over the cervical 
and lumbar spine (spinal latency). The spinal latency was taken as an estimate of 
peripheral motor conduction time (PMCT), and was subtracted from cortical latency to 
yield CMCT. The performance of individual and combined IMC and CMCT markers was 
analysed using the area under the receiver-operating characteristic curve (AUC). 
 
Results: Within a given limb, IMC in the best muscle pair was as good a classifier as 
combinations of IMC from both muscle pairs (AUC upper limb 0.83, lower limb 0.79). In 
the upper limb, IMC performed better than all CMCT markers, including combinations 
of CMCT. In the lower limb, performance of IMC was very similar to that of CMCT in 
individual muscles, but lagged behind combined CMCT markers (AUC 0.90-0.91). Non-
linear combinations of markers performed at best marginally better than their linear 
counterparts, suggesting that linear combinations are sufficient.  
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Conclusion: IMC has potential as a quantitative test for CST involvement in MND. It 
exceeded the performance of CMCT in the upper limb and matched that of individual 
CMCT markers in the lower limb. Unlike CMCT, IMC requires no dedicated equipment, 
and thus its deployment as a clinical test would be relatively inexpensive. 
 
 
5.2 Introduction 
 
Motor neuron disease (MND) is an inexorably progressive, fatal neurodegenerative 
disorder. It is rare, with an estimated incidence of 2 per 100,000 per year (McGuire & 
Nelson, 2006), and encompasses a spectrum of phenotypes; the commonest one, 
amyotrophic lateral sclerosis (ALS), involves loss of pyramidal neurons in the primary 
motor cortex as well as motor neurons in the brainstem and spinal cord. ALS typically 
runs an aggressive course with a median survival of 30 months from symptom onset 
(Chancellor et al., 1993). Diagnosis is primarily clinical and requires evidence of upper 
and lower motor neuron (UMN, LMN) pathology in a defined topography after 
excluding alternative causes, as specified by the El Escorial criteria (Brooks, 1994). 
Subsequent revisions of these diagnostic criteria have placed increasing emphasis on 
EMG features of LMN dysfunction in regions without clinical LMN signs (Brooks et al., 
2000; De Carvalho et al., 2008), thus increasing sensitivity (De Carvalho & Swash, 2009). 
 
One focus of therapy is to slow neuronal degeneration with neuroprotective drugs, 
and early diagnosis is therefore paramount. At symptom onset, fewer than 5% of 
motor units remain in muscles with clinical LMN signs, and up to 50% of motor units 
have been lost in asymptomatic muscles (Aggarwal & Nicholson, 2002). This limits the 
number of potentially salvageable motor neurons. Against this backdrop it is 
remarkable that riluzole, the only neuroprotective agent currently licensed in MND, 
has been shown to extend survival by a median 2-3 months (Bensimon et al., 1994; 
Lacomblez et al., 1996; Miller et al., 2012). It is plausible that earlier introduction of 
riluzole could delay the onset of disability and extend survival further (Swash, 1998). 
For at least two decades, the median time from symptom onset to diagnosis has 
remained constant at around one year (Househam & Swash, 2000; Mitchell et al., 
2010). This interval is unacceptably long in relation to the typical life expectancy in 
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MND, and shortening it would not only maximise the impact of neuroprotective agents 
but also be helpful for arranging best management, providing opportunities for 
entering clinical trials (De Carvalho et al., 2008) and serving the psychological interests 
of the patient (Johnston et al., 1996). 
 
The lack of a reliable test for corticospinal tract (CST) integrity constitutes one 
impediment to early diagnosis (Turner et al., 2009). Clinical signs such as clonus, 
hyperreflexia and extensor plantar responses are useful pointers but may not 
exclusively reflect pathology in the CST (Brown, 1994). In addition, autopsy studies 
suggest that clinical assessment has a low sensitivity, as most cases without clinical 
UMN signs show histological evidence of CST degeneration (Kaufmann et al., 2004). 
Several markers based on transcranial magnetic stimulation (TMS) have been explored, 
particularly lengthening of central motor conduction time (CMCT) and diminution or 
absence of cortical motor evoked potentials (MEPs). Despite initial enthusiasm (Di 
Lazzaro et al., 1999) there have been continued reservations about the diagnostic 
utility of these parameters (Mills, 2003). The triple stimulation technique (TST) has 
boosted diagnostic sensitivity for CST dysfunction (Magistris et al., 1999; Magistris et 
al., 1998), but not only shares the practical disadvantages of other TMS-based 
measures – a requirement for specialist expertise and expensive equipment – but is 
also uncomfortable and time-consuming. MRI approaches for assessing CST integrity 
have included spectroscopy, diffusion-tensor imaging and voxel-based morphometry 
(Turner et al., 2009). However, patients may be unable to tolerate the required period 
of recumbency; adequate performance in early MND at single-subject level is 
unproven (Filippi et al., 2010); and the requisite expertise and high-field MRI facilities 
are not universally available. It is therefore unsurprising that diagnostic criteria have 
not incorporated any TMS- or MRI-based markers of CST function to date, but rather 
continue to bemoan the need ‘for a reliable and sensitive method for assessing UMN 
disorder’ (De Carvalho et al., 2008). 
 
A recently proposed mode of assessment leverages the role of the CST in the 
transmission of oscillatory activity (Fisher et al., 2012). 15-30Hz beta-band oscillations 
can be recorded from the primary motor cortex in animals (Baker et al., 1997; Murthy 
& Fetz, 1992; Sanes & Donoghue, 1993) and humans (Conway et al., 1995; Halliday et 
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al., 1998; Ohara et al., 2000; Pfurtscheller, 1981). They are task-dependent, being 
prominent during hold phases and diminished during movement (Baker et al., 1997; 
Sanes & Donoghue, 1993). Coherence analysis demonstrates that beta-band 
oscillations are synchronised between the cortex and contralateral muscles 
(corticomuscular coherence, CMC; Baker et al., 1997; Conway et al., 1995; Halliday et 
al., 1998; Ohara et al., 2000), suggesting that they are transmitted from cortex to 
muscle. Similarly, coherence is demonstrable between individual muscles in a given 
limb (Baker et al., 1997; Farmer et al., 1993), and such intermuscular coherence (IMC) 
is thought to reflect a shared cortical drive. In practice, IMC is often preferred to CMC 
as no cortical recording is required and significant 15-30Hz IMC is present in most 
normal individuals, whereas CMC is a less consistent phenomenon (Fisher et al., 2012; 
Ushiyama et al., 2011b). 
 
IMC depends on supraspinal pathways, as it is absent after capsular strokes (Farmer et 
al., 1993) and spinal cord lesions (Hansen et al., 2005; Norton et al., 2003). Several 
lines of evidence suggest a critical role for the CST in particular. Firstly, beta-band IMC 
is absent in patients with primary lateral sclerosis (PLS), a pure UMN variant of MND, 
whereas significant beta-band IMC is detectable in patients with progressive muscular 
atrophy (PMA), a pure LMN variant of MND (Fisher et al., 2012). Secondly, selective 
lesioning of the CST in macaques abolishes beta-band IMC (Fisher et al., 2012; 
Nishimura et al., 2009). Thirdly, stimulation of the CST resets the phase of cortical 
15-30Hz oscillations in macaques, suggesting that the CST does not merely act as a 
conduit but forms part of a rhythm-generating network (Jackson et al., 2002). Indeed, 
there is increasing evidence that afferent pathways contribute to 15-30Hz coherence, 
leading to the suggestion that coherence is mediated by an efferent-afferent feedback 
loop (Witham et al., 2011; Witham et al., 2010). 
 
Here, we examine whether IMC is a useful biomarker of UMN function in MND. Unlike 
the previous study from our group, which focussed on patients with selected variants 
which had been followed up for many years (Fisher et al., 2012), we recruited patients 
with all phenotypes of MND as early as possible after referral to the local tertiary 
service. This shifted the emphasis from the rare subtypes of PLS and PMA to the 
commoner ones of amyotrophic lateral sclerosis (ALS) and progressive bulbar palsy 
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(PBP). In addition to IMC, we measured CMCT for comparison. Magnetic stimulation 
was performed over the primary motor cortex (cortical latency) and over the cervical 
and lumbar spine (spinal latency). The spinal latency was taken as an estimate of 
peripheral motor conduction time (PMCT), and was subtracted from cortical latency to 
yield CMCT. Control data for IMC and CMCT were gathered from a large number of 
healthy volunteers (Chapters 2 and 3). 
 
IMC and CMCT were treated as binary classifiers discriminating between diseased and 
normal states, and their performance was assessed using receiver-operating 
characteristic (ROC) curves. These are monotonically increasing functions from (0,0) to 
(1,1) and plot the true positive rate (TPR, the fraction of true positives out of all actual 
positives; equivalent to sensitivity) against the false positive rate (FPR, the fraction of 
false positives out of all actual negatives; equivalent to 1-specificity) for all possible 
discrimination thresholds. Hence, ROC curves illustrate the trade-off between 
increasing TPR and increasing FPR (Pepe & Thompson, 2000). A random guess would 
have a ROC curve running along a diagonal line from (0,0) to (1,1), the so-called line of 
no discrimination. The best possible marker would yield a point at (0,1), referred to as 
a perfect classification, representing 100% TPR and 0% FPR. Generally, points above 
and below the diagonal represent good (better than random) and poor (worse than 
random) discrimination respectively. A consistently poor predictor can be inverted to 
obtain a good predictor, equivalent to reflecting the ROC curve about the diagonal. We 
summarised each ROC curve by calculating the area under the curve (AUC), which 
ranged from 0 for a perfect but inverted classification to 1 for a perfect classification, 
with 0.5 corresponding to a random guess. An AUC of less than 0.5 in the overall 
analysis prompted inversion of the predictor. In addition to IMC and CMCT per se, we 
explored the performance of their optimal linear and non-linear combinations. 
 
We found that IMC performed better than CMCT in the upper limb, and performed 
similarly to CMCT in the lower limb. Unlike CMCT, IMC does not require dedicated 
equipment beyond pre-existing EMG facilities, and this could ease its adoption for 
future studies and potential clinical use. 
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5.3 Methods 
 
5.3.1 Subjects 
Between February 2011 and February 2013, patients were recruited from the tertiary 
Motor Neuron Disease Service at Newcastle Upon Tyne Hospitals, serving a catchment 
population of approx. 2.6 million in the North East of England (Office for National 
Statistics, 2011). Recruitment took place as soon as possible after referral to the 
Service, either in the new patient clinic or during scheduled admission for investigation. 
Successfully recruited subjects were studied in the laboratory within four weeks. Out 
of 101 subjects assessed by the Service, 79 were recruited to the study (Figure 5.1). 
After clinical assessment, investigation and – if necessary – serial follow-up, 63 of these 
were diagnosed with MND. Two subjects were excluded due to sensory neuropathy on 
nerve conduction studies (NCS), leaving 61 subjects to be included in the analysis. A 
breakdown by phenotype is shown in Table 5.1, and clinical features including drug 
histories are summarised in Appendix B. 
 
Control data were obtained from 92 healthy subjects (51 men, 41 women; age range 
22-77 years, mean±SD 48.6±17.2). None had any history of neurological disorders or 
diabetes mellitus, and none took any neurotropic medication. 
 
All subjects provided written informed consent. The studies on patients and control 
subjects were approved by the National Research Ethics Service (County Durham and 
Tees Valley Research Ethics Committee, reference number 08/H0908/3) and Newcastle 
University’s Medical Faculty respectively. Both studies conformed to the Declaration of 
Helsinki. 
 
 92 
 
 
 
Figure 5.1: Subject flow. Numbers of subjects assessed by the MND service, 
participating in the study, diagnosed with MND and included in the analyses are shown 
along with the reasons for drop-out at each stage. (FOSMN=facial-onset sensory and 
motor neuronopathy, FTD=fronto-temporal dementia, MMN=multifocal motor 
neuropathy, MSA=multi-system atrophy, NCS=nerve conduction studies)  
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Table 5.1: Breakdown of MND patients by phenotype. (SOD1=superoxide dismutase 1; 
TDP43=transactive response DNA binding protein 43kDa; *c.229G>T, p.Asp77Tyr in 
exon 3) 
 
Phenotype Subgroup Genetics n   
ALS   39   
 Flail arm   8  
 Flail leg   1  
 Familial   3  
  No known pathogenic mutation in SOD1 or TDP43   2 
  Familial pathogenic mutation in SOD1*   1 
PBP   10   
ALS/PBP overlap   2   
PLS   7   
PMA   3   
 Familial   1  
  No genetic testing performed   1 
Total   61   
 
5.3.2 Recording 
Every effort was made to maintain subjects at a constant level of alertness. Subjects 
were seated in a comfortable chair with their arm resting on a cushion. Surface EMG 
was recorded from abductor pollicis brevis (APB), first dorsal interosseous (FDI), flexor 
digitorum superficialis (FDS) and extensor digitorum communis (EDC) in the upper limb, 
and extensor digitorum brevis (EDB), abductor hallucis (AH), tibialis anterior (TA) and 
medial gastrocnemius (MG) in the lower limb. Adhesive electrodes (Bio-Logic M0476; 
Natus Medical, Mundelein, IL) were placed in a belly-tendon montage over the intrinsic 
muscles of the hand or foot; for the long muscles of the forearm or calf, the electrodes 
were placed 4cm apart, one third along the muscle from its proximal origin. Signals 
were amplified, band-pass filtered (30Hz-2kHz; Digitimer D360, Digitimer, Welwyn 
Garden City, UK) and digitised at 5kHz (Micro1401, Cambridge Electronic Devices, 
Cambridge, UK). 
 
5.3.3 Experiment 1: IMC 
In the upper limb, subjects were asked to perform a repetitive precision grip task. A 
length of compliant plastic tubing (length 19cm, Portex translucent PVC tubing 
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800/010/455/800; Smith Medical, Ashford, UK) was attached to the index finger and 
thumb with Micropore tape (3M Health Care, Neuss, Germany), and subjects were 
asked to oppose both ends of the tubing when prompted by visual and auditory cues. 
This auxotonic task – so-called because force increases with displacement in a spring-
like fashion – required a minimum force of 1N (Fisher et al., 2012) and was similar to a 
precision grip task used in our previous studies, albeit without measuring digit 
displacement (Kilner et al., 2000; Riddle & Baker, 2006). In the lower limb, subjects 
were asked to dorsiflex ankle and toes in the air while resting the heel on the ground. 
Subjects produced 4s of contraction alternating with 2s of relaxation, and at least 100 
repetitions. Where necessary, the recording was divided into a number of sections 
separated by rest to prevent fatigue. Visual feedback of raw EMG traces was provided 
to facilitate consistent task performance. 
 
One upper limb and one lower limb were assessed in each subject. In patients with 
MND, we studied the most affected upper and lower limb as reported by the subject. If 
the subject was unable to perform the coherence task using the most affected limb, 
we assessed the contralateral limb instead; in three cases, the subject was unable to 
perform the lower limb coherence task on either side and the lower limb was excluded 
from IMC and CMCT analyses (Figure 5.1). Where both sides were unaffected or 
equally affected, the limb on the dominant side was assessed. All assessments in 
control subjects were carried out on the dominant side. 
 
5.3.4 Experiment 2: CMCT 
CMCT was always measured on the same side as IMC. As CMCT is known to be highly 
correlated between both sides in MND, studying the less affected side where 
necessitated by the coherence task should not have compromised CMCT performance 
(Mills, 2003). Two patients declined TMS; one control subject did not tolerate upper 
limb TMS and two control subjects did not tolerate lower limb TMS beyond 30% of 
maximum stimulator output. These individuals were excluded from CMCT analysis 
(Figure 5.1). 
 
Magnetic stimulation was delivered using a Magstim 200 stimulator (Magstim 
Company, Whitland, UK) at a frequency of 0.2Hz. For upper limb cortical motor evoked 
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potentials (MEPs), a circular coil (13cm outer diameter) was held over the vertex, with 
its orientation optimised for stimulation of the contralateral hemisphere (A side up: 
left hemisphere, B side up: right hemisphere). For lower limb cortical MEPs, a double 
cone coil was used in an analogous manner (posterior coil current: left hemisphere, 
anterior coil current: right hemisphere). If, at a stimulation intensity of at least 40%, 
resting motor threshold had not been reached and the subject declined further 
escalation, the cortical MEP and thus CMCT was assigned as absent. Otherwise, 
stimulation intensity was set at 10% above the resting motor threshold as defined by 
the Rossini-Rothwell method (Rossini et al., 1994). Cortical MEPs are facilitated and 
their onset latencies minimised by a weak background contraction of the target muscle, 
with no requirement for strictly controlling the force of the contraction (Chen et al., 
2008; Kimura, 2001). Ten MEPs were recorded in the upper limb during opposition of 
index finger and thumb, and in the lower limb during either dorsiflexion (EDB, TA) or 
plantarflexion (AH, MG) of ankle and toes. Upper and lower limb root MEPs were 
recorded at rest with the circular coil centred over the spinous processes of C7 and L1. 
If no clear root MEPs were obtained, the limb was excluded from CMCT analysis 
(Figure 5.1). 
 
In normal subjects, the range of stimulation intensities used was 35-80% and 40-100% 
for cortical MEPs of the upper and lower limbs respectively, and 40-90% and 40-100% 
for corresponding root MEPs. In patients with MND, the equivalent ranges were all 40-
100%. 
 
5.3.5 Data analysis 
Analysis was performed in Matlab (Mathworks, Natick, MA) using custom scripts. 
 
Raw IMC data were visually inspected and the first 100 adequately performed trials 
examined further. Analysis focussed on the early hold phase of the contraction where 
beta-band oscillations are known to be maximal (Baker et al., 1997; Sanes & Donoghue, 
1993). EMG signals were full-wave rectified. Starting 0.8s after the cue prompting 
contraction, two contiguous 0.82s-long sections of data from each trial were subjected 
to a 4096-point fast Fourier transform (FFT), giving a frequency resolution of 1.22Hz. 
Many subjects showed a drop-off in EMG activity so the last 1.56s of the 4s active 
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phase did not enter the analysis. Denoting the Fourier transform of the 𝑙th section of 
the first EMG signal as 𝐹1,𝑙(𝜆), the auto-spectrum is given by 
 
𝑓11(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹1,𝑙(𝜆)�������� (5.1)  
 
where 𝜆 is the frequency (Hz), 𝐿 is the total number of sections and where the overbar 
denotes the complex conjugate. The cross-spectrum for two EMG signals with Fourier 
transforms 𝐹1,𝑙(𝜆) and 𝐹2 ,𝑙(𝜆) was calculated as 
 
𝑓12(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹2,𝑙(𝜆)�������� (5.2)  
 
Coherence was computed as the cross-spectrum normalised by the auto-spectra 
 
𝐶(𝜆) = |𝑓12(𝜆)|2
𝑓11(𝜆)𝑓22(𝜆) (5.3) 
 
Coherence was calculated for the muscle pairs EDC-FDI, FDS-FDI, MG-EDB and TA-EDB. 
The wide anatomical spacing between the paired muscles minimised the risk of volume 
conduction causing inflated coherence values (Grosse et al., 2002). 
 
Under the null hypothesis of linear independence between the signals, a level of 
significant coherence was determined as (Rosenberg et al., 1989) 
 
𝑍 = 1− 𝛼1/(𝐿−1) (5.4)  
 
where the significance level 𝛼 was set at 0.05. 
 
Analyses of coherence described below were conducted separately for each muscle 
pair. 
 
 97 
 
To provide a group summary, coherence spectra were averaged across all patients 
with MND and all control subjects respectively. The significance level for averaged 
coherence was determined using the method described by Evans and Baker (2003). 
 
In each subject, coherence was averaged across the 15-30Hz window. Log-transformed 
15-30Hz coherence could not be modelled adequately with a normal distribution in 
either the MND or the control group (Shapiro-Wilk test, p<0.001 in at least two muscle 
pairs per group, Bonferroni-corrected significance level α/n=0.05/4=0.0125). Therefore, 
we chose to model coherence distributions non-parametrically. The variable kernel 
method adapts the amount of smoothing to the local density of the data (Silverman, 
1986) and estimates the probability density function (PDF) as 
 
?̂?(𝑥) = 1
𝑁
� �
1
ℎ𝑑𝑛,𝑘 ∙ 𝜙 �𝑥 − 𝑋𝑛ℎ𝑑𝑛,𝑘 ��
𝑁
𝑛=1
 (5.5)  
 
where 𝑥  denotes the log-transformed independent variable, 𝑋𝑛  the 𝑛
th log-
transformed observation out of a total 𝑁 observations, 𝑑𝑛,𝑘  the distance from 𝑋𝑛 to its 
𝑘th nearest neighbour, ℎ the global smoothing parameter and 𝜙 the standard normal 
PDF. To understand this intuitively: each observation 𝑋𝑛  was convolved with a 
Gaussian kernel with unit AUC as specified inside the square brackets, and the sum of 
these kernels was normalised by 𝑁 to yield ?̂?(𝑥). The window width of the kernel 
centred on a given observation 𝑋𝑛 was proportional to 𝑑𝑛,𝑘  so that broader kernels 
were associated with observations in regions with sparse data; for any fixed 𝑘, the 
amount of smoothing depended on the global smoothing parameter ℎ. 𝑘 was set as 
√𝑛 rounded to the nearest integer as suggested by Silverman (1986). Theoretically 
optimal methods for calculating ℎ have been described but, for our data, resulted in 
overfitting. Therefore, ℎ was optimised by eye for several datasets; the resulting values 
of ℎ were empirically fitted with simple algebraic functions and the approximation 
ℎ = √𝑛 − 512  was chosen to determine ℎ subsequently. It should be emphasised that 
this expression has no theoretical value, but merely provided a convenient shorthand 
way of determining ℎ objectively for each dataset. 
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Log-transformed coherence has a bounded domain of (−∞,0]. To ensure that the PDF 
was zero for 𝑥>0, ?̂?(𝑥) was modified by reflection in the boundary (Silverman, 1986): 
 
𝑔�(𝑥) = �?̂?(𝑥) + ?̂?(−𝑥)  , 𝑥 ≤ 00  , 𝑥 > 0 (5.6)  
 
The resulting PDF still integrated to unity and observations near the boundary retained 
the same magnitude of contribution to the PDF. The estimated cumulative distribution 
function (CDF) was calculated as 
 
𝐺�(𝑦) = � 𝑔�(𝑥)𝑑𝑥𝑦
−∞
 (5.7)  
 
where 𝑦 is the log-transformed independent variable. 
 
The odds of a subject having MND at a given level of log-transformed coherence 𝑥 
were calculated as the ratio of the PDFs for the MND and control groups: 
 
𝑂𝐷� (𝑥) = 𝑔�𝑀𝑁𝐷(𝑥)
𝑔�𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑥) (5.8)  
 
For MEP data, onset latencies were assigned interactively. In the presence of a 
background contraction, the earliest deflection of the MEP with the shortest latency 
was often ambiguous on superimposed raw traces because of background EMG 
activity, but could be easily identified on averages of rectified MEPs (Figure 5.6). Hence, 
such averages were used for assigning latencies throughout. CMCT was calculated as 
the difference between cortical and spinal latencies. Lower limb CMCT was corrected 
for height using the regression model described in Chapter 2. 
 
The group analyses of CMCT and IMC data differed in three respects. Firstly, CMCT 
readings were analysed on a linear rather than a logarithmic scale. Secondly, as a 
measure of time CMCT has a bounded domain of [0,∞), which was taken into account 
by inverting the inequalities in Equation 5.6. Thirdly, where the cortical MEP was 
absent, the CMCT was assigned an arbitrary value of 50ms which substantially 
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exceeded the range of CMCTs observed in this study. This allowed the data to be 
processed without alterations to the density estimation algorithm, and did not affect 
the density estimates over the plotted range of 0-30ms. 
 
In each limb, coherence readings from both muscle pairs and CMCT readings from all 
four muscles were treated as separate markers 𝑀𝑖. The diagnostic accuracy of these 
markers as tests for MND was quantified using the area under the ROC curve. The ROC 
curve for each marker 𝑀𝑖 was defined as the set of points {FPR(d), TPR(d)} where 
TPR(d) and FPR(d) are the true and false positive rates associated with the positivity 
criterion 𝑀𝑖 ≥ 𝑑 for a discrimination threshold 𝑑 in the range (–∞,0). Where the area 
under the ROC curve (AUC) was less than 0.5, the positivity criterion was inverted, 
equivalent to reflecting the ROC curve about the diagonal. The AUC thus had an 
effective range of [0.5,1], with 0.5 indicating no discrimination capacity and 1 
indicating perfect discrimination capacity. 
 
We sought linear combinations of markers which maximised the AUC associated with 
the composite marker, entering either both coherence markers, all four CMCT markers 
or all six coherence and CMCT markers into the analysis. Each marker was transformed 
to standardised Z-scores. For a set of 𝑛 markers 𝑀𝑖, 𝑛 − 1 raw coefficients 𝛼𝑖 were 
assigned random values in the range [-1,1]. The first coefficient did not require 
transformation, so 𝛾1 = 𝛼1; subsequent coefficients were transformed according to 
the formula: 
 
𝛾𝑖 = 𝛼𝑖�1−�𝛼𝑗2𝑖−1
𝑗=1
  ,          𝑖 > 1 (5.9)  
 
The linear combination of markers was then computed as: 
 
𝑁(𝛾) = �𝛾𝑖𝑀𝑖𝑛−1
𝑖=1
+ �1−�𝛾𝑖2𝑛−1
𝑖=1
∙ 𝑀𝑛 (5.10)  
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From this starting condition, we used the GlobalSearch solver (Matlab global 
optimization toolbox) to find the set of coefficients 𝛼𝑖 associated with the maximal 
AUC. GlobalSearch combines a random scatter search with a local gradient-based 
solver. We permitted up to 104 random trial points seeded from the starting condition 
and up to 104 iterations of the local solver per trial point. For each set of markers, we 
ran GlobalSearch 100 times. Most runs converged to near-identical solutions, and we 
chose the best overall result (Table 5.2). 
 
Using a similar method, we investigated non-linear combinations involving all possible 
first-order products of markers, thus extending the number of coefficients to 
�
𝑛2� + 𝑛 − 1. The non-linear combination of markers was calculated as: 
 
𝑁(𝛾) = �𝛾𝑖𝑀𝑖𝑛
𝑖=1
+ � � 𝛾𝑖,𝑗𝑀𝑖𝑀𝑗𝑛
𝑗=𝑖+1
𝑛−2
𝑖=1
+ �1 −�𝛾𝑖2𝑛
𝑖=1
−� � 𝛾𝑖 ,𝑗2𝑛
𝑗=𝑖+1
𝑛−2
𝑖=1
∙ 𝑀𝑛−1𝑀𝑛 (5.11)  
 
For each marker or combination of markers, the AUC was also evaluated in the ALS and 
PBP subgroups (Table 5.2), with the positivity criteria and any coefficients having 
previously been determined in the whole MND group. Since no further inversion of the 
positivity criteria was permitted, the AUCs for these subgroups had a range of [0,1]. 
Other phenotypes including ALS/PBP overlap, primary lateral sclerosis (PLS) and 
progressive muscular atrophy (PMA) were not evaluated separately due to the low 
number of subjects in each of these groups (Table 5.1). Confidence intervals for AUCs 
were estimated using bootstrapping. Owing to the substantial number of potential 
comparisons, we did not use formal statistical tests when comparing AUCs between 
markers and subgroups. 
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Table 5.2: Area under the ROC curve (AUC) associated with coherence and CMCT markers and their optimal linear and non-linear combinations, and coefficients used for deriving these combinations. The AUC was calculated 
in the entire MND cohort for each individual marker, and coefficients were sought which maximised the AUC for the combination of a given number of markers. These combinations were either l inear, using coefficients 𝛼𝑖, or  
non-linear, referring to the additional inclusion of first-order products of all  possible combinations of markers and using coefficients 𝛼𝑖 and 𝛼𝑖,𝑗 . Combining a given number of markers 𝑛 involved 𝑛 − 1 explicitly defined 
coefficients, with the coefficient for the last marker given implicitly by the square root term (SRT) as defined in Equations 5.10 and 5.11. AUCs were also calculated for the subgroups of ALS and PBP; any combined markers 
employed coefficients previously determined in the entire MND cohort. (comb’n=combination) 
 
 Parameter   Coherence    CMCT      Both  
    EDC-FDI FDS-FDI Linear 
comb’n 
Non-linear 
comb’n 
FDI APB FDS EDC Linear 
comb’n 
Non-linear 
comb’n 
Linear 
comb’n 
Non-linear 
comb’n 
Upper l imb AUC All  phenotypes 0.786 0.831 0.832 0.839 0.659 0.698 0.568 0.707 0.758 0.791 0.891 0.895 
  ALS  0.806 0.848 0.848 0.849 0.675 0.704 0.589 0.705 0.747 0.772 0.890 0.895 
  PBP  0.701 0.793 0.796 0.767 0.207 0.603 0.353 0.555 0.566 0.557 0.804 0.698 
 Linear 
coefficients 
𝛼𝑖 
EDC-FDI    0.047 0.457       0.538 -0.483 
 FDS-FDI    SRT 0.643       SRT -0.510 
 FDI          0.343 0.326 -0.220 -0.014 
  APB          0.458 0.248 -0.325 0.310 
  FDS          -0.479 -0.115 0.383 -0.192 
  EDC          SRT 0.555 -0.375 0.368 
 Non-linear 
coefficients 
𝛼𝑖 .𝑗 
EDC-FDI FDS-FDI    SRT        SRT 
 EDC-FDI FDI            -0.873 
 EDC-FDI APB            0.412 
  EDC-FDI FDS            0.980 
  EDC-FDI EDC            0.907 
  FDS-FDI FDI            -0.776 
  FDS-FDI APB            -0.320 
  FDS-FDI FDS            0.370 
  FDS-FDI EDC            -0.380 
  FDI APB          0.489  0.282 
  FDI FDS          0.430  0.155 
  FDI EDC          0.614  0.667 
  APB FDS          -0.132  0.196 
  APB EDC          0.297  -0.464 
  FDS EDC          SRT  0.849 
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 Parameter   Coherence    CMCT      Both  
    MG-EDB TA-EDB Linear 
comb’n 
Non-linear 
comb’n 
EDB AH TA MG Linear 
comb’n 
Non-linear 
comb’n 
Linear 
comb’n 
Non-linear 
comb’n 
Lower l imb AUC All  phenotypes 0.793 0.769 0.796 0.796 0.795 0.790 0.819 0.777 0.896 0.908 0.927 0.939 
  ALS  0.739 0.715 0.743 0.743 0.814 0.761 0.835 0.772 0.885 0.908 0.911 0.935 
  PBP  0.842 0.850 0.848 0.848 0.842 0.860 0.783 0.773 0.930 0.860 0.956 0.879 
 Linear 
coefficients 
𝛼𝑖 
MG-EDB    0.948 0.949       -0.281 -0.167 
 TA-EDB    SRT 1.000       SRT 0.480 
 EDB          0.324 -0.372 -0.235 -0.276 
  AH          0.482 -0.418 -0.469 -0.335 
  TA          0.901 -0.511 -0.612 -0.479 
  MG          SRT -0.172 -0.373 -0.167 
 Non-linear 
coefficients 
𝛼𝑖 .𝑗 
MG-EDB TA-EDB    SRT        SRT 
 MG-EDB EDB            -0.999 
 MG-EDB AH            0.719 
  MG-EDB TA            0.017 
  MG-EDB MG            -0.790 
  TA-EDB EDB            0.255 
  TA-EDB AH            0.873 
  TA-EDB TA            -0.430 
  TA-EDB MG            -0.034 
  EDB AH          -0.275  -0.176 
  EDB TA          -0.741  -0.784 
  EDB MG          0.995  0.855 
  AH TA          0.629  0.208 
  AH MG          -0.598  0.302 
  TA MG          SRT  -0.323 
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5.4 Results 
 
5.4.1 IMC 
Single-subject power and coherence data for a control subject and a patient with MND 
are shown in Figure 5.2. In subjects from either group, power usually peaked in the 
15-30Hz band. In control subjects, coherence typically also peaked in the 15-30Hz band, 
whereas in patients with MND 15-30Hz coherence was often less pronounced or 
absent. 
 
 
Figure 5.2: Single-subject power and coherence in the upper limb. Raw EMG is shown 
for three sample trials in a normal control subject (black) and in a patient with MND 
(red; A, D, G). The grey rectangles represent the cued contraction phase of the task, 
and the vertical blue lines indicate the two FFT windows during the hold phase. The 
spectra show relative power (B, E, H) and coherence with FDI (C, F) for each subject. 
The 15-30Hz beta-band is designated by the green lines, and the dotted horizontal 
lines indicate the significance level for coherence. In both subjects, the power spectra 
peaked in the 15-30Hz band, but only the control subject showed significant 15-30Hz 
coherence. 
 
In order to illustrate the difference in coherence between both groups, we calculated 
group averages (Figure 5.3). 15-30Hz coherence in all muscle pairs was significant in 
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the control group and lower but still significant in the MND group. Notably, this does 
not imply that individual subjects in each group necessarily possessed significant 
15-30Hz coherence (e.g. subject with MND in Figure 5.2). 
 
 
 
Figure 5.3: Group data for coherence. Average coherence spectra in normal control 
subjects (black) and patients with MND (red) are shown for MG-EDB and TA-EDB in the 
lower limb (A, C) and for EDC-FDI and FDS-FDI in the upper limb (B, D). The dotted 
horizontal lines indicate the significance level for average coherence, with the vertical 
green lines representing the 15-30Hz beta-band. In normal subjects (black), significant 
average coherence was present in the 15-30Hz band for each muscle pair. In patients 
with MND (red), average 15-30Hz coherence was lower but remained significant. Note 
that significant average coherence on a group level does not imply that individual 
subjects within each group necessarily possessed significant 15-30Hz coherence. 
 
These group averages describe general trends but do not allow us to visualise the 
variation within each group. To achieve this, we compared the distributions of 
individual coherence measurements between both groups. Coherence was averaged 
across the 15-30Hz window in each subject, and log-transformed averages were 
compared between MND and control groups for all muscle pairs (Figure 5.4). The 
cumulative distributions of coherence are shown by the stairstep curves in Figure 5.4 A, 
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B, G, H. Coherence was generally lower in MND though the ranges of coherence in the 
MND and control groups largely overlapped. Group distributions were not adequately 
fitted by a normal model, shown as the smooth dotted curves, and were therefore 
modelled using variable kernel density estimation, shown by the smooth unbroken 
curves. PDFs estimated using this model are shown in Figure 5.4 C, D, I, J. The ratios of 
the PDFs for MND and control groups, equivalent to the odds of a subject having MND 
at a given level of coherence, are plotted in Figure 5.4 E, F, K, L. The odds peaked at 
over 10:1 at low coherence values in each muscle pair, and dropped off to less than 
unity at higher coherence readings. 
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Figure 5.4: Coherence in normal control subjects (black) and patients with MND (red) 
with corresponding variable kernel density estimates. The stairstep curves show the 
cumulative probability distribution of average 15-30Hz coherence within each group (A, 
B, G, H). The corresponding density estimation and normal models are represented by 
the smooth unbroken and dotted curves respectively. Non-cumulative probability 
distributions were calculated from the density estimation model (C, D, I, J). The odds of 
a subject having MND at a given level of coherence were computed as the ratio of the 
probability distributions (E, F, K, L). Curves derived from density estimation models use 
a fainter colour where the model was extrapolated outside the range of the measured 
values. Patients with MND generally had lower coherence values than normal control 
subjects. This is reflected in the odds of MND being greater than unity at low 
coherence readings. 
 
Thus far, coherence has been investigated in individual muscle pairs. We extended this 
analysis by linearly combining coherence measurements from both muscle pairs in a 
given limb, and by employing the area under the ROC curve (AUC) as a summary 
measure of performance (Figure 5.5). The AUC for the optimal combination (black) was 
very similar to that for FDS-FDI in the upper limb (red) and for MG-EDB in the lower 
limb (blue), suggesting that single muscle pairs performed as well as the best linear 
combination. 
 
The side panels of the ROC curves allow discrimination thresholds to be read off for 
any chosen TPR or FPR (Figure 5.5 B, D). For example, if one were to accept a FPR of 10% 
in FDS-FDI, the corresponding coherence threshold would be 0.0097 and the TPR, 
equivalent to sensitivity, would be 60.7% (Figure 5.5 B, dashed arrows). 
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Figure 5.5: Optimal linear combination of coherence data. Standardised coherence 
readings from both muscle pairs in a given limb were combined using a parameter α in 
the range [-1,1], where values of 0 and ±1 correspond to exclusive use of one muscle 
pair and other values represent graded combinations. For each value of α, the 
combined measure was evaluated as a binary classifier for MND by determining the 
area under the ROC curve (AUC; A, C). Where the AUC was less than 0.5 (green curve), 
the ROC curve was inverted, thus yielding an effective AUC ranging from 0.5 to 1 (black 
curve); corresponding bootstrapped 95% confidence intervals are shown (shaded 
areas). The dotted lines indicate α values of 0 (red), 1 (blue) and αopt, the value yielding 
the maximal effective AUC (black). αopt was close to 0 in the upper limb (equivalent to 
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use of FDS-FDI coherence alone) and close to 1 in the lower limb (equivalent to use of 
MG-EDB coherence alone), suggesting that coherence readings from a single muscle 
pair performed as well as the best linear combination of both pairs in a given limb. ROC 
curves are illustrated for individual muscle pairs (red, blue) and the optimal 
combination (black; B, D). Side panels indicate coherence at a given level of true or 
false positives; these are only shown for individual muscle pairs as the optimal 
combination is a score measured on an arbitrary scale. The dashed arrows (B) 
demonstrate how, for a given false positive rate (0.1=10%) in FDS-FDI, the diagram can 
be used to find the corresponding coherence threshold (0.0097) and true positive rate 
(0.607=60.7%). 
 
5.4.2 CMCT 
Single-subject MEP data for a control subject and a patient with MND are displayed in 
Figure 5.6. All control subjects exhibited clear cortical and root MEPs. In MND, cortical 
responses were usually small and delayed or, in some cases, absent. Root responses 
were often diminished in amplitude but had normal or near-normal latencies; again, 
they were absent in some patients. 
 
 
 
Figure 5.6: Single-subject cortical (A) and root (B) MEPs in EDB. For each site of 
stimulation, three types of trace are shown: ten superimposed raw sweeps for a 
normal control subject (black, top) and a patient with MND (red, middle), and averages 
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of rectified sweeps for both subjects (bottom). Latencies (dashed lines) were assigned 
using the average of the rectified sweeps. In the subject with MND, the cortical MEP 
was markedly delayed and reduced in amplitude; the root MEP had a latency which 
was comparable to that in the normal subject but amplitude was greatly reduced. 
 
One could argue that cortical or root MEP responses might have been absent in some 
patients because they did not tolerate sufficiently strong stimulation. However, mean 
cortical stimulation intensities in patients who did not show clear cortical MEP 
responses (upper limb: 80.6±12.5%, mean±1.96SE; lower limb: 66.4±10.3%) were at 
least as high as those in patients who did (upper limb: 61.6±4.8%, p=0.003, unpaired t-
test; lower limb: 62.4±4.3%, p=0.434) as well as those in control subjects (upper limb: 
51.4±1.8%, p<0.001; lower limb 56.6±2.0%, p=0.006). Similarly, mean root stimulation 
intensities in patients with MND who lacked root MEP responses (upper limb: 
60.0±6.2%; lower limb: 95±9.8%) were at least as high as those in patients with clear 
root MEP responses (upper limb: 62.2±3.2%, p=0.687; lower limb: 73.6±3.8%, p=0.039) 
as well as those in control subjects (upper limb: 56.3±2.0%, p=0.395; lower limb: 
64.1±3.1%, p=0.004). 
 
The group distributions of individual CMCT measurements were compared using an 
approach similar to that applied to the IMC data. Cumulative distributions of CMCTs 
are shown as the stairstep curves in Figure 5.7 A-D and M-P. In the upper limb, the 
MND and control distributions overlapped at low CMCTs. However, the MND 
distributions featured longer right-hand tails, and between 5.6 and 14.8% of cortical 
MEPs were absent. In the lower limb, CMCTs were generally longer in MND with 11.1 
to 16.7% of cortical MEPs being absent. Nonetheless, the ranges of CMCTs in MND and 
control groups overlapped considerably. Distributions were modelled with variable 
kernel density estimates, represented by the smooth curves. This model gave rise to 
estimated PDFs (Figure 5.7 E-H and Q-T) and odds functions (Figure 5.7 I-L and U-X). In 
the upper limb, the close similarity of the distributions at low CMCTs resulted in the 
odds functions having complex shapes with multiple crossings of unity, whereas in the 
lower limb the greater separation of distributions led to more simply shaped odds 
functions. 
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Figure 5.7: CMCT in normal control subjects (black) and patients with MND (red) with 
corresponding variable kernel density estimates. The stairstep curves represent the 
cumulative probability distribution of CMCTs within each group (A-D, M-P), with the 
smooth curves showing corresponding density estimation models. These models were 
also used to calculate non-cumulative probability distributions (E-H, Q-T). The 
proportion of absent cortical responses in the MND group is indicated; responses were 
present in all normal subjects. The odds of a subject having MND at a given CMCT were 
calculated as the ratio of the probability distributions (I-L, U-X). Curves derived from 
density estimation models use a fainter colour where the model was extrapolated 
outside the range of the measured values. Patients with MND generally had higher 
CMCT readings than normal control subjects, particularly in the lower limb. Although 
the odds of MND were mostly greater than unity at higher CMCT readings, the shape 
of the odds functions was often complex. 
 
Where limb involvement was asymmetrical, we aimed to study the most affected limb. 
If the subject was unable to perform the coherence task on the most affected side, we 
assessed the contralateral limb instead. It could be argued that CMCT would have 
performed better if the most affected side had been studied throughout. To 
investigate this possibility, we compared linear combinations of CMCT from limbs on 
the less affected side and from all other limbs. Bootstrapped samples of AUC values 
were obtained for both groups using the coefficients determined in the whole MND 
dataset. The differences between all possible pairs of AUC values across both groups 
were calculated, allowing the distribution of the difference in AUC to be estimated. 
The difference in AUC was not significantly different from zero (upper limb p=0.101, 
lower limb p=0.354; two-tailed probabilities), thus negating the argument that CMCT 
would have performed better on the most affected side. 
 
5.4.3 Comparison of all individual and combined markers 
The ROC curves associated with the optimal linear combinations of CMCT in upper and 
lower limbs are illustrated in Figure 5.8, and those for the optimal linear combination 
of both CMCT and IMC are shown in Figure 5.9. The AUCs for all individual and 
combined markers are summarised in Figure 5.10 A and D. In the upper limb, 
coherence in FDS-FDI performed as well as linear or non-linear combinations of both 
coherence markers (Figure 5.10 A, black). CMCT to individual target muscles was 
associated with slightly lower AUCs (Figure 5.10 A, red); whilst the AUC was increased 
by combining all CMCT markers, such combinations still did not reach the AUC 
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associated with coherence in FDS-FDI. Combinations of both CMCT and coherence 
markers (Figure 5.10 A, blue) resulted in AUCs which were only slightly higher than the 
AUC for coherence in FDS-FDI. In the lower limb, coherence in MG-EDB had an AUC 
comparable to linear and non-linear combinations of both coherence markers (Figure 
5.10 D, black). AUCs associated with individual CMCT markers (Figure 5.10 D, red) 
reached similar levels compared to MG-EDB; combinations of CMCT markers provided 
a further increase in AUC which was only increased marginally by additional inclusion 
of the coherence markers (Figure 5.10 D, blue). Generally, non-linear combinations 
were not associated with substantially greater AUCs than linear combinations, and in 
some instances performed worse.  
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Figure 5.8: Optimal linear combination of CMCT data. Standardised CMCT readings 
from each muscle in a given limb were combined using three parameters α1-3, allowing 
all relative linear combinations. The combined measure was evaluated as a binary 
classifier for MND by determining the area under the ROC curve (AUC). The ROC curves 
and parameter values shown represent the linear combination with the maximal 
effective area under the curve. Side panels indicate the combined measure at a given 
level of true or false positives. The best linear combination of CMCT performed slightly 
better than CMCT from the best individual muscle, particularly in the lower limb (also 
see Figure 5.10). 
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Figure 5.9: Optimal linear combination of coherence and CMCT data. Standardised 
coherence readings from each muscle pair and CMCT readings from each muscle in a 
given limb were combined using five parameters α1-5, allowing all relative linear 
combinations. The combined measure was evaluated as a binary classifier for MND by 
determining the area under the ROC curve (AUC). The ROC curves and parameter 
values shown represent the linear combination with the maximal effective area under 
the curve. Side panels indicate the combined measure at a given level of true or false 
positives. The best linear combination of coherence and CMCT data performed slightly 
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better than the best linear combination of either coherence or CMCT, particularly in 
the upper limb (also see Figure 5.10). 
 
5.4.4 Subgroup analysis 
Subgroup analyses of AUC by MND phenotype are shown for ALS (Figure 5.10 B and E) 
and PBP (Figure 5.10 C and F). In ALS, AUCs in the upper limb were very similar to 
those in the main analysis. In the lower limb, AUCs associated with coherence markers 
or their combinations dropped slightly, whilst those associated with CMCT markers or 
their combinations remained largely unchanged. In consequence, individual CMCT 
markers had a higher AUC than any coherence-based marker, and this lead was slightly 
greater for combinations of CMCT markers. In PBP, upper limb AUCs were slightly 
lower for coherence-based markers but substantially lower for CMCT-based markers 
when compared to the main analysis. Thus any markers incorporating coherence 
outperformed those based purely on CMCT. Notably, CMCT in FDI and FDS was less 
than 0.5 as the positivity criterion was not permitted to be inverted relative to the 
main analysis, and few subjects entered the CMCT analysis in PBP (n=6). In the lower 
limb, AUCs were very similar to those found in the main analysis. 
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Figure 5.10: Area under the ROC curve (AUC) for individual and combined measures of 
coherence (black), CMCT (red) or both (blue). AUCs are shown for the entire MND 
cohort (‘All phenotypes’; A, D) as well as the ALS (B, E) and PBP (C, F) subgroups. Linear 
and non-linear combinations were optimised using data from the entire MND cohort 
and the optimal parameters applied to the subgroups. The number of subjects 
entering the analysis is given below the relevant markers. Error bars indicate 
bootstrapped 95% confidence intervals. 
 
5.5 Discussion 
 
The distributions of 15-30Hz IMC and CMCT differed between MND and control groups, 
suggesting that both types of marker have potential for assessing UMN function in 
MND. 
 
5.5.1 Analysis 
In the previous study from our group, data were plausibly normally distributed as 
assessed using a Kolmogorov-Smirnov test. The normal model fitted to the data 
resulted in odds functions with a simple shape and a single maximum (Fisher et al., 
2012). The Shapiro-Wilk test used to assess normality in the present study is 
statistically more powerful than the Kolmogorov-Smirnov test, particularly for small 
samples; the larger size of the samples gathered here also boosted power (Razali & 
Wah, 2011). The current data deviated significantly from normality, and a normal 
model would have poorly fitted the left-hand tails of the distributions (Figure 5.4 A, B, 
G, H), which define the odds function at the low levels of coherence expected in MND. 
Whilst a distribution-free variable kernel density model fitted the data well, it often led 
to odds functions with complex shapes and thus questionable utility. 
 
Therefore, we quantified the performance of individual and combined markers using 
the area under the ROC curve, which requires no modelling of the population 
distributions. Furthermore, this approach does not require fixed discrimination 
thresholds to be specified. Deriving these would require information on costs 
associated with errors as well as information on disease prevalence (Pepe & Thompson, 
2000), and was beyond the scope of this study. 
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Combinations of markers were optimised using all relevant data. This presents a risk of 
overfitting, particularly for small subgroups and non-linear combinations with many 
degrees of freedom, so the reported models might perform less well on a different 
dataset. The AUCs associated with combined markers should be viewed as exploratory 
results indicating a ceiling for what may be achieved with optimisation techniques. In 
the future, the problem of overfitting could be avoided by using cross-validation. This 
would involve splitting the data into training and validation sets; the former would be 
used to design the model, with the latter reserved for evaluating performance. 
 
5.5.2 Summary of results 
Despite these provisos, analysis of combined markers helped to make several 
important points. Firstly, IMC in the best muscle pair – FDS-FDI in the upper and MG-
EDB in the lower limb – was as good a classifier as any combinations of IMC from both 
muscle pairs in the respective limb. This implies that only one muscle pair per limb 
needs to be studied. Secondly, in the upper limb, IMC in the best muscle pair 
performed better than all CMCT markers, including combinations of CMCT. Thirdly, in 
the lower limb, the performance of IMC in the best muscle pair was very similar to that 
of CMCT in individual muscles, but lagged behind combined CMCT markers. Finally, 
non-linear combinations performed at best marginally better than their linear 
counterparts, suggesting that linear combinations suffice. 
 
5.5.3 Potential confounders 
Transmitter systems involved in the generation of beta-band oscillations and 
coherence are susceptible to relevant CNS-active drugs. For example, diazepam and 
propranolol have been reported to alter beta-band oscillations and/or coherence 
(Baker & Baker, 2003, 2012). We selected control subjects who did not use any 
neurotropic medication. Since most patients with MND received multiple drugs with 
potential CNS effects it was not realistic to exclude them. Amongst these patients the 
numbers of different agents and their combinations were both high, thus precluding 
subgroup analysis. Importantly, no difference in IMC was previously found between 
patients on and off riluzole (Fisher et al., 2012), a drug with myriad pharmacological 
actions used by 57% of patients in our study. 
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Fatigue is a further factor which can affect coherence. Many previous studies 
employed tasks involving sustained contractions (Conway et al., 1995; Ohara et al., 
2000; Ushiyama et al., 2011b). Whilst such tasks facilitate consistent performance, 
they would be difficult or impossible to execute for patients with neurological deficits. 
Therefore, we used a phasic task with minimal or no instrumentation and explicitly 
allowed subjects to request breaks. Any fatigue which might have occurred despite 
these measures should have caused coherence to be overestimated (Tecchio et al., 
2006; Ushiyama et al., 2011a). With fatigue being more likely in the MND group, the 
distance between the coherence distributions of MND and control groups would have 
narrowed, causing the utility of coherence to be underestimated rather than 
exaggerated. 
 
5.5.4 Pathways probed by IMC 
Sensory afferents have been shown to play an important role in the generation of CMC 
(Baker et al., 2006; Riddle & Baker, 2005; Witham et al., 2011; Witham et al., 2010) 
and IMC (Kilner et al., 2004; Pohja & Salenius, 2003). It is important to ascertain 
normal sensory function before coherence can be used to draw inferences about CST 
integrity. Whilst subclinical sensory abnormalities apparent on nerve conduction 
studies (NCS) are increasingly recognised in MND (Pugdahl et al., 2007), none were 
detected in our patient cohort; all underwent NCS, and sensory abnormalities were 
only detected in two patients with known diabetes mellitus, who were excluded from 
subsequent analysis. It was previously suggested that somatosensory evoked 
potentials (SEP) should also be measured (Fisher et al., 2012). However, the 
association between MND and SEP abnormalities has remained controversial (Hamada 
et al., 2007), and we did not routinely assess SEP. 
 
We assumed that abnormalities in IMC occurring in the absence of sensory deficits 
were attributable to CST dysfunction. This assumption is backed by present knowledge 
of the pathways involved in coherence (Witham et al., 2011; Witham et al., 2010), by 
the absence of coherence after CST damage through capsular strokes (Farmer et al., 
1993), spinal cord lesions (Hansen et al., 2005; Norton et al., 2003) and PLS in humans 
(Fisher et al., 2012), and by the absence of coherence after selective CST ablation in 
macaques (Fisher et al., 2012; Nishimura et al., 2009). However, it is difficult to 
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validate any marker of CST function in MND: at present, there is no gold standard in 
vivo test of CST integrity, and correlating IMC estimates with autopsy findings in a 
sizeable cohort is not realistic. 
 
It is conceivable that disease outside the CST and sensory pathways might have 
contributed to abnormalities of IMC, particularly given the widespread nature of MND 
pathology (Atsuta et al., 2009; Geser et al., 2008). Coherence appeared to be 
diminished in patients with PMA (Fisher et al., 2012), suggesting that it may be 
affected by LMN damage. It would be of great interest to determine whether this is 
the case, as LMN dysfunction would constitute a very common potential confounder in 
MND. 
 
5.5.5 Outlook 
The effect of LMN lesions on coherence requires further study. One approach would 
involve measuring coherence in patients with acquired neurological conditions causing 
a LMN deficit (Chapter 6). However, many disorders do not cause pure LMN 
involvement and/or have low prevalence, making it difficult to recruit an adequately 
sized cohort. An alternative approach would involve computational simulation of the 
effects of LMN dysfunction, for example using a model previously developed by our 
group (Williams & Baker, 2009). 
 
For IMC to be used as a diagnostic biomarker, a classification threshold separating 
normal from abnormal needs to be specified. This requires an analysis of potential 
costs. Eventually, any acceleration of the diagnostic process would be subject to a 
ceiling, as IMC is unlikely to be measured before patients are reviewed by a neurologist 
yet much of the diagnostic delay occurs prior to this point (Househam & Swash, 2000; 
Mitchell et al., 2010). 
 
An evaluation of IMC as a prognostic indicator will be possible once more survival data 
are available for the present cohort. In addition, a longitudinal follow-up study of IMC 
should be considered, ideally recruiting subjects at a pre-symptomatic stage, for 
example from kindreds with mutations in superoxide dismutase 1 (SOD1). In the longer 
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term, a large prospective study will be required to fully delineate the diagnostic utility 
of IMC. 
 
 
5.6 Conclusion 
 
We investigated IMC and CMCT as measures of CST integrity in a cohort of patients 
with MND, assessing performance using the area under the ROC curve. IMC in a single 
muscle pair per limb performed better than individual or combined CMCT measures in 
the upper limb, and drew level with individual CMCT measures in the lower limb, 
where it was only slightly surpassed by combinations of CMCT. Hence, IMC constitutes 
a simple, fast and acceptable marker of CST function which rivals the performance of 
CMCT. However, unlike TMS-based measures, it does not require expensive equipment, 
and could be deployed at minimal cost to existing EMG facilities in clinical 
neurophysiology departments. 
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6  Intermuscular coherence in patients with motor neuron disease mimic syndromes 
   
  A spectrum of evidence suggests that the corticospinal tract is critical to coherence. 
By contrast, the role of peripheral motor nerves and muscles is less clear. In this 
chapter, I probe the role of different parts of the motor system by examining 
intermuscular coherence in patients with a range of neurological conditions. 
 
 
6.1 Abstract 
 
Objective: Intermuscular coherence (IMC) was measured in patients with neurological 
conditions affecting different parts of the motor system in order to elucidate the 
relative contributions of these parts to IMC generation. 
 
Methods: 12 patients with hereditary spastic paraparesis (HSP), 7 patients with 
multifocal motor neuropathy (MMN), 8 patients with inclusion body myositis (IBM), 
and 92 healthy control subjects were included. In the upper limb, IMC was measured 
between extensor digitorum communis (EDC) and first dorsal interosseous (FDI) as well 
as between flexor digitorum superficialis (FDS) and FDI. In the lower limb, IMC was 
estimated between medial gastrocnemius (MG) and extensor digitorum brevis (EDB) as 
well as between tibialis anterior (TA) and EDB. Individual and combined IMC markers 
were analysed using population distributions and the area under the receiver-
operating characteristic curve (AUC). 
 
Results: In HSP, IMC was usually decreased in the lower limb and near-normal in the 
upper limb. In MMN, IMC was slightly diminished in the upper limb and more markedly 
decreased in the lower limb. In IBM, IMC was globally increased. 
 
Conclusion: HSP affects the corticospinal tract (CST) projecting to lower limb muscles, 
and the results support the suggestion that the CST has an important role in mediating 
IMC. MMN is typically thought of as a peripheral motor disorder, and therefore the 
IMC findings are surprising; possible explanations are discussed. The increase in IMC 
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observed in IBM is probably attributable to the altered electrical properties of muscle 
fibres which may facilitate the detection of synchronisation between muscles. 
Computational modelling may help to clarify further how different parts of the motor 
system contribute to IMC generation. 
 
 
6.2 Introduction 
 
At present, there is no sensitive and specific marker of upper motor neuron (UMN) 
function. Clinical signs such as clonus, hyperreflexia and extensor plantar responses 
have limited sensitivity for corticospinal tract (CST) pathology (Kaufmann et al., 2004), 
and do not necessarily reflect pathology in the CST alone (Brown, 1994). Markers 
based on transcranial magnetic stimulation (TMS) have not shown sufficient diagnostic 
utility to gain widespread acceptance (Mills, 2003). Similarly, approaches using 
magnetic resonance imaging (MRI) do not currently reach an adequate level of single-
subject performance (Filippi et al., 2010) and remain confined to research facilities. 
 
A recently proposed marker of UMN function exploits the role of the CST in the 
propagation of oscillatory activity (Fisher et al., 2012). 15-30Hz beta-band oscillations 
can be recorded from the primary motor cortex (Conway et al., 1995; Halliday et al., 
1998; Ohara et al., 2000; Pfurtscheller, 1981). They can be shown to be synchronised 
with beta-band oscillations in contralateral muscles by means of coherence analysis 
(corticomuscular coherence, CMC; Conway et al., 1995; Halliday et al., 1998; Ohara et 
al., 2000). Similarly, beta-band oscillations are coherent between co-contracting 
muscles in a given limb (Farmer et al., 1993), and such intermuscular coherence (IMC) 
is deemed to reflect a shared cortical drive. IMC is often preferred to CMC for practical 
reasons and because it is more consistently detectable in normal subjects (Fisher et al., 
2012; Ushiyama et al., 2011b). 
 
A range of evidence outlined in Chapter 5 indicates that IMC is mediated by an 
efferent-afferent feedback loop in which the CST forms a key component. This has 
prompted the suggestion that, in the absence of a sensory lesion, IMC constitutes a 
marker of CST function (Fisher et al., 2012). The hypothesis is difficult to test directly as 
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there is no gold standard in vivo marker of CST function and histological correlates 
from post mortem assessment of the spinal cord are rarely available. It remains 
possible that, in addition to the CST and afferent pathways, peripheral motor nerves 
are involved in coherence generation. 
 
To help delineate the relative contributions to IMC generation from different parts of 
the efferent pathways, we examined IMC in a range of neurological disorders, 
including hereditary spastic paraparesis (HSP), multifocal motor neuropathy (MMN) 
and inclusion body myositis (IBM). An overview of these conditions is given below. 
 
HSP affects 3-10/100,000 individuals, and the mode of inheritance may be autosomal 
dominant, autosomal recessive or X-linked recessive (for a review, see Salinas et al., 
2008). The condition is characterised clinically by insidiously progressive spasticity and 
weakness of the lower limbs, and pathologically by retrograde axonal degeneration of 
the CST. Pure forms of HSP are dominated by involvement of the CST to the lower 
limbs, though minor bladder dysfunction, muscle wasting or decreases in distal 
vibration sense may occur in longstanding disease. Complicated forms involve a more 
extensive neurological and/or non-neurological phenotype, including polyneuropathy, 
extrapyramidal and cerebellar features, cognitive impairment, epilepsy, retinopathy, 
optic atrophy, deafness and skin lesions. For this study, we selected patients with 
autosomal dominant HSP who carried mutations in the SPG4 and SPG31 genes, which 
are typically associated with a pure phenotype (Finsterer et al., 2012; Salinas et al., 
2008). 
 
MMN is an autoimmune motor neuropathy which has a prevalence of 0.6/100,000 and 
is commoner in men (M:F=2.7:1; for a review, see Vlam et al., 2012). Clinically, it 
causes slowly progressive, asymmetrical distal limb weakness without sensory loss. 
The electrophysiological hallmark is conduction block of peripheral motor nerves 
outside of common entrapment sites in the absence of sensory abnormalities; 
however, this can be difficult to detect. High titres of anti-GM1 antibodies are found in 
approximately 50% of patients but are not entirely specific for MMN. The treatment of 
choice is intravenous immunoglobulin, which typically results in rapid but temporary 
improvements in clinical and electrophysiological function.  
 126 
 
IBM is a condition of unclear cause which affects 0.43-0.93/100,000 individuals, rising 
to 3.53/100,000 above the age of 50 (for a review, see Dalakas, 2006). It presents with 
slowly progressive weakness and atrophy of proximal and distal muscles, often with a 
characteristic predilection for the quadriceps and deep finger flexors. Affected muscles 
demonstrate a distinctive histopathology comprising a combination of autoimmune 
and degenerative features. Despite the pronounced inflammatory component, 
immunosuppression is generally ineffective. 
 
In this study, IMC readings from patients with HSP, MMN and IBM were compared to 
readings from healthy control subjects. IMC was evaluated as a binary classifier using 
the approach described in Chapter 5; receiver-operating characteristic (ROC) curves 
were constructed and summarised by calculating the area under the curve (AUC). In 
addition to IMC measurements from individual muscle pairs, we explored optimal 
linear and non-linear combinations of IMC measurements from both muscle pairs in a 
given limb. 
 
In HSP, IMC measurements were generally lower than normal in the lower limb but 
near-normal in the upper limb. In MMN, IMC readings were mostly lower than normal 
in both upper and lower limbs. In IBM, IMC values were typically greater than normal 
in upper and lower limbs. The somewhat unexpected findings in MMN and IBM raise 
interesting points about the extent of MMN pathology and the impact of myopathy on 
IMC. 
 
 
6.3 Methods 
 
6.3.1 Subjects 
Fourteen patients with genetically confirmed HSP were recruited from the 
neurogenetics service at Newcastle Upon Tyne Hospitals (P. F. Chinnery); all of these 
had a ‘pure’ phenotype suggesting isolated involvement of the CST. Similarly, nine 
patients with an electroclinical diagnosis of MMN and 11 patients with a clinico-
pathological diagnosis of IBM were recruited from the local neuromuscular service (J. A. 
L. Miller). Two patients with HSP were excluded due to a history of spinal surgery and 
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an intrathecal baclofen pump respectively. All patients with MMN received regular 
treatment with intravenous immunoglobulin, and the study was timed such that 
weakness was clinically apparent but did not preclude effective performance of the 
coherence task. Patients with MMN or IBM all underwent nerve conduction studies; 
two patients with MMN and three patients with IBM were excluded due to sensory 
neuropathy. Thus, 12 patients with HSP, seven patients with MMN and eight patients 
with IBM were included in the analysis. Clinical features including drug histories are 
summarised in Appendix C. 
 
Control data were obtained from 92 healthy subjects (51 men, 41 women; age range 
22-77 years, mean±SD 48.6±17.2). None had any history of neurological disorders or 
diabetes mellitus, and none took any neurotropic medication. 
 
All subjects provided written informed consent. The studies on patients and control 
subjects were approved by the National Research Ethics Service (County Durham and 
Tees Valley Research Ethics Committee, reference number 08/H0908/3) and Newcastle 
University’s Medical Faculty respectively. Both studies conformed to the Declaration of 
Helsinki. 
 
6.3.2 Recording 
Every effort was made to maintain subjects at a constant level of alertness. Subjects 
were seated in a comfortable chair with their arm resting on a cushion. Surface EMG 
was recorded from abductor pollicis brevis (APB), first dorsal interosseous (FDI), flexor 
digitorum superficialis (FDS) and extensor digitorum communis (EDC) in the upper limb, 
and extensor digitorum brevis (EDB), abductor hallucis (AH), tibialis anterior (TA) and 
medial gastrocnemius (MG) in the lower limb. Adhesive electrodes (Bio-Logic M0476; 
Natus Medical, Mundelein, IL) were placed in a belly-tendon montage over the intrinsic 
muscles of the hand or foot; for the long muscles of the forearm or calf, the electrodes 
were placed 4cm apart, one third along the muscle from its proximal origin. Signals 
were amplified, band-pass filtered (30Hz-2kHz; Digitimer D360, Digitimer, Welwyn 
Garden City, UK) and digitised at 5kHz (Micro1401, Cambridge Electronic Devices, 
Cambridge, UK). 
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6.3.3 Experimental procedure 
In the upper limb, subjects were asked to perform a repetitive precision grip task. A 
length of compliant plastic tubing (length 19cm, Portex translucent PVC tubing 
800/010/455/800; Smith Medical, Ashford, UK) was attached to the index finger and 
thumb with Micropore tape (3M Health Care, Neuss, Germany), and subjects were 
asked to oppose both ends of the tubing when prompted by visual and auditory cues. 
This auxotonic task – so-called because force increases with displacement in a spring-
like fashion – required a minimum force of 1N (Fisher et al., 2012) and was similar to a 
precision grip task used in our previous studies, albeit without measuring digit 
displacement (Kilner et al., 2000; Riddle & Baker, 2006). In the lower limb, subjects 
were asked to dorsiflex ankle and toes in the air while resting the heel on the ground. 
Subjects produced 4s of contraction alternating with 2s of relaxation, and at least 100 
repetitions. Where necessary, the recording was divided into a number of sections 
separated by rest to prevent fatigue. Visual feedback of raw EMG traces was provided 
to facilitate consistent task performance. 
 
In each subject, one upper limb and one lower limb were assessed. We studied the 
most affected upper and lower limb as reported by the subject. If the subject was 
unable to perform the coherence task using the most affected limb, we assessed the 
contralateral limb instead. Where both sides were unaffected or equally affected, the 
limb on the dominant side was assessed. All assessments in control subjects were 
carried out on the dominant side. 
 
6.3.4 Data analysis 
Analysis was performed in Matlab (Mathworks, Natick, MA) using custom scripts. 
 
Raw IMC data were visually inspected and the first 100 adequately performed trials 
examined further. Analysis focussed on the early hold phase of the contraction where 
beta-band oscillations are known to be maximal (Baker et al., 1997; Sanes & Donoghue, 
1993). EMG signals were full-wave rectified. Starting 0.8s after the cue prompting 
contraction, two contiguous 0.82s-long sections of data from each trial were subjected 
to a 4096-point fast Fourier transform (FFT), giving a frequency resolution of 1.22Hz. 
Many subjects showed a drop-off in EMG activity so the last 1.56s of the 4s active 
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phase did not enter the analysis. Denoting the Fourier transform of the 𝑙th section of 
the first EMG signal as 𝐹1,𝑙(𝜆), the auto-spectrum is given by 
 
𝑓11(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹1,𝑙(𝜆)�������� (6.1)  
 
where 𝜆 is the frequency (Hz), 𝐿 is the total number of sections and where the overbar 
denotes the complex conjugate. The cross-spectrum for two EMG signals with Fourier 
transforms 𝐹1,𝑙(𝜆) and 𝐹2 ,𝑙(𝜆) was calculated as 
 
𝑓12(𝜆) = 1𝐿�𝐹1,𝑙(𝜆)𝐿
𝑙=1
𝐹2,𝑙(𝜆)�������� (6.2)  
 
Coherence was computed as the cross-spectrum normalised by the auto-spectra 
 
𝐶(𝜆) = |𝑓12(𝜆)|2
𝑓11(𝜆)𝑓22(𝜆) (6.3) 
 
Coherence was calculated for the muscle pairs EDC-FDI, FDS-FDI, MG-EDB and TA-EDB. 
The wide anatomical spacing between the paired muscles minimised the risk of volume 
conduction causing inflated coherence values (Grosse et al., 2002). 
 
Under the null hypothesis of linear independence between the signals, a level of 
significant coherence was determined as (Rosenberg et al., 1989) 
 
𝑍 = 1− 𝛼1/(𝐿−1) (6.4)  
 
where the significance level 𝛼 was set at 0.05. 
 
To provide a group summary, coherence spectra for each muscle pair were averaged 
across all patients with a given condition and all control subjects respectively. The 
significance level for averaged coherence was determined using the method described 
by Evans and Baker (2003). 
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In each subject, coherence was averaged across the 15-30Hz window. Cumulative 
distribution functions (CDFs) were constructed from these averages for each muscle 
pair and group. 
  
In each limb, coherence readings from both muscle pairs were treated as separate 
markers 𝑀𝑖. The diagnostic accuracy of these markers as tests for a given condition 
was quantified using the area under the ROC curve. The ROC curve for each marker 𝑀𝑖 
was defined as the set of points {FPR(d), TPR(d)} where TPR(d) and FPR(d) are the true 
and false positive rates associated with a discrimination threshold 𝑑 in the range 
(−∞,0]. The same positivity criteria were used as had been assigned in the main MND 
analysis (Chapter 5); since no inversion of the criteria was permitted, AUCs had a range 
of [0,1]. 
 
We calculated linear and non-linear combinations of both coherence markers in a 
given limb. Each individual coherence marker 𝑀𝑖 was transformed to standardised Z-
scores. The coefficients 𝛼𝑖 were those previously determined in the main MND analysis 
(Chapter 5). Linear combinations required only a single coefficient 𝛼  and were 
calculated as: 
 
𝑁(𝛼) = 𝛼𝑀1 + �1− 𝛼2 ∙ 𝑀2 (6.5)  
 
Non-linear combination involved two coefficients 𝛼1 and 𝛼2. The first coefficient did 
not require transformation, so 𝛾1 = 𝛼1; the second one was transformed according to 
the formula: 
 
𝛾2 = 𝛼2�1− 𝛼12 (6.6)  
 
The non-linear combination was then calculated as: 
 
𝑁(𝛾) = �𝛾𝑖𝑀𝑖2
𝑖=1
+ �1 −�𝛾𝑖22
𝑖=1
∙ 𝑀1𝑀2 (6.7)  
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6.4 Results 
 
Single-subject power and coherence for a control subject and a patient with HSP are 
shown in Figure 6.1. In control subjects, power usually peaked in the 15-30Hz band; 
the peak in this band was often less distinct or absent in patients, particularly those 
with HSP and MMN. In control subjects, coherence typically also peaked in the 
15-30Hz band; this peak was often exaggerated in patients with IBM, but was 
diminished or absent in those with HSP or MMN. 
 
 
 
Figure 6.1: Single-subject power and coherence in the lower limb. Raw EMG is shown 
for three sample trials in a normal control subject (black) and in a patient with 
hereditary spastic paraparesis (HSP; red; A, D, G). The cued contraction phase of the 
task is represented by the grey boxes, and the two FFT windows during the hold phase 
are indicated by the vertical blue lines. Spectra of relative power (B, E, H) and 
coherence with EDB (C, F) are shown for each subject. The 15-30Hz beta-band is 
flanked by the green lines, and the dotted horizontal lines indicate the significance 
level for coherence. In the normal subject, power and coherence spectra show a clear 
peak in the 15-30Hz band. In the patient with HSP, power peaked at 15Hz in EDB but 
showed no clear peaks within the 15-30Hz window in MG and TA; coherence was not 
significant across the 15-30Hz band. 
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To illustrate these differences in coherence between groups, we calculated group 
averages (Figure 6.2). In the control group, 15-30Hz coherence was significant in all 
muscle pairs. In HSP, 15-30Hz coherence was diminished in TA-EDB but was near-
normal in other muscle pairs. In MMN, 15-30Hz coherence was near-normal in EDC-FDI, 
slightly decreased in FDS-FDI, and near the significance level in both muscle pairs in the 
lower limb. In IBM, 15-30Hz coherence was increased in MG-EDB and EDC-FDI, and 
near-normal in the remaining muscle pairs. 
 
 
 
Figure 6.2: Group data for coherence. Average coherence spectra are shown for MG-
EDB and TA-EDB in the lower limb (A, C) and for EDC-FDI and FDS-FDI in the upper limb 
(B, D). The dotted horizontal lines represent the significance level for average 
coherence, with the vertical green lines indicating the 15-30Hz beta-band. In normal 
subjects (black), significant average coherence was present in the 15-30Hz band for 
each muscle pair. In HSP (red), average 15-30Hz coherence was decreased in TA-EDB 
but at near-normal levels in other muscle pairs. In MMN (orange), average 15-30Hz 
coherence was near-normal in EDC-FDI, slightly diminished in FDS-FDI, and near the 
significance level in MG-EDB and TA-EDB. In IBM (blue), average 15-30Hz coherence 
was increased in MG-EDB and EDC-FDI, and near-normal in the two other muscle pairs. 
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Although these group averages report general trends, they do not allow us to visualise 
the variation within each group. To achieve this, we compared the distributions of 
individual coherence measurements between all groups. Coherence was averaged 
across the 15-30Hz window in each subject, and the cumulative distributions of the 
averages plotted on a semi-log scale (Figure 6.3 A, B, E, F). In addition, ROC curves 
were constructed (Figure 6.3 C, D, G, H), and the area under the ROC curve (AUC) was 
calculated as a summary measure of performance for coherence in each muscle pair. 
In HSP, the distribution of coherence in the upper limb was similar to the control group, 
and the ROC curve ran close to the diagonal; in the lower limb, the distribution was 
partly shifted to lower coherence values, which was reflected in the ROC curves lying 
partly above the diagonal. In four patients, IMC readings in the lower limb were 
relatively high, falling into the upper half of the normal range. However, there were no 
apparent differences in age, disability or duration of symptoms between this group 
and other patients with HSP. In MMN, the distribution of coherence in the upper limb 
was slightly shifted to lower values than controls, and in the lower limb this shift was 
more pronounced. Accordingly, the ROC curves lay above the diagonal, more so in the 
lower limbs. In IBM, the distributions in upper and lower limbs were shifted to higher 
values of coherence relative to controls, reflected by ROC curves running below the 
diagonal.  
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Figure 6.3: Comparison of coherence between normal control subjects (black) and 
patients with HSP (red), MMN (orange), and IBM (blue). The stairstep curves represent 
the cumulative probability distribution of average 15-30Hz coherence within each 
group (A, B, E, F), with the corresponding ROC curves shown below (C, D, G, H). In HSP, 
coherence was similar to the control group in the upper limb, with the ROC curve 
running close to the diagonal; in the lower limb, coherence was mostly lower than 
normal and the ROC curve lay partly above the diagonal. In MMN, upper limb 
coherence was slightly decreased and lower limb coherence was more prominently 
decreased compared to controls; this was reflected in ROC curves lying above the 
diagonal, more markedly so in the lower limbs. In IBM, coherence readings were 
generally higher than normal, and the ROC curves lay below the diagonal. 
 
The ROC curves in Figure 6.3 reveal differences between patients and healthy controls 
for coherence calculated from particular muscle pairs. However, it is interesting to see 
whether even greater differences could occur by combining measures from multiple 
muscle pairs. This is illustrated in Figure 6.4, where we extended the analysis to linear 
combinations of coherence from both muscle pairs in a given limb. The required 
coefficient 𝛼 had previously been found by optimisation in the MND dataset (Chapter 
5) and focussed strongly on FDS-FDI in the upper limb and MG-EDB in the lower limb. 
Hence, the ROC curves for the combined marker bore close similarity to the ROC 
curves for these individual muscle pairs. The side panels allow discrimination 
thresholds to be read off for any chosen TPR or FPR (as previously outlined in Figure 
5.5). 
 
AUCs for individual and combined markers are summarised Figure 6.5 and Table 6.1. 
Combined markers included both linear and non-linear combinations of coherence 
from both muscle pairs in a given limb. In HSP, AUCs were close to 0.5 in the upper 
limb (range 0.51-0.59), with slightly higher values (0.64-0.68) being reached in the 
lower limb. In MMN, AUCs were generally higher than in HSP (upper limb: 0.60-0.68, 
lower limb: 0.71-0.74). In IBM, AUCs were all below 0.5 (upper limb: 0.28-0.29, lower 
limb: 0.37-0.40). 
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Figure 6.4: Optimal linear combination of coherence data. Standardised coherence 
readings from both muscle pairs in a given limb were combined using a parameter α, 
allowing all relative linear combinations. The parameter had been derived previously 
using the MND dataset (Chapter 5). ROC curves are shown for the combination of both 
muscle pairs. Since the parameters emphasised coherence in FDS-FDI in the upper limb 
and coherence in MG-EDB in the lower limb, the combined ROC curves are very similar 
to the ROC curves in these individual muscle pairs (Figure 6.3). Side panels illustrate 
the combined measure at a given level of true or false positives.  
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Figure 6.5: Area under the ROC curve (AUC) for individual and combined measures of 
coherence in HSP (red), MMN (orange), and IBM (blue). Linear and non-linear 
combinations were calculated using the parameters previously determined in the MND 
cohort (Chapter 5). Error bars indicate bootstrapped 95% confidence intervals. In HSP, 
AUCs in the upper limb were near 0.5, whilst those in the lower limb were somewhat 
higher. In MMN, AUCs were higher than in HSP in both upper and lower limbs. In IBM, 
AUCs were below 0.5 throughout. 
 
Table 6.1: Area under the receiver-operating characteristic curve (AUC) associated 
with coherence markers and their linear and non-linear combinations. The coefficients 
used to calculate the combined markers had been derived previously in the motor 
neuron disease (MND) cohort (Chapter 5). (comb’n=combination) 
 
 Condition AUC    
  EDC-FDI FDS-FDI Linear 
comb’n 
Non-linear 
comb’n 
Upper limb HSP 0.512 0.592 0.592 0.563 
 MMN 0.598 0.682 0.672 0.648 
 IBM 0.281 0.295 0.291 0.281 
Lower limb HSP 0.677 0.636 0.676 0.676 
 MMN 0.744 0.708 0.734 0.734 
 IBM 0.397 0.365 0.393 0.394 
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6.5 Discussion 
 
6.5.1 Results and their implications 
In HSP, IMC was usually decreased in the lower limb but near-normal in the upper limb. 
As pure HSP should only affect the CST projecting to lower limb muscles, these findings 
are compatible with the hypothesis that the CST has a pivotal role in mediating IMC. It 
was surprising that four patients with HSP showed rather high IMC readings in the 
lower limb without differing from patients with diminished or absent IMC in any 
obvious manner, including age, duration of symptoms and mutated gene. We did not 
examine patients clinically as part of this study, so no comparison of clinical signs or 
scores could be made. Patients with unexpectedly high coherence should be followed 
up with serial IMC measurements over the coming years. 
 
Patients with MMN showed slightly decreased IMC in the upper limb and more 
markedly decreased IMC in the lower limb. MMN is conventionally thought to affect 
peripheral motor nerves only, so this result would suggest that peripheral efferents are 
involved in mediating IMC. However, there is some evidence that MMN may also cause 
dysfunction of the CST and/or sensory afferents. In a large series, 8% of cases were 
noted to display retained or brisk reflexes in an affected limb (Cats et al., 2010), and 
brisk reflexes in MMN have also been reported elsewhere (Bentes et al., 1999; Oshima 
et al., 2002; Traynor et al., 2000a). Whilst ‘brisk’ reflexes were viewed as acceptable, 
‘pathological’ reflexes or other UMN signs were thought to exclude MMN (Cats et al., 
2010; Vlam et al., 2012). However, physiologically and pathologically brisk reflexes may 
not be distinguishable. Furthermore, one study reported two cases with an 
electroclinical phenotype of MMN and high anti-GM1 titres who exhibited 
hyperreflexia, an extensor plantar response in one case, and a prolongation of central 
motor conduction time compared to cases of MMN without UMN signs (Oshima et al., 
2002). Hence, it cannot be excluded that the decreases in IMC we observed here were 
partly attributable to CST dysfunction. There is also clinical, electrophysiological and 
histological evidence that MMN is associated with mild sensory nerve pathology, 
particularly in longstanding disease (Cats et al., 2010; Corse et al., 1996). This is less 
likely to be relevant as patients in our cohort had a shorter duration of disease and 
showed normal sensory function on NCS.  
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In IBM, the global increase in IMC is probably attributable to the altered electrical 
properties of motor units. Normally, voluntary contraction leads to gradual 
recruitment of units, which respond with well-formed, simply-shaped action potentials. 
In IBM, recruitment occurs earlier and individual units show unstable, polyphasic 
discharges; in addition, there are involuntary fibrillation potentials, positive sharp 
waves and complex repetitive discharges (Kimura, 2001). IMC quantifies 
synchronisation between discharges in each muscle. It is likely that, at a given force of 
contraction, synchronisation is more readily detectable in IBM where a larger number 
of units discharges in a polyphasic manner with multiple spikes, compared to the 
normal state where a smaller number of units fires simple biphasic action potentials. 
 
Potential confounders discussed in Chapter 5 included neurotropic medication and 
fatigue during the coherence task. These equally apply to data from patients with HSP, 
MMN and IBM. 
 
6.5.2 Outlook 
HSP and MMN do not necessarily cause a pure lesion in one specific part of the 
nervous system. This issue, which was most prominent in MMN, markedly complicates 
the interpretation of results. Studying motor neuropathies other than MMN would not 
solve the problem as a degree of sensory involvement is almost universal. 
 
Instead, a computational model could be employed to delineate the relative 
contributions to IMC from different parts of the motor system. Such a model was 
previously developed in our group (Williams & Baker, 2009) and could be adapted for 
studying the effects of virtual lesions in silico. 
 
 
6.6 Conclusion 
 
We examined IMC in cohorts of patients with HSP, MMN and IBM in an attempt to 
clarify efferent pathways involved in IMC generation. The results suggest that IMC is 
partly sensitive to dysfunction of the CST and of the distal motor units. Although it 
would be plausible that the proximal motor units – embodied by peripheral motor 
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nerves – may also be involved if IMC is altered, this point requires further clarification. 
Neurological conditions including HSP and MMN can be associated with multiple 
concomitant lesions, some of which may be subclinical, and computational modelling 
represents an alternative approach which could circumvent this problem.  
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7  General discussion 
 
 
7.1 Context 
 
The last few decades have seen the successful development and universal clinical 
deployment of electrophysiological markers of lower motor neuron (LMN) dysfunction. 
By contrast, candidate markers of upper motor neuron (UMN) dysfunction have never 
performed sufficiently well to achieve widespread clinical uptake, and the lack of such 
markers is perhaps most keenly felt in the diagnosis and follow-up of patients with 
motor neuron disease (MND). The work presented in this thesis aimed to further the 
development of biomarkers of UMN function. We investigated a novel biomarker, 
beta-band intermuscular coherence (IMC), together with central motor conduction 
time (CMCT), a marker based on transcranial magnetic stimulation (TMS) whose neural 
substrates are relatively well understood. 
 
 
7.2 Summary and future directions 
 
We showed that CMCT in healthy individuals was significantly correlated with height in 
the lower limb but found no significant predictors in the upper limb (Chapter 2). Our 
regression model can be used to lessen interindividual variability for lower limb CMCT 
and thus should help to improve diagnostic performance. In addition, a review of the 
methods used in previous investigations allowed us to reconcile some past 
discrepancies regarding the correlation of CMCT with age and height. CMCT has now 
been studied for almost 30 years and major future advances appear unlikely. A recent 
development is the MATS (magnetic augmented translumbosacral stimulation) coil, 
which allows direct stimulation of the conus medullaris, thus permitting CMCT to be 
estimated without a residual peripheral component. However, sensitivity for UMN 
dysfunction may well remain unchanged, and studies in disease states are still lacking. 
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Investigating beta-band IMC in the same normal cohort, we found no variation in its 
amplitude with age (Chapter 3). Hence, IMC appeared to be robust to age-related 
changes in the nervous system, allowing us to collate IMC data from healthy 
individuals of all ages into a single normative dataset. The variability of IMC between 
subjects was considerable, and within a given subject variability was greater between 
than within recording sessions. Potential contributors include fluctuations in task 
performance, differences in electrode montage and short-term random variation in 
coherence. These factors require further exploration and, where possible, 
minimisation. Investigation of the following two aspects is also required. Firstly, a 
previous study described that the amplitude and directionality of corticomuscular 
coupling can change over years within individuals (Witham et al., 2011). The 
timecourse of these changes and their relationship to the variability of IMC should be 
characterised. Secondly, there is a disconnect between coherence studies employing a 
sustained contraction, which is easier to standardise, and those using a phasic task, 
which exploits the known task specificity of coherence and is easier to perform for 
disabled subjects. Both types of task should be studied in the same cohort so that the 
relationship between the corresponding coherence estimates can be clarified. 
 
In keeping with a past report, we found that anodal transcranial direct current 
stimulation (tDCS) boosted IMC (Chapter 4). These effects were longer-lasting than 
previously described, and the timecourse of their return to baseline should be mapped 
out in a future study. The potential use of tDCS as a diagnostic adjunct to IMC is 
somewhat hampered by the variability of its effects, and it would be interesting to test 
whether more powerful tDCS protocols elicit more reliable increases in IMC. We were 
not able to reproduce the classical effects of tDCS on TMS-evoked motor potentials 
despite using methods which closely paralleled those reported in the literature. 
Although it is generally assumed that tDCS causes reliable, stable changes in cerebral 
excitability, even classical studies reported substantial inter- and intrasubject 
variability. This result highlights that the effects of tDCS are not as robust as is 
commonly expected. 
 
Our group previously investigated IMC in primary lateral sclerosis and progressive 
muscular atrophy, and we expanded on this by measuring IMC and CMCT in patients 
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with all phenotypes of MND (Chapter 5). We studied IMC and CMCT in individual 
muscles or muscle pairs as well as exploring their linear and non-linear combinations. 
Instead of specifying cut-off values separating normal from abnormal, which would 
have required scrutiny of associated costs and disease prevalence, we focussed on the 
area under the receiver-operating curve (AUC). IMC in a single muscle pair performed 
as well as combinations of IMC in discriminating between normal and MND groups, 
thus suggesting an immediate method of simplifying future studies. IMC outperformed 
CMCT in the upper limb and was comparable to individual CMCT markers in the lower 
limb, lagging only slightly behind combined CMCT markers. Current evidence indicates 
that IMC abnormalities are primarily attributable to CST dysfunction, suggesting that 
IMC constitutes a potential quantitative test of CST integrity. 
 
For the current study, patients were recruited as early as possible after referral to the 
local MND service. The prognostic value of IMC will be analysed once more survival 
data are available. Future work should include a longitudinal study to characterise the 
evolution of IMC throughout the course of MND, ideally following patients from a pre-
symptomatic stage, for example in kindreds with familial forms of MND. Further 
studies and potential clinical uptake of IMC should prove relatively inexpensive since 
the requisite EMG recording facilities are widely available; in addition, a low-cost, 
handheld EMG recorder is being developed locally (Brown et al., 2012). 
 
We examined IMC in patients with other neurological conditions to clarify the 
contribution of different parts of the motor system to IMC generation (Chapter 6). 
Interestingly, most but not all patients with hereditary spastic paraparesis (HSP) 
exhibited diminished IMC, and further follow-up of the subgroup retaining normal 
levels of IMC may prove informative. In multifocal motor neuropathy (MMN), which is 
typically thought of as a peripheral motor disorder, IMC was diminished. This suggests 
that dysfunction of peripheral motor nerves may affect IMC and/or that our patients 
with MMN had subclinical involvement of the corticospinal tract (CST). In inclusion 
body myositis (IBM), IMC was increased, and a plausible explanation would be that 
alterations in motor unit discharges caused by IBM make synchronisation more readily 
detectable. Overall interpretation of results is complicated by HSP and MMN 
potentially affecting multiple parts of the motor system, and an alternative approach 
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would be to study the effects of virtual lesions in a computational model of the motor 
system. 
 
 
7.3 Conclusion 
 
Thus far, coherence analysis has been predominantly used as a research tool, and it 
was only recently applied as a marker of CST integrity. Though many questions 
presently remain unanswered, it is encouraging that, even at this early stage, the 
performance of IMC appears to match or surpass that of a fully-developed TMS-based 
marker. Within a few years, the neural substrates of IMC generation will have been 
clarified and methods of measuring IMC will have seen further optimisation, thus 
nurturing the hope that IMC could ultimately become a widely used biomarker of CST 
function. 
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A  Individual beta-band averages for intermuscular coherence in normal subjects 
 
Table A.1: Individual averages of beta-band IMC in normal individuals. Coherence was measured in each 
individual using the methods described in Chapter 3, and coherence spectra were averaged across the 
15-30Hz window for each muscle pair. 
 
 Coherence     Coherence   
Age EDC-FDI FDS-FDI MG-EDB TA-EDB  Age EDC-FDI FDS-FDI MG-EDB TA-EDB 
22 0.03584 0.02634 0.01173 0.01980  50 0.00704 0.00638 0.04030 0.03634 
22 0.01879 0.05244 0.02544 0.01202  50 0.01060 0.01839 0.00809 0.00867 
22 0.00471 0.00589 0.02451 0.02642  51 0.00818 0.01153 0.01575 0.00759 
23 0.00747 0.01915 0.00998 0.00680  51 0.00892 0.01734 0.04103 0.02721 
23 0.01343 0.14675 0.04977 0.03167  51 0.00874 0.01423 0.02356 0.02004 
23 0.01258 0.03766 0.04194 0.04871  54 0.12905 0.17268 0.01499 0.01723 
23 0.01937 0.02351 0.00926 0.01182  54 0.01843 0.01943 0.00853 0.00400 
23 0.02262 0.06775 0.04315 0.03156  55 0.03984 0.04361 0.02850 0.06455 
23 0.01079 0.02239 0.00700 0.01015  56 0.04164 0.06578 0.00866 0.00717 
23 0.03140 0.02532 0.01115 0.00816  56 0.02342 0.03158 0.06205 0.05880 
26 0.03421 0.14007 0.20579 0.22506  57 0.06110 0.16334 0.22525 0.21587 
28 0.04751 0.05635 0.01351 0.01558  57 0.00642 0.01368 0.00395 0.00695 
28 0.00771 0.00939 0.02352 0.02060  58 0.03642 0.02950 0.04305 0.04826 
28 0.02011 0.04046 0.01147 0.01335  59 0.04533 0.07249 0.02673 0.02695 
28 0.00687 0.01981 0.01825 0.02353  59 0.01085 0.01573 0.00844 0.00743 
29 0.08813 0.11485 0.02048 0.02383       
      60 0.06708 0.13309 0.01252 0.01222 
30 0.04754 0.07448 0.01765 0.01127  61 0.10277 0.16621 0.01263 0.00464 
30 0.00826 0.00731 0.01343 0.01342  62 0.00618 0.00907 0.01357 0.01710 
30 0.00767 0.00774 0.01118 0.02016  63 0.05938 0.12506 0.12967 0.13597 
30 0.01896 0.03496 0.02304 0.01751  63 0.00665 0.01451 0.02196 0.02584 
30 0.03081 0.16687 0.03848 0.03591  64 0.09815 0.18325 0.01855 0.01620 
31 0.04978 0.07083 0.02041 0.02091  64 0.00933 0.08226 0.27788 0.26353 
32 0.00778 0.01555 0.17898 0.11097  64 0.01516 0.03987 0.03035 0.01242 
34 0.02145 0.02848 0.01098 0.00891  65 0.01556 0.02975 0.00437 0.00298 
35 0.01122 0.02501 0.01502 0.00923  65 0.00759 0.00974 0.00978 0.01139 
36 0.01100 0.04003 0.05448 0.05268  67 0.01067 0.01732 0.13317 0.00991 
36 0.01455 0.04611 0.01181 0.01181  67 0.01641 0.01194 0.02014 0.01180 
36 0.00650 0.01319 0.04499 0.03902  68 0.04158 0.21654 0.41962 0.42641 
38 0.02049 0.06925 0.04019 0.03426  68 0.02154 0.02364 0.01291 0.00820 
38 0.00521 0.01071 0.01692 0.01303  69 0.00526 0.01039 0.01038 0.00947 
38 0.04203 0.03473 0.01311 0.00930       
38 0.01587 0.02502 0.03603 0.01712  70 0.05399 0.02224 0.02551 0.02420 
      70 0.00632 0.02096 0.07212 0.05754 
40 0.02446 0.11101 0.49170 0.48146  70 0.03386 0.03341 0.03014 0.03930 
40 0.01155 0.01059 0.00681 0.00612  71 0.05242 0.06781 0.51644 0.49334 
41 0.00760 0.01332 0.02749 0.01741  71 0.04136 0.04999 0.04223 0.03512 
41 0.02380 0.05039 0.01230 0.01347  71 0.01641 0.02948 0.02484 0.02628 
41 0.00830 0.00862 0.06277 0.05806  73 0.03910 0.02756 0.00777 0.00538 
41 0.05002 0.15325 0.26733 0.26086  73 0.01414 0.01381 0.04040 0.04974 
42 0.01019 0.07663 0.02349 0.02440  74 0.13105 0.15805 0.05657 0.06124 
45 0.02234 0.01955 0.01237 0.01387  74 0.02335 0.02569 0.04295 0.04578 
45 0.07707 0.19395 0.01087 0.01092  75 0.04527 0.05964 0.00712 0.01344 
45 0.00551 0.00647 0.01139 0.01200  75 0.01050 0.01094 0.01200 0.00729 
46 0.00938 0.01384 0.02895 0.02367  75 0.01411 0.03814 0.02127 0.04069 
46 0.03181 0.04390 0.26046 0.25017  76 0.00941 0.02234 0.00750 0.01692 
46 0.07881 0.08268 0.01047 0.00800  77 0.01079 0.01230 0.00804 0.01094 
49 0.01950 0.01392 0.05084 0.03426       
49 0.02085 0.03615 0.08788 0.05944       
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B  Clinical details for patients with motor neuron disease 
 
Table B.1: History for patients with MND. (AF=atrial fibrillation, BFZ=bendroflumethiazide, bilat=bilateral, 
CABG=coronary artery bypass graft, COPD=chronic obstructive pulmonary disease, DH=drug history, 
FDR=first degree relative, FH=family history, GTN=glyceryl trinitrate, HT=hypertension, IBS=irritable 
bowel syndrome, IHD=ischaemic heart disease, inh=inhaler, iPD=idiopathic Parkinson’s disease, 
ISMN=isosorbide mononitrate, L=left, LL=lower limb, MS=multiple sclerosis, NK=not known (hospital file 
not retrievable), OA=osteoarthritis, PMH=past medical history, R=right, T2DM=type 2 diabetes mellitus, 
THR=total hip replacement, UL=upper limb) 
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1 M 52 6m R UL weakness, wasting, twitching, 
cramps; then similar symptoms in L UL 
Sigmoid colectomy for diverticulosis Riluzole Nil 
2 F 65 16m Gradual slurring dysarthria; then 
dysphagia, bilat LL weakness and falls 
Recurrent cystitis, asthma Cefalexin, fluoxetine, simvastatin, aspirin, 
trimipramine, salbutamol inh, budesonide 
and formoterol inh, riluzole 
Mother: Lewy body 
dementia 
3 M 70 6m Neck extensor and UL L>R weakness T2DM, hypercholesterolaemia Glicazide, metformin, omeprazole, 
ibuprofen, rosuvastatin, riluzole 
Nil 
4 F 70 9m Weakness of voice and limbs; then gait 
disturbance, falls, dysphagia 
IHD Baclofen, sertraline, atorvastatin, aspirin, 
GTN, citalopram 
Nil 
5 M 55 4m R hand weakness; then L hand weakness, 
R LL weakness, dysarthria 
Asthma Mirtazepine, lisinopril, quinine, riluzole Nil 
6 F 80 9m L hand weakness; then gait disturbance, 
dysarthria, dysphagia for liquids 
Asthma Salbutamol, oxybutinin, quinine, 
theophylline 
Nil 
7 F 72 12m Dysarthria, dysphagia; then drooling Nil Lansoprazole, riluzole Nil 
8 F 41 15m R LL weakness, cramps, twitching; then 
falls 
Subtotal hysterectomy, bilat 
oophorectomy, appendicectomy, ulnar 
nerve decompression at cubital tunnel, OA 
knees 
Nil Nil 
9 F 46 14m L LL stiffness; then R LL stiffness, 
weakness, falls, bilat UL stiffness, spastic 
dysarthria, dysphagia 
Nil Baclofen, citalopram, codeine, 
paracetamol 
Father: MS 
10 F 66 24m R LL weakness; then L LL and R UL 
weakness, restriction to wheelchair, 
dysarthria, occasional dysphagia 
HT, IHD Amlodipine, omeprazole, fexofenadine, 
tolterodine 
Nil 
11 F 59 30m Bilat R>L LL weakness and stiffness; then 
spastic dysarthria 
Asthma Salmeterol and fluticasone inh, baclofen, 
riluzole 
Nil 
12 M 46 6m L hand weakness and wasting; then R LL 
wasting, weakness 
Nil Riluzole Nil 
13 F 75 10m Dysphagia, dysarthria Amiodarone-induced hypothyroidism, 
paroxysmal AF, THR, hysterectomy 
Alendronate, aspirin, bisoprolol, docusate, 
hyoscine, levothyroxine, paracetamol 
Nil 
14 M 68 31m Dysarthria, cough; then fall with ankle 
fracture, slow to remobilise, new 
requirement for two sticks 
R nephrectomy for malignant tumour 
2006 
Riluzole Nil 
15 F 62 6m Dysarthria, dysphagia, L LL cramps and 
weakness 
HT Quinine, lisinopril, aspirin, baclofen, 
riluzole 
Nil 
16 F 58 6m R UL weakness Lumbar surgery, mild asthma, vulval 
dystrophic disease 
Budesonide inh Grandmother: died of 
problems which allegedly 
included muscle 
weakness 
17 F 77 8m Dysarthria; then dysphagia Breast cancer 2001 (mastectomy, 
tamoxifen), L ischaemic optic neuropathy 
2008, asthma, osteoporosis, HT, 
hysterectomy 
Fluticasone and salmeterol inh, aspirin, 
amlodipine, risedronate, paroxicam 
Nil 
18 F 62 7m R then L LL weakness; subsequently R then 
L UL weakness; R LL fasciculation, 
cramping, locking; restriction to 
rollator/wheelchair 
THR, asthma, HT Ramipril, sertraline, riluzole Nil 
19 F 73 26m R LL weakness, falls HT, bilat L4/5 decompression for 
anterolisthesis 2011 
Irbesartan, BFZ, riluzole Nil 
20 F 53 15-
18y 
R then L UL weakness; subsequently bilat 
LL weakness 
Nil Codeine, paracetamol Mother and four 
maternal uncles: MND 
21 M 77 13m Bilat UL weakness IHD, myelodysplasia Clopidogrel, bisoprolol Mother: dementia 
22 M 76 17m R UL weakness, wasting; then L UL 
weakness, wasting, bilat LL weakness 
IHD, CABG Amlodipine, ramipril, atenolol, 
simvastatin, quinine, ISMN, aspirin, 
riluzole 
Nil 
23 F 74 10m Weakness of gait; then dysarthria, cramps Asthma Salbutamol inh, riluzole Nil 
24 M 72 16m R hand weakness HT, hypercholesterolaemia Simvastatin, amlodipine, losartan, riluzole Nil 
25 M 63 6m R hand weakness; subsequently L UL then 
R LL then L LL weakness 
HT, pericarditis, asbestos exposure Aspirin, codeine, paracetamol, riluzole Nil 
26 M 60 19m Bilat LL twitching and muscle aches; then 
spread to all limbs with wasting and 
weakness 
Nil Ibuprofen, riluzole Nil 
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27 F 57 9m Slurring dysarthria, dysphagia mostly for 
liquids; then bilat LL cramps, global limb 
weakness 
IBS, anxiety Amitriptyline, mebeverine, lansoprazole Nil 
28 M 72 14m R LL weakness, stiffness, falls HT, hyperlipidaemia Amlodipine, paracetamol, riluzole Nil 
29 M 67 24m R hand weakness, wasting; then L hand 
weakness, wasting 
IHD Omeprazole, aspirin, simvastatin, riluzole Nil 
30 F 74 34m L then R LL stiffness; subsequently L>R UL 
stiffness, slurring dysarthria, dysphagia 
Pernicious anaemia, HT Strontium, colecalciferol, aspirin, 
amlodipine, folate, vitamin B12, baclofen 
Nil 
31 M 59 23m L LL giving way Nil Baclofen Nil 
32 M 43 22m Bilat proximal LL weakness Acne Oxytetracycline Maternal grandmother, 
mother, two maternal 
uncles, sister: MND 
33 M 58 27m L LL weakness, cramps, falls; then R LL 
weakness, possible bilat UL weakness 
Nil Quinine, citalopram, omeprazole, 
dihydrocodeine, diclofenac, riluzole 
Three FDRs incl. brother: 
MND 
34 F 66 7-8y R LL then UL weakness; L limbs unaffected Breast ductal cancer (local excision) Solifenacin Nil 
35 F 73 23m L>R LL weakness; subsequently L then R 
hand weakness and wasting 
L ankle degenerative disease Amitriptyline, diclofenac, omeprazole, 
riluzole 
Nil 
36 F 67 5m Slurring dysarthria, difficulty chewing, 
cramping of jaw muscles 
T2DM, hiatus hernia Omeprazole, riluzole Nil 
37 F 71 18m R>L LL weakness, L UL weakness Cervical spondylosis, hysterectomy, 
cholecystectomy 
Oxycodone, amitriptyline, chromoglycate Nil 
38 F 48 12m R hand cramps; subsequently R hand then 
UL weakness 
Asthma, psoriasis Beclamethasone inh, riluzole Nil 
39 F 59 3m Dysarthria, dysphagia Nil Citalopram, riluzole Nil 
40 F 64 3m L hand weakness, L foot drop; then 
slurring dysarthria 
Chronic pancreatitis secondary to 
pancreatic cysts, cholecystectomy, HT 
Fluoxetine, lercadipine, atorvastatin, 
lansoprazole, pancrelipase, dosulepin, 
paracetamol, ibuprofen 
Nil 
41 F 37 3m Bilat LL weakness Nil Riluzole Nil 
42 M 61 5-6y Difficulty walking; subsequently R then L 
LL weakness, wasting 
COPD Ibuprofen, tramadol, paracetamol, 
amitriptyline, quinine 
Nil 
43 M 61 20m L then R hand weakness; then dysarthria, 
widespread fasciculation 
CABG Simvastatin, aspirin, lansoprazole, riluzole Nil 
44 F 56 13m R LL cramps, weakness, falls; then L LL 
crams 
T2DM, HT, IHD, hysterectomy, duodenal 
ulcer 
Amitriptyline, atenolol, BFZ, docusate, 
doxazosin, losartan, metformin, 
omeprazole, perindopril, simvastatin, 
gabapentin 
Nil 
45 F 66 26m L hand wasting, weakness, cramping, 
locking; then spread to rest of L UL 
Hypothyroidism Thyroxine Nil 
46 F 73 21m R hand cramps/spasms, weakened grip; 
then similar symptoms in L hand 
Glaucoma Nil Nil 
47 M 68 30m L>R LL weakness; then L>R hand 
weakness, slurring dysarthria, minor 
dysphagia 
Hypercholesterolaemia, asthma, IHD, past 
alcohol excess, surgery for stomach ulcers 
Thiamine, salbutamol inh, salmeterol inh, 
becotide inh, ramipril, paracetamol, 
lansoprazole, bisoprolol, atorvastatin, 
baclofen 
Nil 
48 M 71 15m Bilat LL weakness; then bilat UL weakness, 
weak voice 
Spondylosis, disc prolapse with symptoms 
in R LL 1979, diverticulosis, Barrett's 
oesophagus 
Codeine, lanzoprazole, quinine, riluzole Nil 
49 M 56 12m Bilat UL and LL wasting, weakness; then 
bilat UL and LL fasciculation 
Nil Quinine, riluzole Nil 
50 M 65 NK NK NK Riluzole NK 
51 M 32 4m L hand weakness; then L LL weakness, 
falls, L>R UL weakness 
Drug use (cannabis, amphetamines) Amitriptyline, riluzole Nil 
52 M 55 9m Slurring dysarthria, dysphagia mostly for 
liquids 
Nil Temazepam, riluzole Nil 
53 M 32 52m Tightness in calves, difficulty/inability to 
play football, falls; then bilat LL wasting 
Nil Baclofen, amitriptyline, riluzole Nil 
54 F 56 9m L then R UL weakness; subsequently L LL 
weakness, gait disturbance 
L breast cancer 5y ago (wide local excision, 
chemotherapy, radiotherapy, 
trastuzumab), HT, hypercholesterolaemia 
Irbesartan, lansoprazole, paracetamol, 
simvastatin, riluzole 
Nil 
55 F 65 10m Dysarthria; then dysphagia, drooling, 
cramps in hands and LLs 
COPD, hysterectomy, L Dupuytren's Seretide inh, simvastatin, quinine, aspirin, 
carbocisteine 
Nil 
56 M 53 6m R LL cramps, weakness; subsequently 
fasciculation R then L LL, R UL 
Fixed facial weakness and R hearing loss 
from birth 
Riluzole Nil 
57 M 52 6m Dysarthria, dysphagia, mild UL weakness Nil Mirtazepine, riluzole Nil 
58 F 55 5m Bilat LL weakness, twitching, cramps Nil Nil Sister and paternal uncle: 
MND 
59 F 29 15m Unstable L ankle, falls, foot drop Cystic fibrosis, pancreatic insufficiency, old 
L LL sciatica 
Azithromycin, flucloxacillin, polymyxin E, 
salbutamol inh, fluticasone and salmeterol 
inh, quinine 
Nil 
60 M 66 13m Bilat UL stiffness, weakness; then bilat LL 
weakness, bilat UL and LL wasting 
HT, hiatus hernia, Barrett's oesophagus Amitriptyline, lansoprazole, lisinopril, 
amlodipine, riluzole 
Nil 
61 M 83 12m R hand then UL weakness, knees giving 
way 
T2DM, diverticular disease, primary 
hyperparathyroidism, hiatus hernia 
Atorvastatin, codeine, omeprazole Sister: iPD 
62 M 66 36m Bilat LL weakness, stiffness; then bilat UL 
clumsiness, later slurring dysarthria 
Depression, ulcerative colitis, alcohol 
overuse 
Mesalazine, omeprazole, simvastatin, 
fluoxetine, tamsulosin, levodopa, 
dantrolene, aspirin, codeine 
Nil 
63 M 69 7m Bilat proximal UL weakness, axial 
weakness 
T2DM, HT, localised prostatic cancer Metformin, lisinopril, BFZ, paracetamol, 
riluzole 
Aunt: MS 
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Table B.2: Examination findings for patients with MND. (MRC=Medical Research Council, N=no/absent, 
NA=not applicable, NK=not known, Y=yes/present) 
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1 N N N N N N N Y N Y Y N Y NK N Y N Y Y N Y NK N N N N Y N N N NA N N N N Y N N N NA 
2 Y N Y Y Y Y N Y N Y Y N Y 4-5 N Y N Y Y N Y 4-5 N N Y N Y Y N Y 4-5 N N Y N Y Y N Y 4-5 
3 N N N N N Y N N N Y Y Y Y NK N N N Y Y Y Y NK N N N N Y N N N NA N N N N Y N N Y NK 
4 Y Y Y N N Y N Y NK N Y N Y NK Y Y NK N N N Y NK Y Y Y N N N N Y NK Y Y Y N N N N Y NK 
5 N N Y Y N Y N Y NK Y Y N Y NK N Y NK Y Y N Y NK N N Y N Y N N Y NK N N Y N Y N N N NA 
6 N N Y N N Y N Y N N N N N NA N Y Y Y Y N Y NK N N Y N Y N N Y NK N N Y N Y N N Y NK 
7 Y N NK Y Y Y N N NK N N N Y NK N N NK Y N N Y NK N N N N N N N N NA N N N N N N N N NA 
8 N N NK N N N N N NK N N N N NA N N NK N N N N NA N N Y Y Y N N Y NK N N Y N N N N N NA 
9 Y Y N N N Y Y Y NK N N N N NA Y Y NK N N N Y NK Y N Y Y N N N Y NK Y N Y Y N N N Y NK 
10 Y N NK N N N Y Y NK N Y N Y NK Y Y NK N Y N Y NK Y Y Y N N N N Y NK Y Y Y N N N N Y NK 
11 Y Y Y Y N N N Y NK N Y N Y NK N Y NK N Y N Y NK Y Y Y N N N N Y 4-5 Y Y Y N N N N Y 4-5 
12 N N NK N N N N Y NK Y N N N NA N Y NK Y Y N Y NK Y N Y N Y Y N Y NK N N Y N N N N N NA 
13 N N N Y Y Y N Y NK N Y N Y 4-5 N Y NK N Y N Y 4-5 N N Y N N N N Y 4-5 N N Y N N N N Y 4-5 
14 Y Y N N N Y N Y NK N N N Y NK N Y NK N N N Y NK Y N Y Y N N N Y 4-5 Y Y Y Y N N N Y 4-5 
15 Y N N N N Y N Y NK N N N Y 4-5 N Y Y N N N Y 4-5 N N Y N N N N Y NK N N Y N N N N Y NK 
16 N N N N N Y N Y NK N Y N Y 4-5 N Y NK N N N N NA N N N N N N N N NA N N N N N N N N NA 
17 Y N Y N N Y N N NK Y N N Y NK N N NK Y N N Y NK N N N N N N N N NA N N N N N N N N NA 
18 N N NK N N N N Y N Y Y N Y NK N Y N Y Y N Y NK Y N Y Y Y Y N Y NK Y Y Y Y Y Y N Y NK 
19 N N N N N N N N NK N N N Y 4-5 N N NK N N N N NA N N N N N Y Y Y 4-5 N N N N N Y Y Y 4-5 
20 N N N N N N N N NK N Y Y Y 0-5 N N NK N Y Y Y 0-5 N N N N N Y Y Y 4-5 N N N N N Y Y Y 4-5 
21 N N NK N N N N N N Y Y Y Y 4-5 N N N Y Y Y Y 4-5 N N N N N N N N NA N N N N N N N N NA 
22 N N N N N N N Y N Y Y N Y NK N Y N Y Y N Y NK N Y Y N Y Y N Y 4-5 N N Y N N N N Y 4-5 
23 Y N Y Y N Y N N NK Y N N Y NK N Y NK Y N N Y NK N N N N Y N Y Y NK N N N N Y N Y Y NK 
24 N N N N N N N Y Y Y Y N Y 4-5 N Y N N N N N NA N N Y N N N N N NA N N Y N N N N N NA 
25 Y N Y Y Y Y Y Y Y Y Y N Y NK Y Y Y Y Y N Y NK N Y Y Y Y Y N Y NK N Y Y N Y Y N Y NK 
26 N Y N N N Y N Y NK Y Y N Y NK N Y NK Y Y N Y NK N N Y N Y Y N Y 4-5 N N Y Y Y Y N Y 4-5 
27 N N Y Y Y Y N Y NK Y N N Y NK N Y NK Y N N N NA N N Y N Y N N N NA N N Y N Y N N N NA 
28 N N N N N N Y Y NK Y N N Y 4-5 N Y NK Y N N Y 4-5 Y Y Y Y Y Y N Y 0-5 N N Y Y Y N N N NA 
29 N N NK N N N N N NK Y Y N Y NK N N NK Y Y N Y NK N N N N Y N N N NA N N N N Y N N N NA 
30 Y N Y Y N Y N Y Y N N N Y 4-5 N Y Y N N N Y 4-5 Y N Y Y N N N N NA Y N Y Y N N N N NA 
31 N N NK N N N N Y NK N N N N NA N Y NK Y N N N NA Y Y Y N N N N N NA Y Y Y N Y Y N Y 4-5 
32 N N NK N N N N N NK N Y Y Y 4-5 N N NK N Y Y Y 4-5 N N N N N Y N Y 4-5 N N N N N Y N Y 4-5 
33 N N N N N N N N NK Y N N N NA N N NK Y N Y N NA N N N N Y Y Y N NA N N N N Y Y Y Y 4-5 
34 N N N N N N Y Y NK N N N Y NK N Y NK N N N N NA Y N Y Y N N N Y NK Y N Y N N N N N NK 
35 N N N Y N Y N Y N Y N N Y NK N Y N Y N N Y NK N N Y N N Y Y Y NK N N Y N N Y Y Y NK 
36 N N NK Y Y Y N N NK Y N N N NA N N NK N N N N NA N N N N Y N N N NA N N N N Y N N N NA 
37 N N N N N Y N Y NK Y Y N Y NK N Y NK Y Y N Y NK N N Y N N Y Y Y NK N N Y N N N N Y NK 
38 N N NK N N Y N Y NK Y Y N Y NK N Y NK N N N Y NK N Y Y N N N N N NA N Y Y N N N N N NA 
39 Y Y Y N N Y N Y NK N N N N NA N Y NK N N N N NA N N Y N N N N N NA N N Y N N N N N NA 
40 Y Y Y Y Y Y N Y N N Y N Y 4-5 N Y N N Y N Y 2-5 N N N N Y Y N Y 4-5 N N N N N N Y Y 3-5 
41 N N N N N N N N NK Y N N Y NK N N NK Y N N Y NK N N N N Y N N Y 4-5 N N N N Y N N Y 4-5 
42 N N N N N N N Y N N N N N NA N Y N N N N N NA N N Y N N Y Y Y NK N N Y N N Y Y Y NK 
43 Y Y NK Y Y Y N N NK Y N N N NA N Y NK Y Y N Y NK N N N N Y N N N NA N N N N Y N N N NA 
44 N N NK N N N N Y NK N N N N NA N Y NK N N N N NA N N Y N N Y Y Y NK N N Y N N N N N NA 
45 N N N N N Y N N NK Y Y N Y 4-5 N N NK Y N Y Y NK N N Y N N N N N NA Y N Y Y N N N N NA 
46 N N NK N N N N N NK Y Y N Y NK N N NK N N N N NA N N N N N N N N NA N N N N N N N N NA 
47 N N NK Y N Y N Y NK Y N N N NA N Y NK N N N Y NK Y Y Y N Y N N Y NK Y Y Y N Y N N Y NK 
48 N N N N N Y N Y N Y Y N Y NK N Y N Y Y N Y NK N N Y N Y Y N Y NK N N Y N Y Y N Y NK 
49 N N NK Y N N N Y N Y Y N Y 4-5 N Y N Y Y N Y 4-5 Y N Y Y Y Y N Y 4-5 Y N Y N Y Y N Y 4-5 
50 Y N Y Y Y NK N Y NK Y Y N NK NK N Y NK Y Y N NK NK Y N Y Y Y Y N NK NK Y N Y N Y Y N NK NK 
51 N N NK N N N N Y NK Y Y N Y NK N Y NK Y Y N Y NK Y Y Y Y Y N N N NA Y Y Y Y Y N N N NA 
52 Y Y Y Y Y Y N Y NK Y N N N NA N Y NK N N N N NA N N Y N N N N N NA N N Y N N N N N NA 
53 N N N N N N N Y N Y N N Y NK N Y N Y N N Y NK N N Y N Y Y Y Y NK N N Y N Y Y Y Y NK 
54 N N N N N N N Y NK Y Y N Y NK N Y NK Y Y N Y NK Y Y Y N N N N Y 4-5 Y Y Y N N Y N Y 4-5 
55 Y N Y Y Y Y N Y Y Y N N N NA N Y Y Y N N N NA N N Y N Y N N N NA N N Y N Y N N N NA 
56 N N N N N N N N N Y N N N NA N N N N N N N NA N N Y N Y N N Y NK N N Y N Y N N N NA 
57 Y Y Y Y Y Y N N NK Y N N Y NK N N NK Y N N Y NK N N N N N N N N NA N N N N N N N N NA 
58 N N N N N N N N NK N N N N NA N N NK N N N N NA N N N N Y Y Y Y 4-5 N N N N Y Y Y Y 4-5 
59 N N NK N N N N Y NK N N N N NA N Y NK N N N N NA N N Y N N Y N Y 0-5 N N Y N N Y N Y 0-5 
60 N N NK N N Y N N NK Y Y Y Y 1-4 N N NK Y Y Y Y 1-4 Y N Y N Y Y N Y 4-5 Y N Y N Y Y N Y 4-5 
61 N N N N N N N N NK Y Y Y Y NK N N NK Y N N N NA N N N N N N N N NA N N N N N N N N NA 
62 Y N N N N N N Y N N N N Y 4-5 Y Y Y N N N Y 4-5 Y Y Y Y N N N NK NK Y Y Y Y N N N NK NK 
63 N N N N N N N Y N Y Y N Y 4-5 N Y N Y Y N Y 4-5 N N N N Y Y N N NA N N N N Y Y N N NA 
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Table B.3: Blood results for patients with MND. (AChR=acetyl choline receptor, ANCA=anti-neutrophil 
cytoplasmic antibodies, ESR=erythrocyte sedimentation rate, FBC=full blood count, GAD=glutamic acid 
decarboxylase, HTLV=human T-lymphotropic virus, MAG=myelin-associated glycoprotein, 
Microb’y=microbiology, N=normal/negative, SCA=spinocerebellar ataxia, SOD1=superoxide dismutase 1, 
SPG4=spastic paraplegia 4, TDP-43=transactive response DNA binding protein 43kDa, TSH=thyroid 
stimulating hormone, VLCFA=very long chain fatty acids) 
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Pa
tie
nt
 n
um
be
r 
FB
C 
ES
R 
Vi
ta
m
in
 B
12
 
Fo
la
te
 
Co
pp
er
 
Liv
er
 fu
nc
tio
n 
Th
yr
oi
d 
fu
nc
tio
n 
Gl
uc
os
e 
Cr
ea
tin
e 
ki
na
se
 (<
16
0)
 
VL
CF
A 
He
xo
sa
m
in
id
as
e 
A 
Au
to
-a
nt
ib
od
y 
sc
re
en
 
AN
CA
 
An
ti-
AC
hR
 
An
ti-
GA
D 
An
ti-
GM
1 
An
ti-
M
AG
 
An
ti-
ne
ur
on
al
 
Se
ru
m
 e
le
ct
ro
ph
or
es
is 
Im
m
un
og
lo
bu
lin
s 
Ly
m
e 
se
ro
lo
gy
 
Tr
ep
on
em
a 
se
ro
lo
gy
 
HT
LV
 se
ro
lo
gy
 
 
1 N  N N  N N N 845                
2 N     N                   
3 N N N N  N   N   N  N           
4 N N  N  N  N                 
5 N     N                   
6                         
7 N N    N N N N   N  N     N N     
8 N N N   N  N 443 N  N       N N     
9 N  N N N N  N  N  N   N   N      SPG4 N 
10 N N N N N N N N    N      N       
11                         
12 N     N                   
13 N     N   N     N     N N     
14 N     N N N                 
15 N     N                   
16 N     N N                  
17 N  N N  N  N    N       N N     
18 N  N N  N N                  
19 N  N N  N N N    N       N N     
20         N   N    N   N N    SOD1 and TDP-43 N 
21 N N    N  N N   N    N         
22 N     N                   
23 N     N  N                 
24 N N N   N N  N       N   N N     
25 N N N N  N N N N   N  N     N      
26 N N N   N   223   N   N    N N     
27 N N N   N  N N   N  N     N      
28 N N    N N N N          N N     
29 N     N                   
30    N      N               
31 N N N N N N N N 254   N       N N     
32 N N N   N N N N                
33      N                  SOD1 and TDP-43 N 
34 N N N   N N N N N  N       N N N N N  
35 N N    N                   
36 N N N   N N  172   N       N N  N   
37 N N  N  N TSH 9.41 (0.3-4.7), 
thyroxine 11.9 (9.5-21.5) 
N N   N       N N     
38 N N N  N N N N    N       N N     
39                         
40 N     N            N       
41 N  N N  N  N N   N       N N N N   
42 N N N   N N N N   N N      N N     
43 N     N                   
44 N  N  N N N     N N      N N     
45 N     N                   
46 N     N          N N        
47 N N N N  N N N    N       N N   N  
48 N N    N   323                
49 N N    N N N 564   N       N N     
50 N     N   209                
51 N N N N N N N   N N N N   N   N   N   
52 N   N  N N N N   N  N           
53 N     N   461                
54 N     N                   
55 N N    N  N                 
56 N     N                   
57 N N    N N N N   N  N     N N     
58 N N    N   N               Heterozygous for familial pathogenic mutation c.229G>T, 
p.Asp77Tyr in exon 3 of SOD1 
59 N N    N N N  N N N N   N N  N  N N   
60 N N N N  N N  N   N       N N     
61                         
62   N    N               N  Huntingtin N, fragile X and SCA 1/2/3/6/7/17 screen N 
63 N N N N  N TSH 5.16 (0.3-4.7), 
thyroxine 18.0 (9.5-21.5) 
N 1000                
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Table B.4: Cerebrospinal fluid (CSF) and MRI findings for patients with MND. (bilat=bilateral, C-
spine=cervical spine, CST=corticospinal tract, L=left, L-spine=lumbosacral spine, OCB=oligoclonal bands, 
R=right, SVD=small vessel disease, T-spine=thoracic spine) 
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M
RI
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M
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M
RI
 L-
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1   N   
2  Mild-moderate SVD    
3   Root compression R C4 and bilat C5   
4  Mild atrophy, mild SVD    
5   N   
6      
7 N N    
8 N     
9 N N N   
10 Protein 0.55g/l 
(absent) 
N N N Moderate multilevel degenerative 
change, potential R L3 and L L5 
compression 
11  N N N N 
12  N N   
13   N N N 
14  N N   
15  N N   
16      
17  Moderate atrophy, mild SVD    
18      
19 N  Moderate foraminal stenoses L C3/4 
and bilat C4/5 
Disc protrusions T6/7 and T7/8 
distorting but not compressing cord 
Previous R L4/5 disc surgery, grade 1 
anterolisthesis of L4 on L5 
20  Mild SVD    
21 N (absent)  Multiple foraminal stenoses on R, no 
neural compromise 
  
22      
23      
24  Mild SVD Mild-moderate degenerative changes, 
moderate-severe bilat foraminal 
stenoses C3/4, moderate bilat 
foraminal stenoses C6/7 
 
25      
26     Lateral spinal canal and foraminal 
stenosis L4/5, no neural compromise 
27      
28     Mild degenerative changes, no neural 
compromise 
29   Multilevel degenerative disc disease, 
foraminal impingement C4/5 and 
C5/6, worse on R 
  
30  Bilat linear low signal along posterior 
motor cortex, moderate atrophy 
   
31  Mild atrophy, mild SVD    
32      
33     Disc degeneration and retrolisthesis 
at L5/S1, L S1 root displaced by 
disc/osteophyte complex 
34 N (absent) Mild SVD High cord signal C2-6, mild non-
compressive disc bulges 
  
35   Mild-moderate spondylotic changes, 
mild foraminal stenosis R C5/6 
  
36  Mild atrophy    
37  Mild atrophy Multilevel disc-osteophyte complexes 
C3/4 to C6/7 indenting thecal sac but 
not compressing cord, bilat foraminal 
stenosis at these levels but no 
definite impingement 
Posterior disc bulge L4/5, mild 
impingement L L5 
 
38   N   
39  Mild SVD    
40  N N   
41 N (absent) N N N N 
42  Mild SVD Moderate-severe foraminal stenoses 
L C4/5, bilat C5/6, R C6/7  
N Mild degenerative changes, most 
prominent at L4/5 with possible 
contact on L5 root, more so on R; 
multiple Tarlov cysts, largest 
associated with R S1 root 
43      
44 N (absent)   Degenerative disc disease, no neural 
compromise 
 
45      
46   Mild-moderate foraminal stenosis 
bilat C5/6 
  
47 N (absent)     
48      
49      
50      
51 N Symmetrical high signal in CST N   
52  N    
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53      
54  Mild SVD, mild bilat high signal in CST N N N 
55  N Degenerative disease at C5/6 and 
C6/7, no neural compromise 
N N 
56   Moderate Chiari 1 malformation, no 
syrinx, mild degenerative changes 
Impingement R L5 N 
57  Moderate atrophy    
58      
59 N (absent) N   N 
60   Mild-moderate spondylotic disease   
61      
62 N  Moderate multilevel degenerative 
changes, spinal canal stenosis C3/4 
but no cord compression, moderate 
foraminal stenoses bilat C3/4 to C6/7 
but no root compression 
  
63 Protein 0.88g/l     
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Table B.5: Phenotype, handedness, affected limbs, limbs studied with TMS and IMC, and exclusion 
criteria for patients with MND. (F=familial, FA=flail arm, FL=flail leg, R=right, L=left, LL=lower limb, 
UL=upper limb) 
 
   Affected TMS IMC Exclusion criteria 
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 n
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UL
 
LL
 
R 
UL
 
L U
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LL
 
L L
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1 ALS/FA R R>L R=L Y 
 
Y   Y 
 
Y   
     2 PBP R R=L L>R Y 
 
Y   Y 
 
Y   
   
Y 
 3 ALS R L>R R=L   Y Y   
 
Y Y   Y 
    4 PLS R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     5 ALS R R=L R=L Y 
 
Y   Y 
 
Y   
     6 ALS R L>R R=L Y 
 
Y   Y 
 
Y   
     7 PBP R Neither Neither   
  
  Y 
 
Y   
  
Y 
  8 ALS R Neither R only Y 
 
Y Y Y 
  
Y 
     9 PLS R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     10 ALS R R>L R>L Y 
 
Y   Y 
 
Y   
     11 PLS R L>R R>L Y 
 
Y   Y 
 
Y   
     12 ALS R L>R R>L Y 
 
Y   Y 
 
Y   
     13 PBP R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     14 PLS R Neither L>R Y 
 
Y   Y 
 
Y   
     15 PBP R L>R L>R Y 
 
Y   Y 
 
Y   
     16 ALS R R>L Neither Y 
 
Y   Y 
 
Y   
     17 PBP R Neither Neither Y 
 
Y   Y 
 
Y   
     18 ALS R R>L R>L Y Y Y   
 
Y Y   
 
Y 
   19 PMA R R>L R>L Y 
 
Y Y Y 
  
Y 
     20 ALS (F) R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     21 PMA R R>L Neither Y 
 
Y   Y 
 
Y   
     22 ALS/FA R R>L R=L   Y Y   
 
Y Y   
     23 ALS R R=L R>L Y 
  
Y Y 
  
Y 
     24 ALS/FA R R>L Neither Y 
 
Y   Y 
 
Y   
     25 ALS R R>L R>L   Y 
 
Y 
 
Y 
 
Y 
     26 ALS R R>L R>L Y 
  
Y Y 
  
Y 
     27 PBP R R>L R>L Y 
 
Y   Y 
 
Y   
   
Y 
 28 ALS R R=L R>L Y 
 
Y   Y 
 
Y   
     29 ALS/FA R R>L Neither   Y Y   
 
Y Y   
     30 PLS L L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     31 ALS R R=L L>R Y 
  
Y Y 
  
Y 
     32 PMA R Neither L>R Y 
  
Y Y 
  
Y 
     33 ALS (F) R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
   
Y 
 34 PLS R R>L R>L   Y Y   
 
Y 
 
  
 
Y 
   35 ALS/FA R L>R L>R Y 
 
Y   Y 
 
Y   
     36 PBP R Neither Neither Y 
 
Y   Y 
 
Y   
     37 ALS R L>R R>L Y 
  
Y Y 
  
Y 
    
Y 
38 ALS/FA R R>L Neither Y 
 
Y   Y 
 
Y   
     39 PBP R R>L R>L Y 
 
Y   Y 
 
Y   
     40 ALS/PBP L L>R L>R Y 
 
Y   Y 
 
Y   
     41 ALS R R=L R=L Y 
 
Y   Y 
  
  
 
Y 
   42 ALS L R=L R=L   Y 
 
Y 
 
Y 
 
Y 
     43 ALS R L>R R=L   Y 
 
Y 
 
Y 
 
Y 
     44 ALS/FL R L>R R>L Y Y Y Y Y 
  
Y 
     45 ALS/FA R L>R L>R   Y 
 
Y 
 
Y 
 
Y 
     46 ALS R R>L Neither Y 
 
Y   Y 
 
Y   
     47 ALS R R=L R=L Y 
 
Y   Y 
 
Y   
     48 ALS R R=L R=L Y 
 
Y   Y 
 
Y   
     49 ALS R L>R L>R Y 
 
Y   Y 
 
Y   
     50 ALS R R=L R=L Y 
 
Y   Y 
 
Y   
     51 ALS L L>R R=L   
  
  Y 
  
Y 
  
Y 
  52 PBP R Neither Neither Y 
 
Y   Y 
 
Y   
   
Y 
 53 ALS R Neither L>R Y 
  
Y Y 
  
Y 
     54 ALS R L>R R=L Y 
 
Y   Y 
 
Y   
     55 PBP L R>L R=L Y 
  
Y Y 
  
Y 
     56 ALS R R=L R>L Y 
 
Y   Y 
 
Y   
     57 PBP/ALS R L>R Neither Y 
 
Y   Y 
 
Y   
     58 ALS (F) R R=L R=L Y 
 
Y   Y 
 
Y   
     59 ALS R Neither L>R Y 
 
Y Y Y 
 
Y   
     60 ALS/FA R R=L R=L Y 
 
Y   Y 
 
Y   
     61 ALS/FA R R>L R>L Y Y Y   
 
Y Y   Y 
    62 PLS R R>L L>R Y 
  
Y Y 
  
Y 
     63 ALS R L>R R=L   Y Y   
 
Y Y   
   
Y Y 
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C  Clinical details for patients with motor neuron disease mimic syndromes 
 
Table C.1: Genetic mutations of patients with HSP. (SPG=spastic paraplegia) 
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Ex
on
 
cD
NA
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ha
ng
e 
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nc
e 
1 SPG4 Exon 4-17 del exon 4-17 Large-scale deletion 
2 SPG4 Exon 4-17 del exon 4-17 Large-scale deletion 
3 SPG4 Exon 4-17 del exon 4-17 Large-scale deletion 
4 SPG4 Exon 4-17 del exon 4-17 Large-scale deletion 
5 SPG4 Exon 4-17 del exon 4-17 Large-scale deletion 
6 SPG4 Exon 7 c.1091_1093delGGCinsTGT p.Arg364_Pro365delinsMetSer 
7 SPG4 Intron 10 c.1321+2dupT Splice site disruption 
8 SPG4 Exon 11 c.1384A>G p.Lys462Glu 
9 SPG4 Exon 1 del exon 1 Large-scale deletion 
10 SPG4 Intron 11 c.1414+1G>A Splice site disruption 
11 SPG31 Exon 5 c.337C>T p.Arg113X 
12 SPG31 Exon 5 c.337C>T p.Arg113X 
 
 
Table C.2: Electrophysiological diagnostic category, electrophysiological features, anti-GM1 result and 
responsiveness to intravenous immunoglobulin (IVIg) for patients with MMN (Olney et al., 2003). 
 
 
 
 
Table C.3: Clinico-pathological diagnostic category for patients with IBM (ENMC Research Diagnostic 
Criteria 2011; Rose, 2013). 
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1 Clinically-defined  
2 Clinically-defined  
3 Clinically-defined  
4 Clinically-defined  
5 Clinically-defined  
6 Probable 
7 Probable 
8 Probable 
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bl
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no
rm
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es
 
An
ti-
GM
1 
IV
Ig
 re
sp
on
siv
en
es
s 
1 Definite MMN with conduction block Y 3/0 N N Y 
2 Definite MMN with conduction block Y 2/0 N 1:400 Y 
3 Definite MMN with conduction block Y 2/0 N N Y 
4 Definite MMN with conduction block Y 2/0 N N Y 
5 MMN (without conduction block) Y 0/0 N N Y 
6 MMN (with anti-ganglioside antibodies) N 0/0 N 1:1600 Y 
7 MMN (without conduction block) Y 0/0 N N Y 
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Table C.4: History for patients with HSP, MMN and IBM. (BFZ=bendroflumethiazide, bilat=bilateral, 
BPH=benign prostatic hyperplasia, DH=drug history, DHS=dynamic hip screw, DVT=deep vein thrombosis, 
FH=family history, GORD=gastro-oesophageal reflux disease, HT=hypertension, IHD=ischaemic heart 
disease, L=left, LL=lower limb, N=normal, NK=not known, NOF=neck of femur fracture, PE=pulmonary 
embolism, PMH=past medical history, PPM=permanent pacemaker, R=right, SVT=supraventricular 
tachycardia, THR=total hip replacement, UL=upper limb) 
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Se
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PM
H 
DH
 
FH
 
HSP 1 F 28 16y Poor running from birth, 
always last at school, spastic 
gait noted at age 15 
Occasional 
urgency 
Occasional 
urgency 
N Nil Baclofen Mother affected 
 2 F 50 40y Detrusor overactivity, no gait 
disturbance 
Incontinence 
due to detrusor 
overactivity 
N N Nil Nil Two of four siblings and 
daughter affected 
 3 M 35 30y Late walker, increasingly 
spastic gait 
Frequency, 
urgency 
N N Nil Nil Grandfather in wheelchair 
from age 14, father with high 
insteps, both siblings and one 
of two children affected 
 4 F 57 22y Stiff LLs Urgency, 
frequency 
N N Hysterectomy Tizanidine, lisinopril, aspirin, 
simvastatin, BFZ, codeine, 
paracetamol 
Two of four siblings affected 
 5 M 62 24y Progressive stiffness of LLs, 
gait disturbance, falls 
Long-term 
catheter for 
neuropathic 
bladder 
N N Epilepsy in remission, 
DVT/PE, complicated sacral 
sore requiring defunctioning 
colostomy, HT, peripheral 
vascular disease, GORD, R 
NOF/DHS 
Phenytoin, phenobarbitone, 
BFZ, lisinopril, amlodipine, 
aspirin, tinzaparin, tizanidine, 
atorvastatin, omeprazole 
Paternal grandfather, father, 
three paternal uncles, two of 
four sisters affected 
 6 F 65 13y L>R LL stiffness, falls N N N Polymyalgia rheumatica Nil Father and maternal aunt 
affected 
 7 F 72 65y Tripping over ankles, then 
progressively spastic LLs 
Nocturia, urge 
and stress 
incontinence 
N N Hypothyroidism Thyroxine, tolterodine, 
dantrolene, baclofen 
Son affected 
 8 F 73 5y Stiff LLs, difficulty walking Urgency, 
frequency, 
nocturia 
NK N Asthma, anxiety, depression Chlorpromazine, citalopram, 
trazodone, temazepam, 
amitriptyline, paracetamol, 
oxybutinin, baclofen, 
tolterodine, codeine, 
tizanidine, inhalers 
Mother and seven of nine 
siblings affected 
 9 M 39 11y Progressive deterioration in 
gait after fall 
N N NK Nil NK Adopted; FH not known 
 10 M 49 5y Dragging toes, catching feet, 
stiffness around hips 
Urge and stress 
incontinence, 
nocturia 
N N Nil Solifenacin One of two brothers affected, 
two children asymptomatic 
 11 M 66 63y Walked at normal age, then 
balance deteriorated, toe-
walking so using callipers 
throughout teens, clumsiness 
and wasting of hands from 
mid-50s 
N N N Tendon lengthening in 
adolescence 
Nil Son and grandson affected 
 12 M 43 38y Slowly progressive spastic gait Nocturia N N Nil Nil Father and one of two 
children affected 
MMN 1 M 59 12y L>R UL/LL weakness, cramps; 
subsequently R LL then R UL 
weakness 
NK NK N Asbestos exposure, R 
malignant epithelioid 
mesothelioma (talc 
pleurodesis, palliative 
chemotherapy, radiotherapy) 
Nil (previously on 
cyclophosphamide for MMN) 
Nil 
 2 M 61 27y L UL wasting, weakness, 
paraesthesia; then R hand 
wasting and weakness 
N N N Past alcohol overuse, HT, 
BPH, mastoid revision 
surgery, SVT 
Tamsulosin, finasteride, BFZ, 
metoprolol 
Nil 
 3 M 51 11y R UL weakness; subsequently L 
UL weakness, then bilat LL 
weakness; marked cramps in 
all limbs 
NK NK N HT BFZ (previously on 
cyclophosphamide for MMN) 
Nil 
 4 F 29 2y L UL weakness N N N Eczema Nil Nil 
 5 M 28 6y Progressive R hand weakness NK NK N Asthma Nil Nil 
 6 M 70 8y L then R hand weakness NK NK N HT, R THR, chronic lumbar 
back pain, nerve root blocks, 
R L4/5 microdiscectomy 
Atenolol, gabapentin, 
amitriptyline, amlodipine 
Nil 
 7 M 35 3y R finger locking/spasms; 
subsequently R UL weakness, 
then L ankle weakness 
N N N Nil Nil Nil 
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IBM 1 F 74 39y Discomfort of muscles 
hips>shoulders; then difficulty 
in reaching up and rising from 
low chairs 
NK NK NK Auto-immune 
hypothyroidism, impaired 
glucose tolerance, HT, bilat 
breast cancer (bilat 
mastectomy, tamoxifen) 
Prednisolone, diclofenac, 
verapamil, thyroxine; 
previously on 
methotrexate/azathioprine 
Nil 
 2 M 78 NK NK NK NK NK Cluster headache, HT, 
obesity, 
hypercholesterolaemia, 
depression, airways 
disease ?type 
Carbocisteine, citalopram, 
inhalers 
Nil 
 3 F 64 19y Slowly progressive difficulty 
climbing stairs, running; then 
poor L grip, mild dysphagia 
N N N IHD, impaired glucose 
tolerance, 
hypercholesterolaemia, 
cholecystectomy, Sjögren's 
syndrome 
BFZ, ezetimibe, atenolol, 
aspirin 
Nil 
 4 M 87 10y Stamping gait L LL, problems 
climbing stairs; then poor grip 
and dexterity 
NK NK N HT, gout, mitral stenosis, 
PPM for heart block, B12 
deficiency and iron deficiency 
anaemia, pleural plaques 
from asbestos exposure 
Allopurinol, aspirin Nil 
 5 M 83 7y Falls related to knees buckling, 
difficulty climbing stairs 
NK NK NK NK Aspirin, simvastatin, lisinopril Nil 
 6 F 77 12y Camptocormia, difficulty 
climbing stairs, unable to 
stand from low chairs 
Urgency NK N Nil Nil Nil 
 7 M 64 1y Weakness of L ankle 
plantarflexion then L hand 
N N N Nil Nil Nil 
 8 F 68 5y Difficulty rising from 
squat/climbing and 
descending stairs; then 
difficulty with grip and some 
dysphagia for solids 
NK NK N Hypothyroidism, Sjögren's 
syndrome, vitiligo, 
hysterectomy, 
cholecystectomy 
Thyroxine, colecalciferol, 
strontium 
Nil 
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Table C.5: Blood results for patients with HSP, MMN and IBM. (ANA=anti-nuclear antibody, ANCA=anti-
neutrophil cytoplasmic antibodies, ESR=erythrocyte sedimentation rate, FBC=full blood count, 
N=normal/negative, RhF=rheumatoid factor, TSH=thyroid stimulating hormone, VLCFA=very long chain 
fatty acids) 
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HSP 1 N                   
 2                    
 3 N    N  N             
 4                    
 5 N N   N  N       N N     
 6 N N   N N  N N  N   N N     
 7 N  N N  N  N N N Anti-microsomal >1:6400   N N N    
 8 N     N  N            
 9                    
 10 N N   N  N  N           
 11 N N N N N N N N N  N    N     
 12                    
MMN 1 N  N N N  N    N   N N N N N  
 2 N N N N N N N N   N N  N N     
 3 N N N N N N N N   N   N N     
 4 N N N  N N     N   N N     
 5 N N   N N  N   N  N N N     
 6 N N N  N N N N   N N   N     
 7 N N   N N N N N N N    N     
IBM 1 N N N N N TSH 0.24 (0.3-4.7), 
thyroxine 26.9 (9.5-21.5) 
N 188-603   N   N  N    
 2 N N N N N N N 832   N   N N     
 3 N  N N N N  361-499      N     N 
 4 N N N N N N  N     N N N     
 5 N N   N N  241-270   N   N N     
 6 N N N N  N N N   N         
 7 N       271   N  N N N     
 8 N N   N  N 322-856   ANA, RhF, anti-Ro, anti-La positive   N      
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Table C.6: Cerebrospinal fluid (CSF) and MRI findings for patients with HSP, MMN and IBM. 
(bilat=bilateral, C-spine=cervical spine, L=left, L-spine=lumbosacral spine, OCB=oligoclonal bands, 
R=right, T-spine=thoracic spine) 
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HSP 1      
 2      
 3      
 4     Early osteophytes 
 5  N    
 6 N N N N N 
 7 N (absent) N Degenerative changes C3/4, some 
compression of L C4 root but no 
cord compression 
N  
 8  Moderate atrophy Mild foraminal stenoses R C2/3 and 
L C4/5, moderate-severe foraminal 
stenoses bilat C5/6, no cord 
compression 
N Degenerative changes, mild spinal 
canal stenosis, bilat foraminal 
stenosis L4/5, grade 1 
spondylolisthesis at L5/S1 
 9      
 10  N N N N 
 11   Mild degenerative changes, most 
markedly R C3/4, no neural 
compromise 
N Osteophytes on L, mild lateral recess 
effacement at several levels, no 
neural compromise 
 12    N  
MMN 1 N (absent)     
 2 N (absent)     
 3 Protein 0.5g/l 
(absent) 
N Degenerative changes, no root 
compression on R, moderate-severe 
foraminal stenoses and root 
compression at several levels on L 
  
 4 N N N   
 5 N (absent)     
 6 N (absent)  Spondylotic changes between C3/4 
and C6/7, foraminal stenosis L C6/7 
with compression of C7 root, 
indentation of theca without cord 
compression 
 Multilevel degenerative change, 
stenosis of L5/S1 foramen, very little 
fat around L5 nerve root 
 7 N N Mild foraminal stenosis R C6/7, no 
neural compromise 
  
IBM 1      
 2      
 3      
 4      
 5      
 6      
 7      
 8      
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